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Paediatric high grade glioma (pHGG) and diffuse intrinsic pontine glioma 
(DIPG) are highly aggressive brain tumours. Their invasive phenotype 
contributes to their limited therapeutic response and novel treatments that 
block brain tumour invasion are needed. Here, two novel anti-invasive 
therapeutic strategies are evaluated: glycogen synthase kinase-3 (GSK-3) 
inhibitors and oncolytic viruses (OVs). 
  
Small molecule GSK-3 inhibitors, lithium chloride (LiCl) and the indirubin 
derivative 6-bromoindirubin-oxime (BIO), reduced migration and invasion of 
pHGG cell lines (SF188 and KNS42) and one patient-derived DIPG cell line 
(HSJD-DIPG-007) in 2D and 3D in vitro assays. Following drug treatment, 
pHGG cells demonstrated loss of polarity and altered morphology as seen 
by live cell imaging and cytoskeletal rearrangement of actin fibres and focal 
adhesions as seen by immunofluorescence. 
 
OVs (herpes simplex virus (HSV), reovirus and vaccinia virus (VV)) were 
able to inhibit the migration and invasion of pHGG and DIPG cell lines. 
Oncolytic HSV was the most interesting candidate, as anti-migratory and 
anti-invasive effects did not appear to be a consequence of cytotoxicity or 
altered proliferation. Oncolytic HSV altered pHGG cytoskeletal dynamics, 
stabilising microtubules through the accumulation of post-translational 
tubulin modifications, as evaluated by Western blotting and 
immunofluorescent labelling. Furthermore, oncolytic HSV treatment of pHGG 
cell lines inhibited GSK-3β activity and prevented the localised clustering of 
adenomatous polyposis coli to the leading edge of the cell. These 
observations are highly novel and begin to document the molecular 
mechanisms by which oncolytic HSV may inhibit pHGG migration and 
invasion. 
 
In conclusion, this study is the first to demonstrate that it is possible to target 
migration and invasion of pHGG and DIPG in vitro using either small 
molecule GSK-3 inhibitors or OVs, such as HSV. These agents warrant 
 V 
further in vivo pre-clinical investigation as potential anti-invasive therapeutics 
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Chapter 1: Introduction 
 
1.1 Paediatric central nervous system tumours 
 
Central nervous system (CNS) tumours are the most common solid tumours 
of childhood (1), accounting for a significant proportion of paediatric cancer 
morbidity and mortality (2).  Paediatric CNS tumours have an incidence of 
5.1 cases per 100,000 children, with peaks seen at three to seven years of 
age (1,3). Whereas the majority of tumours result from sporadic mutations, 
genetic cancer predisposition syndromes account for a small percentage of 
cases (4). Overall, the five-year survival for paediatric CNS tumours is 
around 73 % (1); however, this statistic represents an extremely 
heterogeneous group of tumours (Table 1) with prognosis based on 
histology, staging, patient age at diagnosis, disease location and specific 
tumour biology (5).  
 






Low grade glioma 30 - 50 % Cerebral 
hemispheres 
90 - 100 % 
(resectable) 




20 - 25 % Cerebellar vermis 80 - 85 % 
(average risk) 
40 - 70 %  
(high risk) 
Ependymoma 10 % Fourth ventricle 50 - 75 % 
High grade glioma 8 - 12 % Cerebral 
hemispheres 
15 - 35 % 
Diffuse intrinsic 
pontine glioma 
3 - 9 % Brainstem 0 - 5 % 
Craniopharyngioma 6 - 9 % Suprasellar 
midline 
80 - 95 % 







1 - 2 % Cerebellar 
hemispheres 
0 - 33 % 
 
Table 1: Summary of the distribution, location and five-year survival 
of the most common CNS tumours of childhood 




Paediatric CNS tumours are challenging to treat; complete surgical 
resections are limited by the safety of operating within critical brain locations, 
radiotherapy can significantly damage the fragile developing brain and 
several tumours respond poorly to current available chemotherapeutics (6). 
Over the last decade, surgical advancements have helped improve the 
safety and feasibility of resections (4,12), radiotherapy has advanced 
through the use of conformal techniques and proton therapy (6,13,14) and 
chemotherapy protocols and delivery methods have been optimised (3,6,15). 
Improved understanding of tumourigenesis and molecular pathways has led 
to the development of biologically targeted therapeutics, which are currently 
being explored in early phase trials (16-19). However, in spite of this, 
survival statistics over the past two decades have not considerably improved 
and there still remains a group of tumours associated with poor prognosis 
(20). Of these, paediatric high grade glioma (pHGG) and diffuse intrinsic 
pontine glioma (DIPG) represent a significant treatment challenge and novel 
therapeutic strategies for these tumours are clearly needed.  
 
1.2 Paediatric high grade glioma and diffuse intrinsic pontine glioma 
 
1.2.1 Histopathology and classification 
 
For the purpose of clinical studies, glioblastoma, anaplastic astrocytoma, 
anaplastic oligodendroglioma, gliomatosis cerebri, and DIPG comprise the 
group of tumours collectively referred to as high grade gliomas (HGGs) (21). 
pHGGs are tumours of the glial cell lineage (comprised of astrocytes, 
oligodendrocytes and microglia) which are non-neuronal cells that play a role 
in supporting and protecting neurons within the CNS (22). The World Health 
Organisation (WHO) uses a histological grading system to classify brain 
tumours on a scale of grade I (most benign) to IV (most aggressive) (23). 
Low grade gliomas (LGGs) are grade I and II tumours, whereas HGGs 
encompass grade III and IV tumours (23). Grade III tumours (anaplastic 
astrocytoma, anaplastic oligodendroglioma and anaplastic oligoastrocytoma) 
are diffusely infiltrative with distinct nuclear atypia, increased cellularity and 
marked mitotic activity (19,23,24). Grade IV tumours (glioblastoma and 
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gliosarcoma) are classified by the presence of prominent microvascular 
proliferation and necrosis, in addition to the features described for grade III 
tumours (19,23,24). DIPGs are classified as WHO grade II-IV tumours; 
however, grade II tumours have the same clinical behavior as aggressive 
HGGs and are not considered benign (21,25,26).   
 
1.2.2 Epidemiology, clinical presentation and management 
 
Approximately 0.8 per 100,000 children (age<19) develop pHGG per year 
(1).  Overall, incidence increases with age (1), with infratentorial (brainstem 
and cerebellar) tumours seen more commonly within the paediatric 
population and supratentorial (cerebral hemisphere and midline structure) 
tumours developing in adolescent and adult patients (27-29). Although 
prognosis of HGG is poor, with most studies showing five-year survival 
ranging between 15-35 %, age is a significant prognostic factor, with children 
under the age of three years having noticeably better outcomes (29,30). 
HGGs in childhood typically arise after a short clinical history, with de novo 
(primary) tumours. Secondary tumours from malignant transformation of 
LGGs are particularly rare in the paediatric compared to the adult population 
(7 versus 50 %) (29,31,32). The standard treatment approach for non-
brainstem pHGG is maximal surgical resection, radiotherapy and 
chemotherapy. Adjuvant chemotherapy has been shown to improve survival 
compared to radiotherapy and surgery alone (33); however, no significant  
difference in outcome has been seen between different chemotherapy 
schedules (prednisolone, lomustine and vincristine (PCV), “8-drugs-in-1-day” 
regimen or temozolomide) (34,35) and temozolomide is widely adopted as 
the standard of care treatment due to improved tolerability (29).  
 
Brainstem gliomas account for 10 % of pHGGs and 75-80 % of brainstem 
tumours are classified as DIPGs (26,29). DIPG is mainly a disease of mid 
childhood (peak age at diagnosis six- to eight-years-old) and over 50 % of 
children present with the classic triad of cranial nerve deficits, long tract and 
cerebellar signs (36). DIPG is a major cause of brain-related death in 
childhood, with over 90 % of children dying within two years of diagnosis 
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(36-38). Brainstem glioma and DIPG can not be treated surgically, due to 
tumour location. Standard treatment for DIPG includes six weeks of 
radiotherapy to stabilise disease progression and improve neurological 
function; however, effect on overall survival is minimal (36). Unfortunately, 
no chemotherapeutics to date have improved the outcome of DIPG in any 
prospective clinical trial (39).  
 
1.2.3 Molecular biology and genetic alterations 
 
Over the past decade, exome and whole genome sequencing alongside 
molecular and clinical data gathered from clinical trials, has helped shape 
understanding of the biology of pHGG and DIPG. It has now become clear 
that pHGGs are both biologically and clinically distinct from adult HGGs and 
that novel therapeutic strategies should be evaluated using paediatric pre-
clinical models where possible, rather than simply extrapolating data from 
adult-based models (29). Whereas mutations in the isocitrate 
dehydrogenase (IDH)-1 gene are a hallmark aberration in the adult disease, 
this is rarely documented in paediatric tumours (21,40). Additionally, pHGGs 
typically have fewer deoxyribonucleic acid (DNA) copy number changes than 
histologically similar adult tumours and are characteristically associated with 
1q gain (29,41).  
 
Two significant key genomic differences appear to define the paediatric 
disease. Firstly, platelet-derived growth factor receptor alpha (PDGFRA) is a 
predominant target of focal amplification, whereas in adult HGG, epidermal 
growth factor receptor (EGFR) is the common target (29,41,42). Secondly, 
novel oncogenic driver mutations in histone (H) 3.1 (at position K27), H3.3 
(at position K27 and G34) and in the activin A receptor type 1 (ACVR1) 
appear to be unique to pHGG and DIPG (39,43-47). Several groups have 
attempted to use genetic profiling to molecularly classify HGG (42,43,48,49). 
Table two summarises six epigenetically distinct subgroups of glioblastoma, 
based on genome-wide methylation profiling by the German cancer research 
centre (Deutsches Krebsforschungszentrum; DKFZ), which classifies 
tumours based on methylation, age at onset, tumour location, oncogenic 
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drivers, gene expression and survival (39,43). Such molecular stratification 
may be useful for future clinical trial design, allowing a more rational 
approach for patient selection of novel targeted biological agents (39).  
 
 
Table 2: A summary of the six epigenetically distinct subgroups of 
glioblastoma, based on genome-wide methylation profiling by the 
German cancer research centre (DKFZ) 
Taken and adapted from (39). H (histone), TP53 (tumour protein p53), ATRX 
(alpha thalassemia/mental retardation syndrome X), FGFR1 (fibroblast 
growth factor receptor 1), ACVR1 (activin A receptor type 1), PDGFRA 
(platelet-derived growth factor receptor alpha), IDH (isocitrate 
dehydrogenase), CDKN2 (cyclin-dependent kinase 2), EGFR (epidermal 
growth factor receptor), NF1 (neurofibromatosis 1), BRAF (rapidly 
accelerated fibrosarcoma kinase B). 
 
1.2.4 Summary of the unique challenges for researchers studying 
pHGG and DIPG 
 
Development of an effective treatment for HGG is viewed to be a huge 
challenge. Firstly, HGGs represent an extremely heterogenous group of 
tumours and even within individual tumours, there can be subpopulations of 
cells with epigenetic and genetic variation (43,50). Such intra-tumoural 
heterogeneity may contribute to the development of tumour progression and 
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treatment failure through the development of resistant subpopulations of 
cells that harbor mutations, allowing continuous self renewal and 
proliferation (43).  Secondly, brain tumours, as a whole, represent a unique 
treatment challenge to the field of oncology, as systemically delivered 
therapeutics need to cross the blood brain barrier (BBB), a highly organised 
structural unit critical for CNS homeostasis and the prevention of entry of 
biological toxins (51). Although the presence of a brain tumour itself can 
destabilise areas of the BBB (51,52), drug penetration of the BBB must be 
considered when testing novel therapeutics.  Several technologies that allow 
either transient BBB disruption in order to aid local drug delivery (51,53,54) 
or novel administration routes, such as convection enhanced delivery to 
bypass blood-CNS barriers (55,56), are under investigation and offer 
promise of improved brain-drug delivery.    
 
pHGG and DIPG are relatively rare diseases (1) and this has implications for 
recruitment and design of feasible clinical trials. Large international 
collaborative efforts are required in order to effectively test new therapies in 
a timely manner, which are expensive and difficult to facilitate. Challenges to 
research include limited numbers of immortalised pHGG cell lines (there are 
currently none for DIPG) with only some key genetic aberrations present. 
Only recently have pHGG and DIPG neurosphere cultures been developed 
(29). Biological material for DIPG research is particularly rare as tumour 
diagnosis is based upon the presence of characteristic imaging alongside 
typical clinical presentation and, as such, biopsy is not often clinically 
indicated. Over the last decade, there has been a consensus for collecting 
biological material for DIPG. Initially tissue was taken at autopsy; however, 
new consensus guidelines now support conducting a biopsy upfront at 
diagnosis in order to enhance the understanding of the molecular biology of 
the disease and to develop pre-clinical models for new agent testing (57-60).  
 
Compared to adult HGG, there is a lack of robust in vivo models of pHGG 
and DIPG for drug testing. Over the past few years, orthotopic 
xenotransplantation of pHGG or DIPG cells (collected at autopsy, biopsy or 
surgery, in the case of pHGG) into the cerebrum/pons has been successfully 
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used as a pre-clinical tool (29,61-63). Research is currently focused to 
create genetically engineered models of DIPG/pHGG (29,61,64) and the 
development of orthotopic syngeneic mouse models is critical for pre-clinical 
testing of novel treatment approaches, such as immunotherapy. 
 
1.3 Migration and invasion of glioma cells 
1.3.1 Background 
 
A hallmark characteristic of glioma cells and, indeed, of cancer, is their 
ability to invade and diffusely infiltrate normal brain tissue (24,65,66). Thus, 
these tumours inevitably recur, as by the time of surgical resection, tumour 
cells have invaded into the surrounding brain, preventing their complete 
removal (65). Approximately 95 % of malignant gliomas will recur within two 
to three cm of the resection cavity; however, recurrence has been 
documented several centimeters away from the original tumour site, as well 
as in the contralateral cerebral hemisphere (67-70), highlighting the ability of 
glioma cells to migrate across significant distances.  Despite such infiltrative 
and invasive behaviour, HGGs hardly ever metastasise outside of the brain, 
illustrating that invasion is likely to be governed by interactions between 
tumour cells and the brain environment (71). HGG cells are known to 
migrate in specific patterns, following the orientation of white matter tracts, 
capillaries and unmyelinated axons (24,72,73). Interestingly, this pattern of 
migration is similar to the pattern followed by glial progenitors during normal 
brain development (73,74). The next section will evaluate mechanisms 
underlying both the migration and invasion of cancer cells and the key 
agents involved in regulating these processes.  
 
1.3.2 Cell migration  
 
Cell migration is the directed movement of cells from one location to another 
(75,76). This process is critical for many physiological and pathological 
processes in biology and is a prerequisite for invasion (75,76).  Individual 
tumour cells demonstrate different modes of migration, which are mainly 
amoeboid or mesenchymal (77). The mode of migration adopted by the cell 
 8 
is influenced by tumour type, as well as factors within the tumour 
microenvironment such as chemokine and growth factor gradients and 
proteolysis (77).  In amoeboid migration, cells are more rounded and are 
able to squeeze through gaps in the extracellular matrix (ECM). This type of 
migration is referred to as ‘pathfinding’ migration. Typically, cells moving with 
amoeboid morphology move at high speeds (approximately 4 μm min-1) (77). 
Conversely, the mesenchymal mode is characterised by elongated cell 
morphology and relies on proteolytic degradation of the ECM to form a path 
for migrating cells (77,78). Hence, this type of migration is known as ‘path 
generating’.  Cells moving with mesenchymal morphology demonstrate 
relatively low speeds of migration (approximately 0.1-1 μm min-1) (77).  
Glioma cells mainly adopt the mesenchymal pattern of migration (71); 
however, cancer cells can interconvert between the different modes of 
migrations depending on microenvironmental cues (77,79). Such plasticity 
may allow tumour cells to adapt their mode of migration to the surrounding 
microenvironment, promoting tumour aggression (80). Additionally, these 
switches contribute to drug resistance of tumours and highlight one of the 
key challenges involved in trying to pharmacologically target cancer cell 
movement (81,82).   
In addition to the two types of migration, tumour cells can also move in 
groups, demonstrating multicellular patterns of migration. The cells may 
move collectively in clusters or sheets (collective migration), where cells held 
together by cell-cell junctions move through the ECM (77,83). In this mode of 
migration, the front line of elongated leader cells, made up of either tumour 
and/or stromal cells, form tracks via proteolysis which facilitate a pathway for 
movement of sheets of cuboidal-shaped cells (77). Collectively migrating 
cells do not retract their cellular tails in order to propel themselves forward 
but exert a pulling force on neighbouring cells that are connected by cell-cell 
junctions (84). Alternatively, cells may migrate via streaming, where 
individual cells not held together by cell-cell junctions follow each other down 




1.3.3 Mechanisms of cell migration 
 
In order for a cell to move, it needs to be able to adapt and alter its shape. 
This process is made possible by the presence of the cell cytoskeleton, 
which is composed of actin microfilaments, microtubules and intermediate 
filaments (86). To start the process of movement, the cell becomes 
polarised, generating a front-rear axis that allows the cell to have a leading 
protrusive front and a trailing edge (87,88). Polarisation appears to be 
initiated by the small guanosine triphosphatases (GTPases), including cell 
division control protein 42 (Cdc42), Rac, and Rat sarcoma homolog (Rho), 
which play a role in cytoskeletal re-organisation, as well as controlling 
direction sensing for the cell (87,89). The leading edge of the cell protrudes 
into a broad flat lamellipodium and long thin filopodium composed of actin 
filaments, whose polymerisation controlled by Rac and Cdc42, allows 
movement (90,91). Microtubules are also believed to play a role in 
generating protrusive activity and influence the rearrangement and dynamics 
of actin (92). The actin cytoskeleton, forming the front and rear protrusions, 
is attached to the ECM at focal adhesions via integrin receptors, anchoring 
the cell to its substrate and allowing a traction force when actomyosin 
contracts. During this process, the rear focal adhesions detach from the 
ECM, thus allowing retraction of the trailing edge, progressing the cell 
forwards (71,90) (Figure 1). In summary, the mechanism of cell migration 
involves the coordinated repetition of an ordered sequence of events, 
involving cell protrusion, adhesion, contraction and retraction (93) based on 







Figure 1: Structure of a migrating cell 
Polarisation generates a front-rear axis and results in a leading and trailing 
edge. The leading edge protrudes as filopodia and lamellipodia. Adhesions 
form in the filopodia (filopodial adhesion) and lamellipodia (nascent 
adhesion). Adhesion maturation to focal adhesions occurs in the lamellum. 
Actin forms bundles and cross-bridges into filaments. Microtubules assemble 
as arrays initiating from the microtubule organising centre (MTOC). Adapted 
from (87,90,92,94).  
 
1.3.4 Microtubules in cell migration 
 
Microtubules are polymers of α- and β- tubulin dimers that bind to form stiff 
cylindrical hollow tubes that play a critical role in cell migration, cell polarity, 
cell division and neuronal differentiation (93,95,96). Microtubules assemble 
as arrays initiating from microtubule organising centres (MTOCs), with the 
main MTOC associated with the centrosome in the majority of cell types 
(93). In most cells, the MTOC is localised in front of the nucleus, in the 
direction of cell migration (93,97,98). Microtubule polymers have molecular 
polarity, with a minus end anchored at the MTOC and a dynamic plus end 
which reaches into the cytoplasm and cell periphery (95). The plus end 
functions by a process called dynamic instability, which involves 
catastrophes (depolymerisation/shrinkage) and rescues 
(polymerisation/growth), allowing microtubules to search, explore and 
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interact with cellular organelles and target sites (93,95,99,100). Microtubule-
associated motors (MAMs) and microtubule-associated proteins (MAPs) are 
critical for microtubule functioning (93,95). MAMs, such as dyneins and 
kinesins, allow transport of vesicles, organelles, cytoskeletal components, 
proteins and messenger ribonucleic acid (mRNA) along microtubule tracks 
(93,96), whereas MAPs play a role in stabilising or destabilising microtubules 
during dynamic instability.  
 
Plus-end-tracking proteins (+TIPs) (including cytoplasmic linker protein 170 
(CLIP-170), cytoplasmic linker-associated protein (CLASP), end binding 
protein (EB)-1 and -3, adenomatous polyposis coli (APC), dynein, dynactin 
and lissencephaly protein (Lis1)) (101,102) are a sub-group of MAPs that 
specifically bind to growing microtubule ends and play a key role in 
regulating microtubule interactions and dynamics (93,103,104). EB1 and -3 
are a type of +TIPs with a function in promoting persistent growth of 
microtubules (93,105). The EBs can recruit +TIP stabilising factors, such as 
APC, which clusters at microtubule plus ends and act to limit the frequency 
of catastrophes, stabilise microtubules, promote microtubule growth and 
encourage cell migration (93,106,107). APC also plays an essential role in 
regulating the polarity of migrating cells (93,108,109). In this process, 
glycogen synthase kinase-3 (GSK-3)-β is inactivated by Cdc42 at the 
leading edge of the cell. Inactivation of GSK-3β suppresses the 
phosphorylation of APC and, in this unphosphorylated form, APC is able to 
cluster and bind to the plus ends of microtubules promoting directional cell 
protrusion.  This localisation of inactive GSK-3β, resulting in spatially 
restricted APC clustering to plus ends of microtubules, is critical to the 
establishment of cell polarity (110).   
 
Whilst the majority of microtubules undergo dynamic instability and 
demonstrate short half-lives (five to ten minutes (min)), a subgroup of 
microtubules do not undergo this process and subsequently have much 
longer half-lives (more than one hour (h)) (100,111). These ‘stable’ 
microtubules accumulate post-translational modifications, such as 
acetylation, detyrosination, glutamylation and glycylation and are more 
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resistant to microtubule depolymerisation agents (93). Stable microtubules 
may be found in the protrusions of migrating cells, polarising cells and 
differentiated cells (93,100). The post-translational modification of tubulin 
can act to alter microtubule dynamics. For example, tubulin detyrosination 
can inhibit both +TIP protein recruitment and depolymerising motors, 
resulting in subpopulations of microtubules resistant to disassembly (112). 
Additionally, post-translational tubulin modifications can enhance the 
interaction of specific motor proteins with microtubule tracks, allowing for 
preferential transportation of intracellular organelles, vesicles or proteins and 
can support the formation of stable directed tracks from the centrosome to 
the leading edge in migrating cells, that facilitate directional trafficking within 




Where migration is the directed movement of cells from one location to 
another, invasion represents a separate, highly dynamic process, involving 
regulation of cell-cell adhesion, proteolysis of the ECM and cell migration 
(75,84). This process allows cells to move through the ECM into 
neighbouring tissues.  Cells relying on amoeboid migration do not invade in 
a classical sense, as they do not rely on proteolysis of the ECM. Invasion is 
a hallmark feature of cancer pathogenesis and is a key event in metastasis 
(66).  
The ECM of the brain is a dynamic environment with several roles. It can 
provide a pool of growth factors and matrix proteins to help regulate cellular 
functions during normal and pathological remodelling processes and it can 
also act to provide structural support within the brain (82,115,116). The ECM 
of the brain consists mainly of hyaluronic acid, except around blood vessels 
and the pial surface, where the basal lamina consists of type IV and V 
collagen and other fibrous proteins (24,115). Proteases are known to be 
involved in remodelling the ECM in order to allow a passage for cells to 
migrate and, additionally, generate a favourable environment for tumour 
growth (24). Glioblastoma cells are able to express and release specific 
proteases that are able to degrade the surrounding ECM, thus facilitating 
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tumour invasion (82). Three groups of proteases have been linked to this 
process (115): serine proteases (including urokinase-type plasminogen 
activator (uPA) and its membrane-bound receptor (uPAR), which induce the 
degradation of fibronectin and laminin) (117), cysteine proteases (including 
Cathepsin B which degrades laminins and collagen) (118) and matrix 
metalloproteinases (MMPs) (in particular, MMP2 and -9, which are linked as 
promoters of glioblastoma invasion) (119). Specific inhibitors act to control 
protease activity and an imbalance of the levels of their expression may also 
contribute to glioma invasion (82).  
Integrins are adhesion molecules that play a key role in cell migration and 
invasion by communicating signals between the ECM and the intracellular 
environment (16,65). The integrin receptor is a transmembrane glycoprotein 
constructed of an α- and β- subunit that connects to the focal adhesion 
kinase (FAK)/Src family protein tyrosine kinase/Crk-associated substrate 
(Cas) signalling network. This activates GTPase proteins to control 
cytoskeletal modifications necessary for cell movement (71). 18 α- and eight 
β- subunits exist, resulting in the development of a range of integrin 
receptors made up of different α/β integrin pairs, each capable of interacting 
with different ECM proteins (65,82). In glioblastoma, pro-migratory ECM 
proteins are upregulated and increased expression of corresponding integrin 
receptors to these proteins have been documented in glioblastoma tumour 
specimens (82). Importantly, integrin αvβ3 and αvβ5, which allow 
communication between the ECM and endothelial cells during angiogenesis 
and play a role in invasion by acting as adhesive receptors, have been 
shown to be expressed at high levels in glioblastoma tumour samples 
(65,82,120). These specific integrins have been linked to glioblastoma 
tumour progression as they are associated with an increase in expression in 
higher grade tumours (82,121,122). Finally, integrins appear to be critical for 
glioblastoma invasion. This was demonstrated in vitro by antibody blockade 
of integrin receptors resulting in reduced adhesion, motility and invasion of 
glioblastoma cells (82,123,124).  
In order to invade, tumour cells must alter their attachment to other cells, as 
well as to the ECM. Changes in the levels of adhesion molecules play a key 
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role in this process (66).  One such molecule that plays an important role in 
tumour invasion is epithelial-cadherin (E-cadherin), a transmembrane 
glycoprotein that mediates cell-cell adhesion and helps to assemble 
epithelial cell sheets (66,125). Expression of E-cadherin appears to inversely 
correlate with the ability of tumours to invade and metastasise, with reduced 
levels of E-cadherin associated with a more invasive tumour phenotype (66). 
Epithelial cells can undergo changes in cell-cell adhesion and can transform 
to acquire a more invasive phenotype through a developmental regulatory 
programme called epithelial-mesenchymal transition (EMT) (66). During 
EMT, loss of function mutations in cadherins, proteolytic cleavage of 
cadherins and upregulation of cytokines that alter cell-cell adhesion occur 
(126). This is also accompanied by the de novo expression of vimentin 
(126,127). Overall, these changes allow cells to acquire a much more 
invasive phenotype (126,127). EMT is controlled by a set of transcription 
factors, including Slug, Snail, Twist and Zing finger E-box binding homeobox 
(Zeb)-1 and -2, which are able to alter cell morphology (from polygonal to 
spindly/fibroblastic), increase expression of ECM proteases and increase 
resistance to apoptosis, all of which favour tumour motility and invasiveness 
(66).  
EMT is a reversible process and tumour cells are capable of undergoing 
mesenchymal-epithelial transition (MET) (66). This plasticity appears to play 
an important role in cancer metastasis, as colonies of cancer cells that have 
metastasised to distant tissue are able to revert to their original epithelial 
phenotype, which may be histologically more similar to that of the primary 
tumour and may assist integration into distant tissue/organs (66,128).   
Finally, the surrounding tumour stroma, consisting of angiogenic vascular 
cells, infiltrating immune cells and cancer-associated fibroblasts (CAF), also 
plays a role in promoting cancer progression and can adapt to facilitate 
tumour invasion (129,130).  CAF are able to secrete effector molecules 
which promote invasion (130). Examples of such effector molecules include 
secretion of transforming growth factor beta (TGF-β), which can activate 
EMT, and hepatocyte growth factor (HGF), capable of stimulating invasion 
and proliferation (130-134). Stromal mesenchymal cells secrete cytokines, 
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such as Regulated on Activation, Normal T Expressed and Secreted 
(RANTES), which are involved in facilitating tumour cell invasion (66,135). 
Immune cells, such as mast cells and macrophages, resident in the stroma, 
can also support cancer cell invasion by secreting ECM-degrading enzymes, 
including MMPs or cysteine and serine proteases in response to cytokine 
signalling from tumours (66,130,136). Macrophages secrete growth factors 
such as epidermal growth factor (EGF), which facilitate chemotaxis and 
invasion of tumour cells into the surrounding tissues and blood vessels 
(130,137). Additionally, stromal macrophages may play a role in inhibiting 
the expression of known metastasis suppressor genes (130,138-140). Taken 
together, it is clear to see that the tumour microenvironment is a key 
regulator of cancer cell invasion and must be considered when designing 
potential anti-invasive cancer therapies.  
 
1.4 Therapeutic targeting of cancer migration and invasion 
 
An effective therapeutic strategy for the treatment of HGG must target the 
process of tumour infiltration into normal surrounding brain tissue. Improved 
understanding of the molecular mechanisms underpinning cell migration and 
invasion have resulted in the development of biologically targeted anti-
invasive therapies. This next section will review such approaches for the 
management of both adult and paediatric HGG. 
 
1.4.1 Integrin targeting  
 
Cilengitide is a peptidomimetic designed to function as a selective antagonist 
of ανβ3 and ανβ5 integrins (141,142) and is thought to play a role in 
disrupting angiogenesis, invasion and tumour cell growth (142). Pre-clinical 
in vitro and in vivo studies have demonstrated that cilengitide has anti-
glioma activity, both alone (143,144) and in combination with temozolomide 
and radiotherapy (145,146). Phase I/II clinical trials of cilengitide for adult 
HGG, both as a single agent or in combination with 
temozolomide/radiotherapy, have shown modest proof of concept anti-
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tumour activity, with preferential benefit for patients with O(6)-
methylguanine-DNA methyltransferase (MGMT)-methylated tumours 
(142,147-153). However, rather disappointingly, a phase III randomised 
study of cilengtide combined with temozolomide chemoradiotherapy in adult 
patients with a new diagnosis of MGMT promoter-positive glioblastoma 
(CENTRIC European Organisation for Research and Treatment of Cancer 
(EORTC) study), failed to reach its primary end point, showing no difference 
in survival with the addition of cilengitide to temozolomide/radiotherapy in 
this patient cohort (154). Single agent cilengitide has been evaluated 
separately for paediatric patients with refractory HGG in a phase II study but, 
again, demonstrated no treatment effect. Despite the negative results 
observed in trials of cilengitide therapy, there may still be a role for other 
integrin antagonists as a treatment for HGG and further pre-clinical research 
is required (82).  
 
1.4.2 FAK/Src inhibition 
 
The FAK/Src tyrosine kinase signalling network plays a critical role in 
regulating cell migration (71). FAK is activated by integrins to recruit Src 
signalling proteins that are involved in the regulation of actin and focal 
adhesions to promote cell migration (71). Expression of FAK is elevated in 
glioma and has been shown to promote migration and infiltration (155,156). 
Liu et al. have shown that a novel dual tyrosine kinase inhibitor, TAE226, 
capable of inhibiting FAK and insulin-like growth factor 1 receptor (IGF-1R), 
reduced invasion of glioma cells by at least 50 % compared to controls in an 
in vitro matrigel invasion assay and significantly increased survival in an 
intracranial xenograft model, highlighting its clinical potential (157). Src 
family kinase-specific pharmacological inhibitors have also been developed 
and have been shown to inhibit invasion of adult glioma cells in vitro (158). 
Dasatinib is a potent Src inhibitor and has been evaluated clinically for use in 
several solid tumours (159). Currently, there is interest in developing 
dasatinib in early phase trials for adult glioma and paediatric DIPG (160-
164). Dasatinib has been shown to reduce proliferation and invasion of DIPG 
cell lines (164). Interestingly, dasatinib has been shown to block 
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bevacizumab-induced glioma invasion, highlighting the potential for 
evaluation of combination anti-invasion and anti-angiogenesis therapy (165).    
1.4.3 Protease inhibitors 
 
Proteases are capable of degrading the ECM, thus creating a path allowing 
cancer cells to migrate. MMPs can be inhibited either by the overexpression 
of their tissue inhibitors or by the use of synthetic MMP inhibitors (MPIs). 
MPIs have been shown to reduce glioma invasion in two-dimensional (2D) 
and three-dimensional (3D) in vitro models. The MPI AG3340 promoted 
survival and profoundly inhibited glioma growth and invasion in treated mice 
compared to controls (166,167) and the MPIs marimastat and barmistat 
have also been shown to block glioma invasion in 3D in vitro culture systems  
(166). Disappointingly, the overall results of clinical trials of MPIs have not 
shown therapeutic benefits in a range of human cancers (including glioma) 
and have been associated with unacceptable toxicity in patients (168-170). 
Marimastat failed to improve survival in a phase III randomised, double-
blind, placebo-controlled trial in patients with glioblastoma who had 
undergone surgery and radiotherapy (170). Pre-clinical studies have also 
focused on evaluating inhibition of the cysteine protease, cathepsin B and 
the serine proteases, uPA and its receptor, uPAR. In vitro studies have 
demonstrated that blockade or reduction in expression of these proteases 
can inhibit HGG cell adhesion, invasion and migration, suggesting their 
potential for clinical evaluation (115,171-174).  
 
1.4.4 Cytoskeleton targeting  
 
It is unsurprising that many cancer chemotherapies have been developed to 
target elements of the cell cytoskeleton. Microtubule targeting agents play a 
key role in the treatment of many solid tumours, including CNS malignancies 
and mainly act by deregulating microtubule dynamics, which results in 
mitotic arrest (175). Microtubule-targeting drugs can act either as 
destabilising agents (such as vinca alkaloids and colchicine-site binders), 
which inhibit microtubule polymerisation or can be classified as stabilising 
agents (for example, taxol and docetaxel), capable of enhancing microtubule 
polymerisation (175). Alongside their effects on mitosis and cell proliferation, 
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both destabilising agents and stabilising agents are able to reduce glioma 
cell invasion in an in vitro system (176,177).  Most of the microtubule-
targeting drugs available on the market act by binding to different sites on 
tubulin molecules (175). Newer agents are under development for different 
targets, including motor proteins (for example, AZD4877 is currently under 
development due to its role as a potent inhibitor of the mitotic spindle 
kinesin, Eg5) (178-180), MAPs such as the tau protein (181) or mitotic 
centromere-associated proteins (175,182).   
 
Other approaches targeting the cytoskeleton have been evaluated. Small 
molecule inhibitors that target actin dynamics, such as cytochalasin, 
phalloidin and jasplakinolide have been assessed in vitro and demonstrate 
anti-migratory activity (183-185). Myosin II is a molecular motor that 
facilitates glioma invasion by generating the compressive force to squeeze 
cells through small intercellular spaces and pre-clinical 3D tissue models of 
invasion have shown that myosin II inhibition can block glioma invasion 
(186). Despite such clinical potential, it must be taken into account that actin 
and myosin are critical to normal cell motility and intracellular transportation 
and, thus, targeting these key molecules in humans could be associated with 
unreasonable toxicity (186). For this reason, small molecule actin/myosin 
inhibitors have not undergone translation for cancer treatments (184,186).   
Finally, research has also focused on targeting upstream proteins involved in 
cytoskeleton signalling pathways (184). Rho family small GTPases are 
signalling molecules that play a role in multiple cellular pathways controlling 
cell proliferation, survival and invasion (187). Ras homology growth-related 
(RhoG) is overexpressed in human glioblastoma tissue and appears to 
mediate glioblastoma cell invasion (187). Small interfering ribonucleic acid 
(siRNA) depletion of RhoG has been shown to reduce glioblastoma cell 
invasion in an ex vivo brain slice assay (187).  Unlike actin/myosin, RhoG 
appears to play a restricted role in normal cells (187,188) and, therefore, 
drugs developed to specifically inhibit RhoG may have a role as an effective 




1.4.5 Targeting EMT 
 
During the process of EMT, cancer cells develop a more invasive phenotype 
and are able to disseminate to distant metastatic sites (66). Targeting this 
process could have a significant impact on patient outcome, as localised 
organ-contained tumours are associated with improved prognosis and are 
more amenable to different modes of cancer treatment, including surgery 
and radiotherapy (189). EMT may be pharmacologically targeted using one 
of four strategies (189). The first approach entails blocking signals from the 
tumour microenvironment that facilitate the onset of EMT. This involves 
blocking cytokine or growth factor signalling pathways (for example, TGF or 
EGF induction of EMT) or using small molecules to block cell surface 
receptors activated by such signals (189). A second approach is to block 
intracellular signal transduction pathways that induce EMT. This could 
involve molecular targeting of transcription factors such as Snail, Slug, Zeb 
and Twist, critical to EMT induction, or blocking of other upstream signal 
transducers (189). Thirdly, selective pharmacological targeting of cancer 
cells expressing mesenchymal marker proteins such as vimentin or neural-
Cadherin (N-Cadherin) could reduce the presence of cancer cells 
possessing an invasive phenotype (189-191). Finally, formation of metastatic 
colonies may be preventable by blocking MET and blocking growth factors, 
such as fibroblast growth factor receptor isoform FGFR2IIIc, which conveys 
an epithelial phenotype on cancer cells, may be a therapeutic strategy to 
prevent MET (189,192). Although these different approaches are currently 
being investigated in several cancer models, including glioma, successful 
clinical translation will involve consideration of a personalised stage-specific 
approach. For example, targeting of EMT induction will have a limited role in 
patients with advanced metastatic disease (189). Additionally, EMT-targeted 
therapies must be evaluated with caution, as the delivery of therapies 
inhibiting the mesenchymal state could also enhance the speed of 




1.5 GSK-3 inhibition 
 
1.5.1 GSK-3:  structure and activity 
 
GSK-3 is a serine/threonine protein kinase with two main isoforms: GSK-3α 
and GSK-3β (193).  A third splice variant of GSK-3β (GSK-3β2) has recently 
been identified (194). GSK-3α and GSK-3β are encoded by two distinct 
genes, mapped at 19q13.2 (GSK-3α) and 3q13.3 (GSK-3β) (195). Both 
isoforms share approximately 85 % identity, 98 % of which is in the catalytic 
domain (196).  Despite such similarity, both isoforms appear to play different 
roles within the cell. For example, GSK-3β knock-out mice are non-viable, 
with late embryonic toxicity attributed to liver degeneration (197), whereas 
GSK-3α knock-out mice are viable but have metabolic and neuro-
developmental sequelae (198,199). GSK-3 was originally noted to have an 
important role in glycogen metabolism; however, it is now clear that GSK-3 
isoforms are involved in multiple cellular signalling pathways and play a part 
in orchestrating cell division, cell death, cell survival, DNA damage 
response, cell migration, neuronal development and neuronal functioning 
(196). Given such diversity in function, it is unsurprising that GSK-3 is 
implicated in the pathogenesis of several diseases, including cancer, 
metabolic disorders (diabetes, heart disease) neurological disorders 
(Alzheimer’s, Parkinson’s) immune dysfunction and psychiatric disease 
(193,195,196,200,201). 
 
The GSK-3 family of kinases are able to phosphorylate over 40 proteins and 
12 transcription factors (201). Both GSK-3α and GSK-3β preferentially 
phosphorylate substrates that have already been ‘primed’ by 
phosphorylation following activity of other kinases (201). Activity of GSK-3 
itself is controlled by post-translational phosphorylation. Phosphorylation of 
GSK-3β at serine nine (Ser9) is inhibitory and at tyrosine 216 (Tyr216) is 
activating (196). For GSK-3α, phosphorylation of serine 21 (Ser21) is 
inhibitory and tyrosine 279 (Tyr279) is activating (196). When GSK-3β is 
phosphorylated at Ser9, this acts as a pseudosubstrate, preventing other 
substrates entering the kinase catalytic site. Conversely, when Tyr216 
 21 
remains unphosphorylated, this blocks entry to the catalytic site, a process 
which is reversed by Tyr216 phosphorylation (196). GSK-3β activity is also 
modulated by its interaction with other proteins in complex formations (202). 
Axin and presenilin are examples of such proteins and play a role in 
controlling the specific function of GSK-3β within the cell.  
 
1.5.2 GSK-3 in tumourigenesis  
 
The role of GSK-3 in cancer development is unclear and it may be that there 
is a fine balance between GSK-3 acting as a tumour suppressor or a tumour 
promoter (201). Increased GSK-3β levels have been observed in ovarian, 
thyroid, colon, liver, glioma and pancreatic cancers; however, non-
melanoma skin cancers are associated with reduced GSK-3β expression 
(195,203-207). One well-described role for GSK-3 in inhibiting cancer 
development is its involvement as a regulator in Wnt/β-catenin signalling. 
When Wnt signals are absent, β-catenin forms a complex with axin, APC 
and GSK-3. Active GSK-3 phosphorylates β-catenin, which targets β-catenin 
for ubiquitylation and proteolytic destruction. In the presence of Wnt signals, 
GSK-3 is inactivated and, thus, β-catenin accumulates, moves to the 
nucleus and increases transcription of proto-oncogenes, such as c-MYC and 
cyclin-D1, as well as genes involved in cell migration and invasion, such as 
MMP7 (195). The fact that GSK-3 can suppress the Wnt/β-catenin pathway 
and reduce β-catenin, suggests that GSK-3 may have a role as a tumour 
suppressor (201).  Additional evidence supporting the role of GSK-3 as a 
tumour suppressor includes the ability of GSK-3β to promote p53-induced 
apoptosis (195,208,209) and the observation that GSK-3 inhibition promotes 
EMT and cell invasion (201,210).   
 
GSK-3 may also function to promote tumourigenesis. GSK-3β knockdown in 
pancreatic cancer cell lines arrested proliferation, increased apoptosis and 
significantly decreased vascular endothelial growth factor (VEGF) (211). 
When modelled in vivo, the authors showed that GSK-3β knockdown 
inhibited tumour growth and angiogenesis, highlighting the possible role of 
GSK-3β in tumour development and the potential therapeutic benefits of 
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GSK-3β inhibitors (211). GSK-3β has also been shown to promote ovarian 
cancer proliferation both in vitro and in vivo (212). Hence, the role of GSK-3 
as a tumour promoter or suppressor appears to be cancer-type-dependent. 
 
1.5.3 The role of GSK-3 in cell migration 
 
GSK-3 has a multi-faceted role in controlling cell migration and can influence 
the dynamics of the actin cytoskeleton, microtubule remodelling and cell-
ECM adhesions (213). The Rho family of GTPases (including Rho, Rac and 
adenosine diphosphate ribosylation factor 6; Arf6) regulate actin 
cytoskeleton organisation and dynamics and contribute to lamellipodia 
formation at the front of the cell (213,214). GSK-3 appears to inhibit p190 
Rho GTPase-activating proteins (RhoGAP) which, in turn, can activate Rho 
in fibroblasts, triggering downstream effectors that result in actin 
polymerisation (213,215). Additionally, GSK-3 can function as an upstream 
regulator of Rac and Arf6, again promoting actin polymerisation and 
lamellipodia formation in the migrating cell (213,216,217). As described in 
section 1.3.4, GSK-3 also plays a role in determination of cell polarity. The 
localised inactivation of GSK-3 results in APC clustering at the plus end of 
microtubules at the leading edge of cells, controlling the direction of 
movement (110). GSK-3 can also influence MAPs, MAMs and proteins of 
the MTOC (213). For example, GSK-3 phosphorylation can facilitate the 
release of intracellular cargo from kinesin motors in neurons (213,218). The 
MAP CLASP can act to stabilise microtubules and GSK-3 may indirectly 
target CLASP by affecting association with intermediate binding proteins in 
order to inhibit microtubule stabilisation (213,219,220).  Paxillin is a docking 
protein that plays a key role in focal adhesions by recruiting signalling 
molecules into the complex (221).  Phosphorylation of paxillin appears to be 
mediated in part by GSK-3 and plays an important role in formation of 
adhesions, cell spreading and cytoskeletal rearrangement (213,222). Finally, 
GSK-3 has been shown to inhibit FAK catalytic activity and this control of 
FAK activity is critical for adhesion dynamics during cell spreading and 




1.5.4 GSK-3 inhibitors  
 
It is unsurprising that there is substantial interest in developing 
pharmacological inhibitors of GSK-3. As highlighted above, GSK-3 has a 
broad range of substrates and plays a role in the pathogenesis of a wide 
range of diseases. To date, more than 50 GSK-3 inhibitors have been 
described (201). GSK-3 inhibitors act by either: i) competing with adenosine 
triphosphate (ATP) or metal-binding sites (i.e. magnesium) essential for 
catalytic reactions; ii) modulating the inhibitory or activating phosphorylation 
sites of the kinase; or iii) inhibiting the formation of protein complexes that 
are critical for binding substrates (196).  
 
Lithium was one of the first GSK-3 inhibitors to be described and is a non-
specific inhibitor of GSK-3 (IC50 ~2 mM), acting both directly (as a 
competitive inhibitor of Mg2+) and indirectly (by increasing the inhibitory 
phosphorylation of GSK-3) (224). Lithium is also able to target inositol 
monophosphatase (IMPase), phosphomonoesterases, phosphoglucomutase 
and the arrestin-2/Akt complex (225). Despite such a wide range of targets, 
there is evidence to demonstrate that lithium effectively targets GSK-3, as 
lithium increases intracellular β-catenin levels, activates glycogen synthase 
and reduces the phosphorylation of tau in neurons (225-228). There is a 
wealth of clinical experience of using lithium as a mood stabilising agent for 
the treatment of bipolar disease; however, more recently, lithium has been 
evaluated in patients with neurodegenerative diseases, such as Alzheimer’s 
disease and motor neuron disease (226,229-231), as well as patients with 
cancer (232-234). It is well documented that lithium has a narrow therapeutic 
index, with safe effective therapy achieved at concentrations between 0.5-
1.5 mM (226). Above 1.5 mM, lithium is often toxic in vivo, mainly secondary 
to nephrotoxicity (226,235,236).   
 
Indirubins are bis-indole isomers of indigo, collected from natural sources, 
including plants, molluscs, bacteria and mammalian urine (237). Indirubins 
have been identified as the active ingredient of the Chinese medicine 
Danggui Longhui Wan, which has been shown in clinical trials to have anti-
 24 
leukaemic activity (238-240). In 2001, Leclerc et al. showed that indirubins 
are powerful inhibitors of GSK-3 (IC50 5-50 nM) and cyclin-dependent 
kinases (IC50 50-100 nM) (241), rendering them promising anti-cancer 
agents. 6-bromoindirubin-oxime (BIO) is an indirubin derivative that has 
been shown to be a selective inhibitor of GSK-3β both in vitro and in vivo 
and can activate Wnt signalling, thus stabilising β-catenin (242,243).  There 
has been interest in the pharmacological development of indirubins, in 
particular for Alzheimer’s disease, as inhibition of GSK-3 may be able to 
prevent the hyperphosphorylation of tau proteins, which are pathological for 
the disease (243,244). Investigation of indirubins for cancer treatment is 
mainly in the pre-clinical phase (245,246).  
 
In the last decade, novel GSK-3 inhibitors have been developed and are 
beginning to make their way into the clinic (196,226). One such example is 
AZD1080, an orally bioavailable brain-permeable selective GSK-3 inhibitor, 
that has been used in a phase-I study of healthy volunteers to determine its 
pharmacologic profile (247). This trial demonstrated that AZD1080 could 
target GSK-3 activity in humans, as prolonged suppression of glycogen 
synthase activity was recorded in blood cells (247).  Although there is 
concern that GSK-3 inhibitors may be tumourigenic through their ability to 
increase β-catenin levels and transcription of proto-oncogenes, current 
evidence suggests otherwise (195). Mice treated with GSK-3 inhibitors do 
not appear to have increased incidence of cancers (201) and patients who 
received lithium therapy for treatment of mental illness do not have elevated 
prevalence of cancer (248). Finally, Gould et al. have shown that mice 
predisposed to cancer development by the activation of Wnt signalling 
pathways do not demonstrate a significant increase in the number of 
tumours developed when treated with 60 days of lithium therapy (249). 
Despite such encouraging observations, this concern should be addressed 
for each GSK-3 inhibitor undergoing clinical development (196).  
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1.5.5 Potential of GSK-3 inhibitors in the treatment of glioma  
Studies have demonstrated that GSK-3 plays a central pathological role in 
the development and maintenance of HGG. Miyashita et al. found higher 
expression of GSK-3β and phosphorylated GSK-3βy216 (active form) in adult 
glioblastoma, compared to non-neoplastic brain tissue (207). The authors 
also showed that inhibition of GSK-3β with the inhibitor AR-A014418 
suppressed the viability and proliferation of glioma cells and induced 
apoptosis by activating retinoblastoma (Rb)-mediated pathways (207). 
Interestingly, AR-A014418 significantly sensitised glioma cells to 
chemotherapy and radiotherapy (207). Aguilar-Morante et al. also showed 
that the GSK-3β inhibitor, TDZD-8, induced apoptosis and decreased 
proliferation of mouse glioma cells in vitro and significantly improved survival 
in an orthotopic mouse model (250). Kotliarova et al. have also 
demonstrated that GSK-3 inhibition can arrest cell proliferation and induce 
both intrinsic and extrinsic apoptosis pathways in glioma, which may be 
mediated by c-MYC (251). In this study, GSK-3 inhibition was also able to 
inhibit pro-survival signals by causing a reduction in intracellular nuclear 
factor-kappa B (NF-κB) activity (251).  
Work by Nowicki et al. demonstrated the effects of GSK-3 inhibition on adult 
glioma migration and invasion. The authors showed that inhibition of GSK-3 
with lithium blocked invasion of adult glioma cells in spheroid, wound-healing 
and brain slice assays (236). Subsequent studies also showed that 
indirubins (including BIO) reduced invasion of adult glioma cells in vitro and 
in vivo and improved survival in a mouse intracranial xenograft model. 
Furthermore, indirubins were also able to block migration of blood vessel 
endothelial cells and reduce angiogenesis in tumour models (246).  
 
1.5.6 Summary  
 
Invasiveness is a key feature of HGG cells and significantly contributes to 
the dismal prognosis for this disease. Compared to the adult disease, very 
little is known about the migratory and invasive characteristics of pHGG cells 
and the effects of GSK-3 inhibitors on paediatric gliomas are unknown. 
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Although the efficacy of a number of anti-invasive therapeutics for adult and 
paediatric glioma have been demonstrated in pre-clinical and limited clinical 
studies, further work is needed to develop novel anti-invasive therapeutic 
approaches that work in synergy with chemotherapeutics and target the 
numerous biological pathways involved in glioma pathogenesis.  
 




Oncolytic virotherapy, which uses viruses to selectively infect and destroy 
cancer cells (252), offers a novel treatment approach for poor prognosis 
paediatric CNS tumours, including pHGG and DIPG. While there is 
extensive literature on oncolytic virotherapy for adult brain malignancies 
such as glioblastoma, work on paediatric CNS tumours is only just beginning 
to gather momentum. This section of the introduction will summarise the 
biological characteristics of several oncolytic viruses (OVs) that have the 
potential for development as anti-cancer agents for poor prognosis children’s 
brain tumours and will evaluate the pre-clinical and clinical evidence for the 
use of oncolytic virotherapy for HGGs.  
 
1.6.2 Oncolytic viruses as anti-cancer agents: direct and immune 
mediated mechanisms of cancer cell death 
 
 
OVs selectively infect and lyse cancer cells, while sparing normal tissue 
(252,253). Once a virus has entered a cell, it aims to take advantage of 
cellular resources in order to replicate and synthesise new viruses (252). To 
allow sufficient time to adequately replicate, viruses inhibit cellular death 
pathways, ensuring that cell death can only occur once all valuable cellular 
resources have been maximally exploited (252).  Cells have evolved to have 
mechanisms in place in order to limit viral replication and infection. In normal 
cells, detection of viral infection via the identification of viral pathogen-
associated molecular patterns (PAMPs), including viral capsids, DNA, 
ribonucleic acid (RNA) and protein products, initiates signals promoting the 
production of pro-inflammatory cytokines, including type-I interferons (IFN) 
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(254). These activate downstream anti-viral signalling pathways, including 
upregulation of protein kinase R (PKR), a cell cycle regulator that is capable 
of inhibiting cell protein synthesis and initiating apoptosis (254-256). 
Together, this intracellular anti-virus response promotes the death of virus-
infected cells, preventing further virus replication (254). Cancer cells are 
more susceptible to killing by viruses (254). IFN signalling and PKR activity 
may be downregulated, hence limiting viral clearance through the 
suppression of protein synthesis and induction of apoptosis (254). Thus, 
within cancer cells, OVs are able to make use of abnormal signalling 
pathways in order to block apoptosis, allowing more time for successful virus 
replication (254). Following successful replication, OVs induce host cell 
death and this may be achieved by one of several mechanisms, including 
apoptosis, necrosis, pyroptosis and autophagy (252,254).   
 
There has recently been a shift in the oncolytic virotherapy paradigm to 
suggest that OVs may also generate tumour cell killing through the induction 
of potent innate and adaptive anti-tumour immune responses (257,258). 
Following infection with an OV, cancer cells respond by releasing cytokines 
(in particular type-I IFN), PAMPs, danger-associated molecular pattern 
signals (DAMPs) (including heat shock proteins, calreticulin, ATP, uric acid 
and high mobility group box 1 protein (HMGB-1)) and reactive oxygen 
species (ROS) (254). DAMPs, PAMPs and type-I IFN can generate the 
innate immune response, through recruitment of natural killer (NK) cells, 
which can kill virus-infected tumour cells (253,254). ROS, cytokines, PAMPS 
and DAMPs may also activate antigen-presenting cells (APCs), which take 
up and present viral- and tumour-associated antigens (TAAs) released from 
infected cancer cells (254). APCs present viral antigens and TAAs to CD8+ T 
cells and CD4+ T helper cells. The CD8+ T cells can then mature into 
cytotoxic effector cells and accumulate at sites of tumour growth, killing 
cancer cells upon antigen recognition, as part of an adaptive anti-tumour 
immune response (253,254). 
 
Tumours have evolved multiple strategies in order to avoid immune system 
detection and subsequent destruction by T cell-mediated attack (259).  
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Tumour-derived soluble mediators and cytokines can disrupt the function of 
dendritic cells (DCs), which play a key role in tumour antigen presentation to 
B and T cells (259-264). Altered activity of tumour-expressed chemokines 
can suppress T cell movement and recruitment into tumours (259,265,266). 
Immunosuppressive leukocyte populations such as regulatory T cells (T-
regs) and myeloid-derived suppressor cells (MDSCs) are recruited and 
expanded within cancers (259,267,268). Furthermore, the tumour 
microenvironment is rich with soluble mediators, such as TGF-β, interleukin 
(IL)-10, prostaglandin E2, histamine, hydrogen peroxide and adenosine 
which can inhibit cytotoxic T cell function and, finally, tumours express 
surface proteins such as programmed cell death ligand (PD-L)-1 and PD-L2 
which can further suppress T cell function (259,269,270).  
 
OVs can be exploited for their ability to enhance the immunogenicity of the 
tumour microenvironment (253). OV-induced cancer cell death enhances the 
availability of TAAs for uptake by DCs (253). This is achieved in the context 
of danger signals, such as inflammatory cytokines, DAMPs and PAMPs 
released by cancer cells following OV infection (253,254). In consequence, 
DC activation is enhanced, increasing tumour antigen presentation in an 
appropriate costimulatory context to the adaptive immune system (253). 
This, in turn, increases the activation of cytotoxic CD8+ T cells, enhancing 
the anti-tumour immune response (253,259). Additionally, OVs are capable 
of altering the balance of cytokine production within tumours, which can 
enhance T cell responses and inhibit tumour-derived immunosuppressive 
properties (253). For example, reovirus treatment has been shown to reduce 
tumour secretion of the immunosuppressive cytokine IL-10 (253). Reovirus 
treatment can also increase IL-8 and RANTES secretion, both of which are 
involved in DC, monocyte and neutrophil recruitment to tumours, as well as 
IL-6, which acts to inhibit the immunosuppressive function of T-regs (253). 
Finally, IFN-γ is a critical anti-viral mediator secreted by CD4+, CD8+ and NK 
cells and is central to the elimination of viruses by the immune system 
(271,272). Alongside its ability to traffic specific immune cells to sites of 
inflammation, enhance NK cell activity and stimulate macrophages, IFN-γ 
can also upregulate cell surface expression of class I major 
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histocompatibility complex (MHC) in response to intracellular viral infection 
(271). This increases the potential for cytotoxic T cell recognition of foreign 
viral peptides and subsequent destruction of virus-infected cells (271). In the 
context of oncolytic virotherapy, this upregulation of MHC class I on virus- 
infected cancer cells promotes the induction of cell-mediated immunity which 
results in tumour cell killing.  
 
1.6.3 Oncolytic virus selectivity and replication  
 
 
Viruses have specific cellular tropisms that determine the tissues that they 
will naturally selectively infect (252). It has been observed that many wild-
type viruses are able to preferentially infect cancer cells over normal cells 
and this may be secondary to aberrations in cancer cell signalling, surface 
molecules and stress responses that viruses are able to exploit to gain cell 
entry (66,254). There are several well-described mechanisms that OVs can 
employ in order to selectively target tumour cells (273). These may be 
achieved naturally or through viral engineering. DNA viruses (excluding 
poxviruses) and retroviruses can be made tumour selective by inserting 
tumour specific promoters into their genome that regulate the expression of 
certain genes that are essential for virus replication (273). Translational 
targeting may also be employed, which takes advantage of defective IFN 
signalling in cancer cells (273). Viruses can be modified to disable proteins 
that suppress IFN signalling so that in normal host cells, replication is 
aborted (273). When such a modified virus enters a cancer host cell with 
defective IFN signalling, IFN-mediated translational shutdown is prevented 
and the viral infection progresses (273). Viruses can also be modified to 
disable proteins that prevent apoptosis, hindering their replication in normal 
cells. However, when such virus enters a cancer cell, which may naturally 
possess mutations preventing its ability to undergo apoptosis, the virus can 
replicate and, again, infection progresses (273). Finally, viruses may gain 
entry into cancer cells by targeting cell surface receptors expressed either 
more abundantly or exclusively by cancer cells (254,273). Some OVs may 
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have a natural tropism for such receptors; however, viruses can also be 
engineered in order to target receptors specific to cancer cells (254).  
 
1.6.4 Virus structure and replication cycle 
 
Viruses are made up of two basic components. An inner core of nucleic acid 
is surrounded by an outer protein capsid, which functions to protect the 
genome from digestion by nucleases and plays a role in attachment of the 
virus to host cells (274). Some viruses may have an additional layer of 
cover, called an envelope, which consists of a lipid bilayer interjected by 
glycosylated proteins (274).  A fully assembled infectious virus is referred to 
as a virion (274). Viruses can undergo a replication cycle.  The virion must 
first attach to a target cell receptor via proteins on its outer surface; an 
enveloped virus enters the cell via fusion at the plasma membrane, whereas 
a non-enveloped virus will enter by physical permeation of the host 
membrane and particle translocation (273,275). Once the virus has entered 
the cell, it is uncoated to reveal its genome, which then must be replicated 
and transcribed (273,275). Genome replication may occur in the cytoplasm 
or nucleus of the host cell and the location is specific for each individual 
virus (273). The virus can then express and translate genes encoding either 
non-structural (expressed early) or structural proteins (expressed late). Non-
structural proteins serve to amplify the viral genome, overcome cell death 
mechanisms to allow time for viral replication and enhance the expression of 
structural proteins required for virus re-assembly (273). Replicated viral 
genomes are then packaged in capsids and progeny virus exit the cell via 
routing pathways, ready to infect and replicate in neighbouring cells 
(273,275).  
 
The following section highlights the individual structure, biology and 
mechanism of cancer cell tropism for three OVs: herpes simplex virus 
(HSV), vaccinia virus (VV) and reovirus, which were the subjects of 
investigation in this research project.  
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1.6.5 Herpes simplex virus 
 
HSV-1 is a member of the alphaherpesvirus subfamily of herpesvirus (276). 
The virus consists of an inner core of double-stranded DNA (152 kb), 
encoding approximately 74 genes (276,277). The HSV-1 genome is 
protected by an icosahedral capsid, which is surrounded by a tegument 
composed of viral proteins (276,278). Finally, an outer envelope of 
glycoproteins, that play a critical role in regulating HSV-1 entry into host 
cells, completes the virus structure (276). In order to replicate, HSV-1 must 
bind to entry receptors on the host cell via glycoproteins; although seven 
glycoproteins are implicated in this process, only glycoprotein D, B, H and L 
are critical for function (276). Host cell receptors for HSV entry include 
nectin-1/nectin-2 and herpesvirus entry mediator (HVEM) (276).  Once 
bound, the virion can gain entry into the host cells by either pH-independent 
fusion with the host plasma membrane or by endocytosis (276). Subsequent 
DNA synthesis and nucleocapsid assembly occur in the host cell nucleus, 
causing it to re-organise and increase in size, whereas virion processing and 
maturation occur in the cytoplasm (278). The virus DNA does not integrate 
into the host cell DNA (279). Following viral replication, host cells die as viral 
particles lyse the cell in order to spread to infect neighbouring cells (279).      
 
Approximately 30 kb of the HSV-1 genome codes for non-essential genes 
and this property can be exploited for the purpose of oncolytic virotherapy, 
as these genes can be deleted and/or replaced to reduce pathogenesis and 
enhance selective tumour infection (254,279). One such example is the 
oncolytic HSV1716 (SEPREHVIR), modified to contain a deletion of the 
infected cell protein (ICP) 34.5 neurovirulence gene, which is critical for 
HSV-1 infection of neurons and plays a role in antagonising the type-I 
IFN/PKR protective response (254,279). Overall, deletion of ICP34.5 
enhances cancer cell selectivity and improves safety by preventing virus 
infection of neurons (254,279). A range of oncolytic HSV strains have been 
engineered to enhance selectivity and reduce virulence of HSV-1 (280-284). 
Additionally, oncolytic HSVs have been modified to contain genes such as 
granulocyte macrophage colony stimulating factor (GM-CSF) that act to 
enhance systemic anti-tumour immune responses (254,280). Talimogene 
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laherparepvec (ICP34.5 deletion, US11 deletion, GM-CSF insertion) is one 
such example, which has recently been approved by the United States Food 
and Drug Administration (285) and has been shown to have therapeutic 
benefit against melanoma in a phase III trial (280).   
 
1.6.6 Vaccinia virus 
 
VV is a member of the poxvirus family and characteristically has large ovoid 
or brick shape virions (286). Like HSV-1, it is a double-stranded DNA virus 
(approximately 190 kb) and is able to host large transgene insertions 
(254,287). Vaccinia forms two distinct infectious virion particles. The first, 
entitled intracellular mature virus (IMV), is surrounded by a single membrane 
and remains inside a cell until cell lysis (286). The second consists of an IMV 
surrounded by an additional cell membrane and exits the cell prior to cell 
death (286). On exit, if this virion is maintained on the cell surface, it is 
referred to as a cell-associated enveloped virus (CEV) (286). Following 
release from the cell surface, it is termed an extracellular enveloped virus 
(EEV) (286). IMVs and EEVs play different roles in the viral life cycle and are 
functionally, structurally and antigenically different. For replication, VV sheds 
its membrane in order to release naked viral core/genome into the host cell 
cytoplasm (286). IMVs and EEVs achieve this in different ways. For IMVs, 
the outer membrane may fuse with the host cell plasma membrane, allowing 
deposition of the viral core (286). Alternatively, IMVs enter the cell via 
macropinocytosis (a form of endocytosis accompanied by cell surface 
ruffling (288)), allowing the formation of a vesicle containing the IMV. The 
IMV membrane then fuses with the membrane of the vesicle, dispelling the 
naked core into the cytoplasm (286). Once in the cytoplasm, the naked core 
is transported on microtubules to the perinuclear regions of the cell, where 
they are uncoated to allow viral DNA transcription and replication (286). 
Progeny virions are then assembled as IMVs within virus factories in the 
cytoplasm (286). Some IMVs are wrapped by a double membrane and 
transported to the cell surface, where they fuse with the host plasma 
membrane and reside as CEVs (286). These may be disseminated as EEVs 
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or they may develop a polymerised actin tail that propels them to 
neighbouring cells, encouraging local virus spread (286).    
 
VV replication appears to be dependent on activated EGFR/Ras pathway 
signalling in the host cell (289). This may explain why VV has a natural 
tropism to cancer cells, which are known to possess upregulated Ras 
signalling (254). Although VV is naturally selective of cancer cells, the virus 
has been attenuated for safety by disrupting the thymidine kinase (tk) gene, 
which expresses an enzyme essential for viral DNA synthesis (254,278,289). 
The oncolytic VV JX-594 also expresses GM-CSF under the control of a 
synthetic promoter; GM-CSF is an immunostimulatory cytokine which is able 
to enhance tumour kill via activation of the immune system (289). Another 
clinical VV, GL-ONC1, is a replication competent OV that has been 
engineered to contain disrupted tk, F14.5L and haemagglutin genes, 
conferring tumour selectivity and limiting virulence in normal tissue (290-
292). Haemagglutin is a glycoprotein that plays a key role in binding to host 
cell receptors to initiate virus infection (293). The F14.5L gene encodes an 
intracellular mature virus envelope protein that mediates cell adhesion and 




Reovirus is a member of the Reoviridae family (295). The reovirus genome 
consists of ten segments of double-stranded RNA (23 kb), enclosed by two 
concentric icosahedral protein capsids, which are non-enveloped (254,295). 
In order to gain entry into host cells, reovirus attaches via interactions with 
cell surface glycans and junctional adhesion molecule A (JAM-A) (296,297). 
β-1 integrin mediates internalisation of the virus via endocytosis, 
subsequently activating Src kinases (296,298,299). The virus then localises 
and traverses through endosomes, where it is partially uncoated and 
disassembled by cysteine cathepsin proteases resulting in the formation of 
infectious subvirion particles (ISVPs) (296). ISVPs then penetrate the 
endosome membrane, releasing the transcriptionally active viral core into 
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the cytoplasm, where proteins are translated and new capsids are formed, 
prior to virion release (296).    
 
Three reovirus serotypes have been isolated but it is the reovirus type 3 
dearing strain that exhibits a natural preference for cancer cells, as it 
replicates in cells with activated Ras signalling (252,287). In the normal 
host cell, reovirus activates PKR, which, in turn, inhibits translation of viral 
proteins, preventing viral replication and spread (254,300). In the Ras-
activated cancer cell, PKR is kept in an inactive state, allowing viral 
translation, replication and oncolysis to take place (254,300). The 
specificity of reovirus type 3 dearing strain for Ras-transformed cells, 
coupled with its relatively non-pathogenic nature in human subjects (301), 
makes it an attractive anti-cancer agent to develop. Wild type reovirus type 
3 dearing strain has been developed and evaluated clinically in adults and 
children under the trade name of Reolysin® (302-307). 
 
1.6.8 The effects of oncolytic viruses on cell migration 
 
Very little is known about the effects of OVs on cancer cell invasion and 
migration. However, what is clear from the literature is that once a virus 
enters a host cell, the host cell’s cytoskeleton plays a critical role in 
regulating the virus life cycle (308). Viruses rely on the host cell cytoskeleton 
for efficient transportation of capsids to the nucleus or sites of replication in 
the cytoplasm (308,309). Microtubules appear to form networks, which are 
critical for propelling and transporting viruses encased within vesicles, 
organelles or cytosolic complexes within the cell. Actin is essential to control 
the direction of such movements and also facilitates virus entry and egress 
from cells (308-310). Viruses, such as wild-type HSV, are able to stabilise 
host cell microtubules through the induction of post-translational tubulin 
modifications. This process may be critical for viral replication by creating a 
direct transport network for the virus to reach critical locations in the cell 
throughout its life cycle (311). Hence, an OV may be able to influence 
tumour cell migration, through interplay with the host cancer cell 
cytoskeleton. Consistent with this hypothesis, Abdullah et al. report that 
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Newcastle disease virus (NDV)-infected glioma cells have repressed motility 
when observed by live cell imaging (312).  
 
It is also possible that viruses, such as HSV, may be able to influence the 
migration of immune cells. Pretchel et al. demonstrated that HSV is able to 
reduce the migration of DCs using a transwell assay with a chemokine 
gradient. The authors showed that HSV downregulates surface expression 
of the migration-mediating surface molecules chemokine (C-C motif) 
receptor (CCR)-7 and chemokine (C-X-C motif) receptor (CXCR)-4, which 
reduces the ability of DCs to migrate towards the corresponding 
chemokines, chemokine (C-C motif) ligand (CCL)-19 and chemokine (C-X-C 
motif) ligand (CXCL)-12 (313). This may be a mechanism that HSV uses to 
escape the immune system, as reducing DC migration to secondary 
lymphoid organs prevents antigen presentation and T cell stimulation (313). 
Theodoridis et al. have also shown that HSV can inhibit migration of DCs in 
3D collagen gels. The authors suggest that this effect is a result of HSV 
activating lymphocyte function-associated antigen 1 (LFA-1), which functions 
as an adhesion molecule and increases adhesiveness of extracellular matrix 
proteins to DCs, consequently impairing their migration (314).  
 
The ability of OVs to target cell migration and invasion remains an 
interesting concept and is explored within this thesis. If OVs have the 
potential to act not only as cytotoxic and immunogenic agents but also as 
anti-migratory agents, this would be a highly sought after therapeutic option 
for poor prognosis invasive tumours, such as paediatric and adult HGG. 
 
1.7 Oncolytic virotherapy for paediatric CNS tumours 
 
1.7.1 Pre-clinical studies  
 
Oncolytic virotherapy research for paediatric CNS tumours is in its infancy 
and only a limited number of pre-clinical studies have been published in this 
field. It is unsurprising that the majority of studies evaluate efficacy in 
medulloblastoma, as this is the most common malignant brain tumour of 
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childhood and confers a dismal prognosis at relapse (315). Over 15 years 
ago, Lasner et al. published that the HSV variant 1716 could infect and 
destroy D283 medulloblastoma cells and demonstrated that intra-tumoural 
injection of the virus into D283 tumour-bearing mice conferred a statistically 
significant survival advantage when compared to controls (316). Around the 
same time, Pyles et al. also demonstrated the therapeutic potential of 
another modified HSV strain (3616UB) that was able to arrest growth of 
DAOY cell xenografts in CD17 severe combined immunodeficiency (SCID) 
mice (282). Finally, Freidman et al. have recently published that mouse 
xenografts of human-derived medulloblastoma cells and cancer stem cells 
were highly sensitive to killing by HSV G207, as well as a novel HSV IL-12 
producing virus (M002) (317).  
 
Reovirus type 3 dearing has also been investigated in medulloblastoma. 
Yang et al. have demonstrated that medulloblastoma cell lines and primary 
human-derived cell cultures were sensitive to infection with reovirus type 3 
dearing and that intra-tumoural reovirus treatment of a mouse 
medulloblastoma model could significantly improve survival and inhibit 
development of spinal and leptomeningeal metastases (318). Other 
publications have also demonstrated that medulloblastoma is sensitive to 
killing by measles virus (319,320), myxoma virus (321) and seneca valley 
virus (SVV) infection (322).  
 
A limited number of studies have focused on oncolytic virotherapy for pHGG. 
Friedman et al. have shown that a paediatric cerebellar glioblastoma 
xenograft, DM456, contains tumour and cancer stem cells that are more 
sensitive to killing by a range of modified HSVs than adult glioma xenografts 
(323). SVV (NTX-010) has also been tested on a range of paediatric brain 
tumours, including glioblastoma, medulloblastoma and ependymoma (324). 
Some positive response was seen to virus treatment in glioma lines; 
however, NTX-010 was not effective on the medulloblastoma and 




1.7.2 Clinical evidence 
 
There are already a handful of encouraging reports in the literature that lay 
the foundations for the development of oncolytic virotherapy for paediatric 
CNS tumours. Case reports evaluating NDV MTH-68/H in paediatric patients 
with intracranial tumours have provided a useful insight into the feasibility, 
safety and efficacy of oncolytic virotherapy in this patient group. Csatary et 
al. report three paediatric patients (18 months to 12 years at diagnosis) with 
grade III/IV glioma at relapse who received regular intravenous (i.v.) NDV 
continuous maintenance therapy for several years. At time of publication, all 
three patients demonstrated between seven- to nine-years of survival with 
good quality of life, which exceeds the quoted median duration of survival of 
approximately 18-24 months (28,325-327). Another case report describes a 
12-year-old boy with treatment-resistant grade III anaplastic astrocytoma, 
who received i.v. and inhaled NDV, alongside valproic acid. Although 
treatment initially resulted in tumour regression, the patient eventually died 
from progressive disease (328). Encouragingly, NDV antigen and 
constituents were found in tumour tissue, confirming the successful systemic 
delivery of the virus to the tumour and demonstrating the virus’ ability to 
infect and replicate in paediatric human cancer cells (328). Finally, another 
paediatric patient with recurrent glioblastoma tolerated i.v. NDV with no 
major side effects in a clinical trial (329).   
 
Oncolytic virotherapy with Reolysin®, JX-594 and NTX-010 has been 
evaluated by clinical trials in a limited number of paediatric patients with 
extra-cranial solid tumours (303,330,331). Overall, therapy was well 
tolerated (303,330,331). The above studies have begun to answer the 
questions regarding the dosing, safety and efficacy of delivering virotherapy 
to children. However, the next step for the field is the development and 
delivery of phase I trials evaluating a range of potential OVs specifically for 
paediatric CNS tumours. Two such trials are currently open for recruitment. 
The first aims to evaluate the maximum tolerated dose (MTD) and safety of 
delivering intra-tumoural injection of HSV1716 to paediatric patients (age 12-
21) with refractory or recurrent HGG at the time of surgery (332). The 
second sets out to evaluate the MTD and safety of delivering i.v. Reolysin® 
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in combination with subcutaneous GM-CSF to paediatric patients (age 10-
21) with high grade recurrent or refractory brain tumours (333).  
 
1.8 Oncolytic virotherapy for adult glioma 
 
 
Since the early 1990s, there has been a growing interest in developing 
oncolytic virotherapy for the treatment of glioblastoma (334). The first 
laboratory engineered virus, a thymidine kinase-negative mutant of HSV 
(dlsptk) was, in fact, evaluated in a mouse model of adult glioma (334,335). 
Martuza et al. demonstrated that HSV dlsptk had cytotoxic effects against 
human glioma cell lines and was able to prolong survival in nude mice with 
intracranial U87 glioma (335). Although promising for clinical translation, tk 
inactivation rendered the virus resistant to several anti-viral therapeutics 
(which rely on active tk to inhibit viral replication) and this loss of 
susceptibility to anti-viral drugs rendered these viruses unsafe for clinical 
use, as there would be no strategy to overcome uncontrollable viral 
replication within patients (336). Despite this, the study by Martuza et al. 
paved the way for the development of clinically safe oncolytic HSV, 
alongside a range of other OVs (335,336). To date, over 15 different OVs 
have been evaluated in pre-clinical studies for the treatment of adult glioma, 
which has led to the development of a range of early phase clinical studies 
for this patient group (334). Table three summarises published clinical trials 
to date of adult patients with HGG. Overall, clinical trials have demonstrated 
that oncolytic virotherapy for glioma is feasible and safe and not associated 
with major virus-related adverse effects (334). Although the majority of these 
studies are phase I, there are some encouraging observations that highlight 
the potential of clinical response with oncolytic virotherapy in HGG. One trial 
of intra-tumoural injection of reovirus reports a patient with over six-year 
survival (337) and a trial of HSV1716 reports three patients remaining 
disease free for between 15-22 months (338). Finally, in a phase I/II trial 




The next stage for the adult field is to improve the delivery of OVs to 
intracranial tumour locations. Intra-tumoural injection limits the number of 
opportunities for treatment, whereas systemic delivery may be fraught with 
problems in effectively penetrating the BBB and overcoming the potential for 
neutralisation of the virus by the patient’s immune system before it can 
access the tumour target. There is clearly a fine balance between minimising 
destruction of administered virus by the host immune system, whilst 
enhancing the immune system’s response to kill and ablate virus-infected 
cancer cells (252,253). One avenue of research is currently focused on 
developing cellular carriers that deliver viruses to tumours while hiding them 
from the neutralising effects of the immune system (252). Furthermore, 
viruses can be modified to express tumour antigens, so that when they are 
appropriately delivered to the immune system the anti-tumour immune 
response is enhanced (252,339,340). Finally, the potential for synergistic 
interactions between OVs, radiotherapy and chemotherapy for HGG must be 
evaluated in clinical trials, alongside the potential of combining OVs and 
novel immunotherapeutics such as checkpoint inhibitors, which appear to 














HSV G207 (281) ICP34.5 deletion 
UL39 disruption 
I Single intra-tumoura injection No 21 No toxicity or SAE attributed to virus 
G207 (342) ICP34.5 deletion 
UL39 disruption 
Ib 2 intra-tumour injection 
(pre/post surgery) 
No 6 Transient fever, delirium, and 
hemiparesis in one patient 
G207 (343) ICP34.5 deletion 
UL39 disruption 
I Single intra-tumour injection 
24 h prior to RT 
Yes, 5 Gray 
RT 
9 No toxicity or SAE attributed to virus 
1716 (344) ICP34.5 deletion I Single intra-tumour injection No 9 No toxicity or SAE attributed to virus 
1716 (345) ICP34.5 deletion I Single intra-tumour injection No 12 No toxicity or SAE attributed to virus 
1716 (338) ICP34.5 deletion I Single intra-tumour injection No 12 No toxicity or SAE attributed to virus 
Reovirus  Reolysin® 
(337) 
Nil I Single intra-tumour injection No 12 No grade III/IV SAE attributed to virus 
Reolysin® 
(346) 
Nil I 72 h intra-tumour infusion No 15 One grade III SAE (convulsion) 
probably related to virus, no grade IV 
attributed to virus 
Adenovirus ONYX-015 
(347) 
Type 2/5 chimera 
E1B deletion 
I Single injection to resection 
cavity 






I/II Multiple i.v. doses No 14 No toxicity or SAE attributed to virus 
Table 3: Summary of published clinical trials for adult HGG.  
SAE (severe adverse effect), RT (radiotherapy), i.v. (intravenous). Adapted from (254,334,336)
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1.9 Project rationale 
 
pHGG and DIPG are highly aggressive brain tumours associated with dismal 
prognosis. Their invasive phenotype contributes to their limited therapeutic 
response and very few studies have focused on identifying existing or novel 
agents that are capable of impairing the migration and invasion of these 
tumours. The work contained within this thesis sets out to develop novel 
anti-invasive therapeutic strategies for pHGG and DIPG and aims to: 
 
1) Characterise the migratory and invasive properties of pHGG and 
DIPG cells 
The in vitro migratory and invasive properties of a panel of paediatric 
glioma cell lines will be examined using a range of 2D and 3D assays.  
Hypothesis: We hypothesise that pHGG and DIPG cell lines will 
demonstrate a highly migratory and invasive phenotype in vitro. 
 
2) Evaluate the effect of known GSK-3 inhibitors on the migration and 
invasion of paediatric glioma cells 
The effects of small molecule GSK-3 inhibitors (lithium chloride (LiCl) and 
BIO) on pHGG and DIPG cell migration and invasion will be determined 
using 2D and 3D assays. 
Hypothesis: We hypothesise that GSK-3 inhibitors will decrease in vitro 
migration and invasion of pHGG and DIPG. 
 
3) Investigate the effects of a range of OVs on paediatric glioma 
migration and invasion 
The effects of the OVs, HSV, reovirus and VV on the migration and 
invasion of pHGG and DIPG cell lines will be evaluated. Additionally, the 
interaction between OVs and the pHGG cytoskeleton will be investigated.  
Hypothesis: We hypothesise that OVs will interact with the cancer cell 
cytoskeleton and this will, in turn, reduce the migratory and invasive 
ability of paediatric glioma cell lines.  
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2 Chapter 2: Materials and methods 
 
2.1 Cell lines and media 
 
 
Paediatric glioma cell lines SF188 (Grade IV, glioblastoma) and KNS42 
(Grade IV, glioblastoma) were obtained from Dr Chris Jones (Institute of 
Cancer Research, London). These cells have been comprehensively 
characterised in terms of genomic alterations and gene expression patterns 
(348). Cells were grown in Dulbecco’s Modified Eagle’s medium (DMEM) 
(Sigma-Aldrich) with 10 % heat-inactivated foetal calf serum (HI-FCS) 
(Labtech) and 0.5 % penicillin-streptomycin (Sigma-Aldrich). For 
experiments involving OVs, penicillin-streptomycin was omitted from the cell 
culture medium. Cell line identity was verified by serial tandem repeat 
profiling  (Claire Taylor, in-house testing at Cancer Research UK Leeds 
Centre, genomics facilities). The patient autopsy-derived DIPG cell line 
HSJD-DIPG-007 was obtained from Dr Angel M Carcaboso (Hospital Sant 
Joan de Dèu Barcelona, Barcelona, Spain). Cells were cultured as 
neurospheres in working medium (Table 4). Murine glioma GL261-luciferase 
(GL261-Luc) transfected cells were obtained from Professor Richard Vile 
(Mayo clinic, Rochester, USA) and were grown in DMEM supplemented with 
10 % HI-FCS and 1 µg/ml puromycin (Sigma-Aldrich). All cell lines were free 
of mycoplasma contamination (Sarah Perry, in-house testing at Leeds 






























  1 ml 
Recombinant 
human EGF 




Peprotech 20 ng/ml 20 µg/ml 50 µl 
Human-
PDGF-AA 
Peprotech 10 ng/ml 20 µg/ml 25 µl 
Human-
PDGF-BB 
Peprotech 10 ng/ml 20 µg/ml 25 µl 
Heparin 
solution 0.2 % 
Sigma-
Aldrich 
2 µg/ml 2 mg/ml 50 µl 
 
Table 4: Constituents of working medium for HSJD-DIPG-007 
neurosphere culture 
TSM (tumour stem medium), EGF (epidermal growth factor), FGF (fibroblast 
growth factor), PDGF (platelet-derived growth factor) 
 
2.1.1 Cell culture 
 
Cells were cultured in a Sanyo CO2 incubator at 37 °C in a humidified 
atmosphere of 5 % CO2 (in air). Cells were maintained in either 150 cm2 or 
75 cm2 plastic tissue culture flasks (Corning). SF188, KNS42 and GL261-
Luc were harvested at or near confluence by washing with phosphate 
buffered saline (PBS), then adding trypsin (10x solution, diluted 1:10 in 
Hank’s Balanced Salt Solution (Sigma-Aldrich)). Cells were frozen and 
stored in liquid nitrogen at -196 °C in 10 % dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich) culture medium.  
 
HSJD-DIPG-007 cells were grown as neurospheres suspended in medium. 
Medium was replaced once per week or upon changing colour. Cells were 
passaged when growth was such that medium required changing within four 
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days of replacement. To passage, cell suspensions were centrifuged at 300 
g for 4 min. Cell pellets were incubated for five min at 37 °C with 0.5 ml 
TrypLE Express Stable Trypsin Replacement Enzyme without phenol red 
(Thermo Fisher Scientific) and then triturated 20-30 times with a p1000 
pipette (Starlab) in 1.5 ml Eppendorf tubes (Sarstedt) to disaggregate. Cells 
were re-suspended in 10 ml TSM in FalconTM tubes (Corning) and 
centrifuged for five min at 400 g. Cell pellets were re-suspended in 5 ml of 
working medium and incubated overnight in 25 cm2 plastic tissue culture 
flasks at 37 °C. Neurosphere suspensions were then transferred into 75 cm2 
plastic tissue culture flasks until ready for further passage. For 
cryopreservation, disaggregated neurospheres were re-suspended in 1 ml of 
Synth-a-Freeze defined cryopreservation medium (Thermo Fisher Scientific), 
kept at -80 °C for 24 h and then stored in liquid nitrogen at -196 °C.  
 
For cell counts, cells were viewed/imaged with a Nikon eclipse TS100 
microscope and camera and counted using an improved Neubauer 




Chemicals used were LiCl (Sigma-Aldrich), BIO (Calbiochem), sodium 















Viruses used are summarised in table five. 
Oncolytic 
virus 
Strain GFP/RFP Modification Stock 
concentration 
Supplier 

























integrated into the 
F14.5L, J2R and 














integrated into the 
F14.5L, J2R and 







Table 5: Summary of viruses studied 
GFP (green fluorescent protein), RFP (red fluorescent protein) 
 
2.4 Migration and invasion assays 
 
2.4.1 Spheroid invasion assay in collagen  
 
Spheroids were formed by placing 1x103 cells per well in an ultra-low 
attachment round-bottom 96 well plate (Corning) and incubating for 72 h at 
37 °C. The medium was removed and 100 µl of neutralised rat tail collagen 1 
(BD Biosciences) was added to each well and allowed to polymerise at 37 
°C for 15 min to entrap the spheroid. Collagen was neutralised with 1 M 
sodium hydroxide (NaOH) in 5x DMEM (Thermo Fisher Scientific). For 
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evaluation of the effects of GSK-3 inhibitors on invasion, the collagen was 
overlaid with 100 µl of cell culture medium ± GSK-3 inhibitors: LiCl at 40, 20, 
10, 5 mM in NaCl or BIO at 10, 5, 1, 0.5 µM in DMSO. For investigation of 
the effects of OVs, the collagen was overlaid with 100 µl of cell culture 
medium ± 8x102, 8x103, 8x104 or 4x105 pfu/well of virus, which approximates 
to a nominal 0.1, 1, 10 or 50 pfu/cell. Spheroid expansion and invasion into 
the collagen matrix was monitored for 72 h using the EVOS cell imaging 
system (Thermo Fisher Scientific) at x4 magnification. Images were 
analysed with Volocity 3D Image Analysis software (Perkin-Elmer) and 
Image J (http://rsbweb.nih.gov/ij). In order to quantify invasion, two zones 
were defined: the invasion zone represents the area outside the spheroid 
core into which approximately 75 % of cells invaded, while the leading edge 
zone represents the total area containing any invading cells away from the 
core (Figure 2). This method has been previously described (349) and 
improved the accuracy of the analysis. For comparison of invasion between 




Figure 2: Invasion of cells from tumour spheroids can be represented by zones 
Images of invading tumour spheroids into their surrounding collagen matrix were obtained 
using the EVOS cell imaging system. Volocity 3D Image Analysis software and Image J 
were used to define zones for quantification of tumour spheroid invasion. The invasion zone 
represents the area containing approximately 75 % of invading cells and the leading edge 
zone accounts for the whole area containing any invading cells. White scale bar represents 
1000 µm. 
 
area of zone – area of core 
             total area 
           MI  = 
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2.4.2 Transwell migration assay 
 
Transwell assays were performed using 8 µm pore transwell inserts (Greiner 
Bio-One) pre-coated with 5 µg/ml of the chemo-attractant fibronectin (Sigma-
Aldrich). Cell lines were pre-treated ± 20 mM LiCl or 5 µM BIO for 1 h.  5x104 
cells were then placed into transwell inserts in triplicate and allowed to 
migrate for 4 h. Migrated cells were fixed with 1 % glutaraldehyde (Sigma-
Aldrich) in PBS and visualised by staining with 0.1 µg/ml DAPI (Biotium). 
Migration was determined by imaging DAPI nuclear stain with the EVOS cell 
imaging system and quantifying the fluorescence signal for the individual 
transwells using Volocity 3D Image Analysis software.  
 
2.4.3 Migration on nanofibre scaffolds 
 
1x103 cells in 20 µl drops were suspended from the lids of petri dishes for 24 
h to form aggregates in hanging drops (350). To enhance visualisation of the 
migrating cells and confirm migration, CellTrackerTM green 5-
chloromethylfluorescein diacetate (CMFDA) dye (Thermo Fisher Scientific) 
was added to the cell suspension according to manufacturer’s instructions 
prior to hanging drop formation. Cell aggregates were manually transferred 
into wells of aligned poly--caprolactone nanofibre-coated culture plates 
(Nanofiber solutions), which allows cell migration on a 3D scaffold stimulated 
by topographical cues (i.e. the surface shape and features are able to 
influence migration) (351). These were incubated at 37 °C with cell medium 
± 20 mM LiCl or 5 µM BIO in triplicate and migration was monitored for 72 h 
using the EVOS cell imaging system at x4 magnification. Migration was 
quantified using Image J software.  
 
2.4.4 Scratch migration assay  
 
Cells were seeded at 1x105 cells/well into 24 well plates (Corning) such that 
after 24 h of growth they reached 80-90 % confluence as a monolayer. After 
24 h incubation at 37 °C, a line was drawn on the underside of each well 
across the centre with a fine marker. A gentle and slow scratch using a p200 
pipette tip (Starlab) was applied across the centre of the monolayer, 
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perpendicular to the marker line. The well was then washed twice with 
culture medium to remove detached cells and replenished with fresh culture 
medium ± virus (HSV, reovirus or VV at 50, 10, 1, 0.1 and 0.01 pfu/cell).  
Migration of cells across the scratch was determined by imaging at 0 h and 
24 h with the EVOS cell imaging system at x4 magnification. Migration was 
quantified using Image J software to determine the percentage change in the 
area of the scratch over the 24 h time period.   
 
2.5 Live cell imaging 
 
2.5.1 Live cell imaging with the Nikon Biostation IM system 
 
10 µl of cells in 500 µl of culture medium were placed in each quarter of an 
Ibidi imaging dish (Nikon) and allowed to adhere for 2 h at 37 ºC. For 
evaluation of the effects of GSK-3 inhibitors on random cell 
movement/morphology, equal volumes of medium were then replaced in 2 of 
4 quadrants with either 20 mM LiCl or 5 µM BIO. For evaluation of the 
effects of OVs, equal volumes of medium were replaced in 3 of 4 quadrants 
with either HSV, reovirus or VV at an approximation of 10 pfu/cell. The Ibidi 
dish was then cultured in the incubation/imaging chamber of the Nikon 
Biostation IM live cell imaging system. Cells were imaged for 24 h (GSK-3 
inhibitor experiments) or 48 h (virus experiments) at 3 min intervals at 37 ºC 
with 5 % CO2 in air. To evaluate effects on pHGG cell lines following GSK-3 
inhibitor drug washout, 20 mM LiCl- or 5 µM BIO- treated medium was 
removed following 24 h of imaging, cells were gently washed with PBS and 
imaged in drug free culture medium for a further 24 h. The Biostation IM- 
associated software was used to create movies for analysis. Cell tracking, 
velocity and displacement analysis was performed in Image J with MTrack 
(www.imagescience.org/meijering/software/mtrackj/). For tracking, the 
nucleus of each cell was identified and tracked over the 24 h or 48 h period 




2.5.2 Live cell imaging with the IncuCyte ZOOM® 
 
For live cell imaging of the scratch assay, 24 well plates were set up as per 
section 2.4.4 and placed in the IncuCyte ZOOM® (Essen BioScience) 
incubator at 37 ºC with 5 % CO2 in air. Plates were imaged using the x4 
microscope objective, with images of each well taken hourly. IncuCyteTM 
software (Essen BioScience) was used to create movies.  
 
Imaging of HSV and VV infection within cells forming spheroids was 
achieved by setting up a spheroid in collagen invasion assay in a 96 well 
plate (see section 2.4.1). The collagen was overlaid with 100 µl of cell 
culture medium ± 8x104 pfu/well of HSV or VV expressing GFP. The 96 well 
plate was placed in the IncuCyte ZOOM® incubator at 37 ºC with 5 % CO2 in 
air and was imaged using the x4 microscope objective, with images of each 
well taken hourly for 70 h. IncuCyteTM software was used to create movies 
and visualise GFP expression. 
 
2.6 Cell viability and growth assays 
 
2.6.1 WST-1 assay 
 
Cell viability of both monolayers and spheroid aggregates incubated with 
culture medium ± GSK-3 inhibitors was measured using the water soluble 
tetrazolium-1 (WST-1) assay (Roche). Cell viability of spheroid aggregates 
incubated with culture medium ± virus was also determined by WST-1 
assay. 
 
For analysis of monolayers, cells were seeded (SF188 at 2.5x103 cells/well, 
KNS42 at 5x103 cells/well in 50 μl culture medium) into flat-bottom 96 well 
plates (Corning) and left to adhere overnight. Cells were treated with a 
further 50 μl volume of culture medium ± LiCl at 40, 20, 10, 5 mM in NaCl or 
BIO at 10, 5, 1, 0.5 µM in DMSO. At 24, 48 and 72 h, 10 µl of WST-1 was 
added to each well and, after 4 h, absorbance at 450 nm was detected using 
a colorimetric microplate reader (Thermo Fisher Scientific). An internal 
control well containing BIO 10, 5, 1, 0.5 µM only (no cells) was also 
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evaluated and absorbance from these control wells was subtracted from the 
readings obtained for BIO-treated cells to account for the absorbance of the 
red pigmentation of the compound.  
 
For analysis of spheroids, 1x103 cells per well in 50 μl culture medium were 
seeded in an ultra-low attachment round bottom 96 well plate to form 
spheroid aggregates. Following 72 h incubation at 37 °C, cells were treated 
with a further 50 μl volume of culture medium ± LiCl at 40, 20, 10, 5 mM in 
NaCl or BIO at 10, 5, 1, 0.5 µM in DMSO. For experiments to determine the 
effects of OVs on spheroid aggregate viability, cells were treated with 50 μl 
volume of culture medium ± 8x102, 8x103, 8x104 or 4x105 pfu/well of virus. At 
24 h intervals for up to 96 h, 10 µl of WST-1 was added per well and, after 4 
h, absorbance at 450 nm was detected using the colorimetric microplate 
reader. Additionally, for GSK-3 inhibitor experiments and for virus 
experiments with the HSJD-DIPG-007 cell line, tumour spheroids were 
imaged at 0, 24, 48 and 72 h using the EVOS cell imaging system and 
changes in spheroid core area were calculated using Image J software to 
evaluate growth over time: a methodology recommended by the 
manufacturers of a commercially available 3D spheroid proliferation assay 
(352).   
   
2.6.2 MTT assay 
 
Cells were seeded as monolayers at 8x103 cells per well in 100 µl of culture 
medium in flat bottom 96 well plates (Corning) and incubated at 37 ºC 
overnight. 100 µl of culture medium or virus dilutions (HSV, reovirus and VV 
at 10, 5, 2.5, 1.25, 0.625, 0.3125 and 0.156 pfu/cell) was added to each well 
in triplicate. At 24, 48, 72 and 96 h, 20 µl of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) was added to each well 
and, after 4 h, incubation at 37 C, the medium was replaced with 200 µl of 




2.6.3 LIVE/DEAD® assay 
 
Cells were seeded into 12 well plates (Corning) at 1x105 cells/well in 2 ml 
culture medium and left to adhere for a minimum of 4 h at 37°C. 100 µl of 
culture medium ± virus (HSV, reovirus or VV at 50, 10, 1, 0.1 and 0.01 
pfu/cell) was then added to each well. At 24, 48, 72 and 96 h, cell-free 
culture medium was collected for analysis by enzyme-linked immunosorbent 
assay (ELISA). Cells were harvested into fluorescence-activated cell sorting 
(FACS) tubes (Corning), centrifuged at 400 g for 5 min then washed in PBS. 
Cell pellets were then incubated for 20 min with 1 ml of PBS containing 1 µl 
LIVE/DEAD® fixable dead cell stain (Thermo Fisher Scientific). For cells 
treated with either HSV or reovirus, a red LIVE/DEAD® cell stain was used 
and for cells treated with VV, a yellow LIVE/DEAD® cell stain was used to 
account for the RFP encoded by the VV. Following incubation, cells were 
washed twice in PBS and cell pellets were fixed in 300 µl of 1 % 
paraformaldehyde (PFA) (Sigma-Aldrich). Fixed cells were stored at 4 °C 
until acquisition on the FACS Attune cytometer (Thermo Fisher Scientific). 
Analysis was carried out using Attune Flow Cytometric software V2.1 
(Thermo Fisher Scientific). 
 
2.6.4 Ki-67 intracellular FACS assay 
 
Cells were seeded into 12 well plates at 1x105 cells/well in 2 ml culture 
medium and left to adhere for a minimum of 4 h at 37 °C. 100 µl of culture 
medium ± virus (HSV or reovirus at 1 or 10 pfu/cell) was then added to each 
well. At 24 h, cells were harvested into FACS tubes, washed in PBS and 
fixed in 50 µl of 10 % PFA per tube on ice for 15 min. Cells were then 
washed with FACS buffer (see appendix 2) and re-suspended in 1 ml 0.3 % 
saponin (Sigma-Aldrich) for 15 min at room temperature to permeabilise. 
Cells were then washed with FACS buffer and 5 µl of Ki67 PE-Cy7 mouse 
anti-human antibody (BD Biosciences) was added to each tube and 
incubated for 30 min at room temperature, shielded from light. Cells were 
then washed in 2 ml of 0.1 % saponin and re-suspended in 500 µl FACS 
buffer. Ki67 staining was examined using the FACS Attune cytometer.  
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2.7 Immunofluorescence  
 
For immunofluorescence (IF) studies, cells were grown on sterile 22 x 22 
mm cover slips (Scientific laboratory supplies) in 6 well dishes (Corning) 
seeded at 2x105 cells/well. To assess the effect of GSK-3 inhibitors on cell 
morphology, cells were mock-treated with culture medium (± NaCl or DMSO 
as negative controls) or treated with either 20 mM LiCl or 5 µM BIO and 
allowed to grow over a 72 h period. To assess the effects of GSK-3 inhibitors 
on β-catenin distribution, cells were mock-treated or treated with 20 mM LiCl 
or 5 µM BIO for 24 h. To investigate the effects of HSV on tubulin acetylation 
and detyrosination, cells were mock-treated or treated with either 10 pfu/cell 
HSV or 100 nM Taxol for 24 and 48 h. To evaluate the cellular location of 
APC, cells were mock-treated for 24 h or treated with either 10 pfu/cell HSV 
or 5 µM BIO. Finally, dedicator of cytokinesis 3 (DOCK3) intensity was 
investigated by treating cells in medium ± 10 pfu/cell HSV for 24 h.  
 
Antibodies for IF studies are listed in table 6. For the identification of focal 
adhesions, a staining kit for vinculin (1:500 dilution) (Millipore) was used. 
Actin filament and nuclear staining was performed with rhodamine-phalloidin 
(1:500 dilution) (Thermo Fisher Scientific) and DAPI (1:10,000 dilution) 
(Thermo Fisher Scientific). 
 
For IF studies of microtubules, acetylated tubulin, detyrosinated tubulin, APC 
and DOCK3, cells were fixed with ice-cold 100 % methanol (Sigma-Aldrich) 
for 2 min at -20 °C, followed by three washes with PBS. For IF of the actin 
cytoskeleton, focal adhesions and β-catenin, cells were fixed with 4 % PFA 
for 20 min at room temperature followed by 5 min incubation with 0.5 % 
Triton X-100 (Sigma-Aldrich) in PBS for permeabilisation and finally three 
washes with PBS. All coverslips were then blocked with 0.05 % skimmed 
milk (Marvel) in PBS for 5 min at room temperature. Primary antibodies were 
diluted (as stated in table 6) in blocking buffer (0.05% skimmed milk in PBS) 
and then centrifuged for 5 min at 13,000 rpm. The supernatants were 
removed and used for primary antibody incubation. Coverslips were 
incubated upside down in 200 µl of primary antibody solution in a humidified 
incubation chamber for 1 h and then washed three times in PBS. Coverslips 
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were incubated in secondary antibody solutions, containing DAPI and 
mounted on microslides in Fluoromount-G (SouthernBiotech). The coverslips 
were allowed to set overnight and imaged using the Axioplan Z imaging 
microscope (Zeiss).  For IF studies of acetylated and detyrosinated tubulin, 
fluorescence intensity of each image was calculated in Image J software 
using a standard threshold across all images. The fluorescence intensity 
was then divided by the number of cells in each image to calculate the 
intensity of acetylated or detyrosinated tubulin per cell.  
 
Table 6: Primary and secondary antibodies used for immunofluorescence studies  
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2.8 Western blotting 
 
 
For Western blotting, cell lysates were obtained from cells grown in 25 cm2 
plastic tissue culture flasks (Corning) treated under the following conditions: 
to determine the effects of LiCl and BIO on GSK-3 isoform expression, cells 
were treated with either 20 mM LiCl, 20 mM NaCl, 5 µM BIO or DMSO at the 
same concentration for 24 h. To investigate the effects of HSV on GSK-3 
expression and acetylated and detyrosinated tubulin expression, cells were 
treated ± 10 pfu/cell HSV and harvested at 24 or 48 h. Once harvested, cells 
were centrifuged at 400 g for 5 min with ice cold PBS and supernatants were 
discarded in order to obtain a dry pellet. 2 ml of ice cold 
radioimmunoprecipitation assay (RIPA) buffer (see appendix 2) + 25 µl/ml 
protease inhibitor (Sigma-Aldrich) was added to each cell pellet and left for 
15 min on ice to create cell lysates. 
 
Protein concentration of each cell lysate was determined by Bradford protein 
assay. Briefly, 5 µl of protein sample (diluted 1:1 with ddH2O), or bovine 
serum albumin (BSA) protein standards (Sigma-Aldrich) (in serial dilution 
from 1.5 µg/µl to 0 µg/µl) were placed in flat-bottom 96 well Maxisorp® plates 
(Nunc). Protein concentration was determined using a DCTM Protein Assay 
kit (Bio-Rad), according to the manufacturer’s instructions. Absorbance at 
690 nm was detected using the colorimetric microplate reader. Protein 
sample concentration was evaluated using the curve derived from the BSA 
protein standards.  
 
20-40 μg of protein mixed with loading buffer (see appendix 2) was loaded 
into wells in Tris-glycine sodium dodecyl sulphate (SDS) polyacrylamide gel 
(see appendix 2). A PageRuler plus pre-stained protein ladder (Thermo 
Fisher Scientific) was also loaded to estimate protein size. Proteins were 
separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) (150 v, 3 watts per gel for approximately 60 min in a tank filled 
with running buffer (see appendix 2)) and transferred to nitrocellulose (Bio-
Rad) (25 v over 2 h in a tank filled with transfer buffer (see appendix 2)).  
Once unpacked, the nitrocellulose was washed and blocked. For blots to be 
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treated with β-actin antibody, the nitrocellulose was rinsed for 5 min in Tris-
Buffered Saline and Tween®20 (TBST) (Sigma-Aldrich) (see appendix 2) 
and then blocked with 3 % milk in TBST buffer overnight. For blots treated 
with all other antibodies, nitrocellulose was rinsed for 5 min in PBS and then 
blocked for 1 h with 5 % BSA diluted in PBS. The nitrocellulose was then 
exposed to primary antibody (see table 7) diluted with either 3 % milk in 
TBST for 2 h (β-actin) or 2.5 % BSA in PBS plus 0.1 % Tween®20 (PBST) 
overnight (all other blots). Nitrocellulose was then washed four times in 
either TBST (β-actin) or PBST (all other blots) and exposed for 1 h to 
secondary antibody (see table 7). Following four further washes with TBST 
or PBST, proteins were detected by the addition of SuperSignalTM West Pico 
Chemiluminescent substrate (Thermo Fisher Scientific) and visualised using 
the ChemiDoc MP imaging system (BioRad) and Image lab (BioRad) 
software.  Protein band intensity was analysed using Image J software. The 











































































































Table 7: Primary and secondary antibodies for Western blotting  









Flat-bottom 96 well Maxisorp® plates were coated with 100 µl of capture 
antibody diluted in either PBS (VEGF) or coating buffer (IL-8) (see appendix 
2) at optimised concentration (see table 8).  Plates were wrapped and 
incubated overnight at 4 °C and then washed three times with PBST using 
the SkanWasher300 (Molecular Devices). Plates were then blocked with 200 
µl per well of PBS + 10 % HI-FCS for 2 h at room temperature. Following 
three further washes with PBST, 100 μl of recombinant cytokine standards 
(in serial halving dilution) or sample supernatants were added to the plates 
in triplicate. Loaded plates were covered and left overnight at 4 °C and then 
washed six times with PBST. Optimised concentrations of detection antibody 
(table 8) diluted in block solution (PBS + 10 % HI-FCS) were added at 100 μl 
per well and left for 2 h at room temperature. Plates were again washed six 
times with PBST, before 100 μl Extravidin®-alkaline phosphatase conjugate 
(Sigma), diluted at 1:5000 in PBST, was added per well for 1 h. After three 
further washes with PBST, followed by three washes with ddH2O, 
Sigmafast™ p-Nitrophenyl phosphate alkaline phosphatase substrate 
(Sigma) was prepared according to the manufacturer’s instructions and 
added at 100 µl per well.  Plates were kept in the dark to develop. 
Absorbance at 405 nm was detected using the colorimetric microplate 
reader. The concentration of cytokine detected in each sample was 







IL-8 1:500 1:500 BD Biosciences 
VEGF 1:180 1:180 R&D systems 
 
Table 8: Coating and detection antibody concentrations for ELISA 







2.10 In vivo studies 
 
In vivo experiments were conducted at the Department of Immunology, 
Mayo Clinic, Rochester, Minnesota, USA and were ethically approved by the 
Mayo foundation institutional animal care and use committee.  
 
2.10.1 GL261-Luc model of migration 
 
To establish intracranial tumours, 5 x 104 GL261-Luc cells in 2 μl PBS were 
stereotactically injected into the brains of 6-8-week-old C57 black 6 (BL/6) 
mice (The Jackson Laboratory) (n=8 per group). Coordinates for intracranial 
injection were 1 mm anterior and 2 mm lateral to the bregma. Cells were 
injected 2 mm deep. For one group of mice, GL261-Luc cells were premixed 
with HSV at 10 pfu/cell prior to intracranial injection. Four mice per group 
were sacrificed on day 15 of the experiment and the remainders were 
sacrificed on day 25 by exposure to CO2 gas in a rising concentration. 
Brains were immediately harvested into 4 % PFA. 
 
2.10.2 DIPG in vivo experiment 
 
DIPG neurospheres were disaggregated with TrypLE (as described in 
section 2.1.1) and counted the evening before surgery, then left in culture 
overnight. Cells were collected immediately prior to surgery and re-
suspended in either 2 µl PBS (control) or 2 µl HSV at 10 pfu/cell. To 
establish intracranial tumours, 5 x 105 disaggregated HSJD-DIPG-007 cells 
(pre-treated with PBS or HSV) were stereotactically injected into the brains 
of two groups of 4-5 week-old nonobese diabetic severe combined 
immunodeficiency (NOD.SCID) mice (The Jackson Laboratory) (n=6 per 
group (control vs. HSV-treated cells)). Location for injection was -1X, -0.8Y, 
5Z from the bregma (353). Use of these coordinates targets the fourth 
ventricle but allows the cells to still grow and invade into the brainstem and 
cerebellum. Tumours were left to establish and mice were sacrificed when 
showing clinical signs of disease i.e. severe ataxia or >15 % weight loss. 
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Following death, brains were immediately harvested into 4 % PFA. Survival 
data was collected for analysis of treatment effects between groups.  
 
2.10.3 Analysis of brains collected from in vivo studies 
 
Brains were transferred from 4 % PFA to 70 % ethanol (Sigma-Aldrich), then 
sliced into coronal sections and placed in an embedding cassette (Thermo 
Fisher). Brains were embedded in paraffin, and then sectioned to four 
microns thick using a manual rotary microtome (Leica) and mounted on 
glass slides. Tissue sections were stained with Haematoxylin and Eosin 
(H&E). Briefly, tissue was dewaxed in xylene (Thermo Fisher Scientific), 
dehydrated in ethanol and then washed in water before incubation with 
Mayers haematoxylin (Atom Scientific) for 3 min. Tissue was washed in 
water, followed by Scott’s tap water (0.2 % sodium bicarbonate, 2 % 
magnesium sulphate in water), then washed again with water before the 
addition of Eosin Y stain (Atom Scientific) for 2 min. Tissue was then washed 
in water, followed by ethanol and xylene before mounting with a cover slip 
using distyrene plasticizer xylene (DPX) (Solmedia). Nuclei were stained 
blue and cell cytoplasm and extracellular matrix were stained pink. Slides 
were analysed with the help of a consultant neuropathologist (Dr Azam 
Ismail, Department of Histopathology, St James’s University Hospital), to 
identify the presence of brain tumours and their invasion/migration into the 
surrounding normal brain. Images were taken using the SPOT Insight 
camera (SPOT Imaging, Diagnostic Instruments) and SPOT software (SPOT 
Imaging, Diagnostic Instruments) with the Leitz DMRB (Leica) microscope at 
x5, x10 or x20 magnification.  
 
2.11 Statistical analysis 
 
 
Statistical analysis was carried out using Graph Pad Prism 6 (Graph Pad 
Software), SPSS version 21 (IBM) and Excel (Microsoft). Statistical 
significance between multiple groups was determined by analysis of 
variance (ANOVA). Statistical significance between two groups was 
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determined by Student’s two-tailed t-test. Survival data from the DIPG in vivo 
experiment was analysed using the log rank test. p-values <0.05 were 




3 Chapter 3: Cell migration and invasion in paediatric glioma: 





pHGG and DIPG are highly aggressive tumours associated with dismal 
treatment outcomes (29). Both pHGG and DIPG are known to have diffuse 
infiltrative growth patterns and this invasive phenotype contributes to their 
limited therapeutic response (24,65). Despite intensive treatment, tumours 
inevitably recur, as by the time of surgical resection (pHGG) or localised 
radiotherapy (DIPG and pHGG) tumours have already invaded into the 
surrounding brain, preventing their complete removal/eradication (65). As a 
result, there is a pressing clinical need to develop novel therapeutic 
approaches that effectively target and reduce paediatric brain tumour 
migration and invasion.  
 
One such approach may be through the use of GSK-3 inhibitors. GSK-3 is a 
serine/threonine protein kinase that plays a key role in orchestrating cell 
migration through regulating cellular structure, motility, adhesion and 
cytoskeleton dynamics (195,202,213). Pharmacological inhibitors of GSK-3, 
including LiCl and the indirubin derivative BIO, have been evaluated in pre-
clinical studies of adult HGG and have been shown to be able to block both 
in vitro and in vivo migration and invasion (236,246). The effects of GSK-3 
inhibitors on pHGG and DIPG migration and invasion are unknown and 
given the distinct biological and clinical phenotype of the adult and paediatric 
diseases (29), warrant separate investigation.  
 
The results within this chapter report on a comprehensive analysis of cell 
migration and invasion of two pHGG cell lines and one rare patient-derived 
DIPG cell line, using a range of 2D and 3D assays. Additionally, the 
hypothesis that the small molecule GSK-3 inhibitors, LiCl and BIO, are 
capable of inhibiting the migration and invasion of pHGG and DIPG cells in 
vitro, is tested. These agents represent novel anti-invasive candidates that 
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may improve the clinical management of these challenging childhood 
tumours.  
 
3.2 Paediatric glioma cell lines can readily form tumour spheroids 
 
Tumour spheroids represent a useful model for examining tumour biology in 
vitro as they are three-dimensional and comprise of a surface with ready 
access to nutrients and oxygen and an inner hypoxic core (236). Moreover, 
once embedded in a matrix such as collagen, cells can migrate outward from 
the core and invade into the surrounding collagen matrix, representing a 
model of the process of tumour invasion (236). The spheroid-forming 
potential of four paediatric glioma cell lines (SF188 (glioblastoma), Res186 
(pilocytic astrocytoma), KNS42 (glioblastoma) and UW479 (anaplastic 
astrocytoma), was initially investigated.  However, serial tandem repeat 
profiling revealed concerns with the identity of two cell lines (Res186 and 
UW479) and consequently these cell lines were excluded from further 
analysis. Similar to the findings of Vinci et al. (354), it was noted that both 
SF188 and KNS42 readily formed round dense spheroids within 24 h when 
cultured in low adherence 96 well round-bottomed plates (Figure 3).  
 
The patient-derived primary DIPG cell line HSJD-DIPG-007 normally grows 
as neurospheres suspended in culture medium. The ability of HSJD-DIPG-
007 to form individual spheroids in low adherence 96 well plates was also 
investigated. This method offered the advantage of being able to create 
spheroids with the same fixed number of cells, improving uniformity of the 
tumour model. HSJD-DIPG-007 readily formed dense spheroids within 24 h 












Figure 3: Paediatric glioma cell lines readily form tumour spheroids 
SF188, KNS42 and HSJD-DIPG-007 were seeded into ultra-low attachment 96 well plates 
at 1x103 cells per well and cultured for 72 h. Spheroid formation was evaluated at 24, 48 




3.3 Paediatric glioma tumour spheroids display different patterns of 
invasion 
 
After embedding in collagen, the invasive behavior of the paediatric glioma 
spheroids was monitored over 72 h using the EVOS cell imaging system. 
The cell lines exhibited distinct invasive characteristics and patterns. SF188 
displayed a cogwheel pattern of invasion with what appeared to be long thin 
symmetrical protrusions branching from the central core. KNS42 and HSJD-
DIPG-007 invaded by extending flattened protrusions and spreading in a 
sheet like manner (Figure 4A). During invasion of HSJD-DIPG-007 
spheroids, the tumour core became elongated and lost definition. This was 
not observed for SF188 or KNS42 spheroids. The observed differences in 
invasive patterns were also reflected by the migration indices obtained for 
the leading edge for each cell; (the migration index was used as a 
measurement for comparison of invasion between cell lines and is described 
in section 2.4.1); KNS42 migrated significantly less than SF188 and HSJD-
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DIPG-007 (mean±SEM: SF188 leading edge: 0.87±0.014; HSJD-DIPG-007 
leading edge: 0.78±0.1; KNS42 leading edge: 0.59±0.31 p<0.001). No 
statistically significant difference was observed between the migration index 







Figure 4: Tumour spheroids of paediatric glioma cell lines have different patterns of 
invasion 
(A) SF188, KNS42 and HSJD-DIPG-007 tumour spheroids were encased in collagen and 
incubated in culture medium for 72 h. Images shown were taken at 72 h at a magnification 
of x4 and are representative of n=3 individual experiments. The white scale bar represents 
1000 µm. (B) Images generated were analysed using Volocity 3D Image Analysis software 
and Image J by calculating the area of the invasion zone and the leading edge zone (as 
defined in section 2.4.1). A migration index (MI) for both the invasion front and leading edge 
((area of zone – area of core) ÷ total area) was calculated. KNS42 invaded significantly less 
than SF188 and HSJD-DIPG-007. Graph shows mean±SEM of multiple repeats pooled from 
at least n=3 individual experiments for SF188 and KNS42 and one individual experiment 
with multiple internal repeats for HSJD-DIPG-007. *** p<0.001 by two-tailed t-test.   
 
3.4 LiCl and BIO inhibit invasion of paediatric glioma tumour 
spheroids in a 3D assay 
 
The small molecule GSK-3 inhibitors, LiCl and the indirubin derivative BIO, 




































glioblastoma cell lines (236,246). Moreover, indirubin derivatives show 
therapeutic efficacy in animal glioblastoma orthotopic xenograft models and 
block invasion in vivo (246). However, whether these agents exert similar 
effects upon migration and invasion in pHGG and DIPG cell lines has not 
been previously determined.  
 
Tumour spheroids from each cell line were embedded in collagen, overlaid 
with the drugs (LiCl and BIO) at varying concentrations as indicated and 
invasion was imaged over 72 h (Figure 5A and B). A migration index was 
then calculated from the images obtained for each condition as described in 
section 2.4.1 to compare the invasion front and leading edge zone for each 
treatment (Figure 6).  
 
LiCl and BIO reduced invasion of pHGG and DIPG tumour spheroids in a 
concentration-dependent manner (Figure 6). After 72 h, 10 or 5 µM BIO 
significantly blocked invasion of both pHGG cell lines (SF188 and KNS42) 
(Figure 6A and B) (mean±SEM: SF188 leading edge: control 0.869±0.014, 
BIO 10 µM 0.292±0.069 p<0.001, BIO 5 µM 0.401±0.065 p<0.001; KNS42 
leading edge: control 0.587±0.31, BIO 10 µM 0.157±0.036 p<0.001, BIO 5 
µM 0.166±0.033 p<0.001). Invasion of the DIPG cell line at 72 h was 
significantly blocked by BIO at both 5 and 1 µM (Figure 6C) (mean±SEM 
HSJD-DIPG-007 leading edge: control 0.784±0.1, BIO 5 µM 0±0 p<0.001, 
BIO 1 µM 0.36 ± 0.040 p<0.001).  
 
Treatment with 40 and 20 mM LiCl for 72 h also caused a statistically 
significant reduction of invasion for SF188 and KNS42 (for both the invasion 
and leading edge zone (Figure 6A and B)) (mean±SEM: SF188 leading 
edge: control 0.869±0.014, LiCl 40 mM 0.256±0.042 p<0.001, LiCl 20 mM 
0.667±0.05 p=0.005; KNS42 leading edge: control 0.587±0.31, LiCl 40 mM 
0.123±0.02 p<0.001, LiCl 20 mM 0.112±0.026 p<0.001). LiCl at 20 and 5 
mM significantly reduced the invasion of HSJD-DIPG-007 following 72 h of 
treatment (Figure 6C) (mean±SEM HSJD-DIPG-007 leading edge: control 





Figure 5: Inhibition of paediatric glioma tumour spheroid invasion by LiCl and BIO 
Tumour spheroids (SF188) were encased in collagen and incubated in LiCl at 40, 20, 10, 5 
mM in NaCl (A) or BIO at 10, 5, 1, 0.5 µM in DMSO (B) for 72 h.  Tumour spheroid invasion 
was evaluated at 24, 48 and 72 h using the EVOS cell imaging system at x4 magnification. 
White scale bar represents 1000 µm. Images shown are representative of n=3 individual 




Figure 6: The effect of LiCl and BIO treatment on the migration index of tumour 
spheroids of paediatric glioma cell lines 
SF188 (A), KNS42 (B) and HSJD-DIPG-007 (C) tumour spheroids were encased in 
collagen and incubated in culture medium ± LiCl at 40, 20, 10, 5 mM in NaCl or BIO at 10, 
5, 1, 0.5 µM in DMSO for 72 h.  Tumour spheroid invasion was evaluated at 72 h using the 
EVOS cell imaging system. Images generated were analysed using Volocity 3D Image 
Analysis software or Image J by calculating the area of the invasion zone and the leading 
edge zone (as defined in section 2.4.1). A migration index (MI) for both the invasion zone 
and leading edge zone ((area of zone – area of core) ÷ total area) was calculated. Graphs 
show mean±SEM of multiple repeats pooled from up to n=3 individual experiments for 
SF188 and KNS42 and one individual experiment with multiple internal repeats for HSJD-
DIPG-007 (For HSJD-DIPG-007: control n=4, LiCl 20 mM n=6, LiCl 5 mM n=5, Bio 5 and 1 


















































































































































































































































To confirm that the observed effects on tumour spheroid invasion after drug 
treatment were not due to changes in spheroid viability or growth, the effects 
of the two inhibitors on spheroid viability were assessed using a WST-1 
assay. This assay has previously been used to determine viability of cells 
grown as spheroids (355). In the 3D spheroid system, both pHGG cell lines 
(SF188 and KNS42) displayed viability of at least 75 % or above for all 
treatments with LiCl and BIO (Figure 7). When normalised to the NaCl or 
DMSO corresponding control, it appears that the anti-invasive effects of LiCl 
and BIO are not accompanied by a marked loss of viability of SF188 and 
KNS42 cell lines when cultured as multicellular spheroids.   
 
Additionally, an evaluation of tumour spheroid growth was made by 
measuring changes in the spheroid area over time for each drug treatment. 
Growth was only significantly reduced by 40 mM LiCl for SF188 (Figure 8). 
Given that a statistically significant reduction in invasion was seen with 20 
mM LiCl in all cell lines with no significant reduction in tumour spheroid 
growth, it is unlikely that the anti-invasive effects of LiCl are attributed to 



















Figure 7: The effects of LiCl and BIO on pHGG tumour spheroid viability 
SF188 (A) or KNS42 (B) were seeded in an ultra-low attachment 96 well plate at 1x103 cells 
per well to form spheroid aggregates. Following 72 h incubation, cells were treated with 
culture medium or drugs (LiCl at 40, 20, 10, 5 mM in NaCl or BIO at 10, 5, 1, 0.5 µM in 
DMSO). Cell viability at 24, 48 and 72 h was determined by WST-1 assay and was 
expressed as a percentage of controls. Graphs show mean±SEM of one experiment 

























































































































































Figure 8: The effects of LiCl and BIO on pHGG tumour spheroid growth 
SF188 (A and B) or KNS42 (C and D) were seeded in an ultra-low attachment 96 well plate 
at 1x103 cells per well to form spheroid aggregates. Following 72 h incubation, cells were 
treated with culture medium or drugs (LiCl at 40, 20, 10, 5 mM in NaCl (A and C) or BIO at 
10, 5, 1, 0.5 µM in DMSO (B and D)). Tumour spheroids were imaged at time 0, 24, 48  and 
72 h following drug treatment. Growth over time ((area of spheroid at a given time point ÷ 
area of spheroid at time 0 h) x100) was calculated. Graphs show mean±SEM of one 













































































































































































































3.6 LiCl and BIO inhibit GSK-3 in paediatric glioma cell lines 
 
The effects of LiCl and BIO on migration and invasion has previously been 
investigated in adult glioma and their anti-migratory and anti-invasive activity 
has been attributed to their ability to inhibit GSK-3 and stabilise β-catenin 
(236,246). In order to confirm that LiCl and BIO target GSK-3 in pHGG, 
Western blot analysis of the activated and inactivated forms of GSK-3 
protein following drug treatment was conducted. Based on qualitative 
analysis, LiCl appeared to increase Ser9 phosphorylated GSK-3β 
(inactivated form), although this was also accompanied by an increase in the 
activating phosphorylated tyrosine form of GSK-3αβ.  BIO was observed to 
cause a decrease in the activating phosphorylated tyrosine form of GSK-
3αβ, although this was also associated with a decrease in the inactivated 
form of GSK-3β (Figure 9). To further examine these results, β-catenin 
localisation and staining patterns were evaluated by IF post-drug treatment 
(Figure 10). GSK-3 plays an important role in Wnt/β-catenin signalling and 
when it is inactivated, β-catenin accumulates and is re-located to the 
nucleus.  Conversely, active GSK-3 phosphorylates β-catenin and targets it 
for ubiquitylation (195). SF188 cells treated with either LiCl or BIO displayed 
reduced staining of β-catenin at the plasma membrane and enhanced 
cytoplasmic and peri-nuclear staining, demonstrating the ability of LiCl and 
BIO to target GSK-3. This was more marked for cells treated with BIO than 
LiCl (Figure 10A). For KNS42, both surface and intracellular staining of β-
catenin was observed in the control; however, BIO and LiCl treatment again 
resulted in the increased internalisation of β-catenin into the cytoplasm, 







Figure 9: LiCl and BIO affect GSK-3 in paediatric glioma cell lines   
pHGG cell lines SF188 and KNS42 were treated with 20 mM LiCl and 5 µM BIO. Following 
24 h incubation, cell lysates were obtained. Western blotting determined the expression of 
GSK-3 substrates: (total GSK-3β (A), Ser9 phosphorylated GSK-3β (inactivated form) (B) 
and Tyr216/279 phosphorylated GSK-3 αβ (active form) (C)) in LiCl and BIO treated cell 
lysates compared to NaCl or DMSO treated controls. All blots included a β-actin control to 
evaluate protein loading and transfer. A and C are representative of n=2 separate 
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Figure 10: The effects of LiCl and BIO on β-catenin localisation 
2x105 cells (SF188 (A) and KNS42 (B)) were grown on sterile cover slips and mock-treated 
with culture medium or medium containing either 20 mM LiCl or 5 µM BIO for 24 h. The 
effects of LiCl and BIO on β-catenin localisation were evaluated by immunofluorescent 
labelling. Arrows indicate β-catenin localisation. Red labeling: β-catenin, Green labeling: 
actin, blue labeling: DAPI staining. Magnification x63. White scale bar represents 50 μm. 
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3.7 Migration of pHGG cells in transwell assays is inhibited after 
treatment with LiCl and BIO 
 
In order to investigate any anti-migratory effects of LiCl and BIO on SF188 
and KNS42 monolayers, a 2D transwell assay was performed. As HSJD-
DIPG-007 grows as neurospheres, this cell line could not be used in 2D 
assays.  
 
Both pHGG cell lines SF188 and KNS42 were able to migrate through the 
transwell membranes, with SF188 demonstrating the most migration over 
four hours (data not shown). SF188 appears to be more migratory than 
KNS42 in both 2D and 3D assays (Figure 4, 6 and data not shown). Overall, 
treatment with 20 mM LiCl and 5 µM BIO in the transwell experiments 
resulted in a trend towards reduced cell migration in both SF188 and KNS42 
(Figure 11). 5 µM BIO treatment resulted in a trend towards reduced 
migration in both of the pHGG cell lines and this reached statistical 
significance for KNS42 (Figure 11) (mean±SEM: SF188 migration (% of 
control): control 100±0, 5 µM BIO 84.7±0.601 p=0.103; KNS42 migration (% 
of control): control 100±0, 5 µM BIO 58.9±9.17 p=0.023). Treatment with 20 
mM LiCl resulted in a trend towards reduced migration in both cell lines and 
reached statistical significance for SF188 (Figure 11) (mean±SEM SF188 
migration (% of control): control 100±0, 20 mM LiCl 58.7±8.11 p=0.0014; 
KNS42 migration (% of control): control 100±0, 20 mM LiCl 76.7±11.1 
p=0.160).  
 
In conclusion, LiCl and BIO at concentrations of 20 mM and 5 µM, 
respectively, appear to have statistically significant anti-migratory effects on 
pHGG cells.  Consequently, all subsequent migration assays and IF studies 
were performed on cells treated with LiCl or BIO at these concentrations. 
Additionally, at the same highest concentrations of NaCl or DMSO, no 
adverse effects on cell morphology or migration were observed, thus we 
carried out all subsequent experiments using growth medium (DMEM plus 











Figure 11: LiCl and BIO inhibit migration of paediatric glioma cells in a 2D Transwell 
assay 
5x104 cells pre-treated for an hour with either culture medium, 20 mM LiCl or 5 µM BIO 
were placed in the upper chamber of a transwell and left to migrate for 4 h. Migrated cells 
were visualised by DAPI staining and photographed using the EVOS cell imaging system. 
Volocity 3D Image Analysis software was used to quantify the area covered by migrated 
cells. Graph shows mean±SEM of n=3 individual experiments. *p<0.05, **p<0.01 by one-
way ANOVA for each cell type and treatment. 
 
 
3.8 Effects of LiCl and BIO on pHGG monolayer cell viability 
 
Next, the effect of LiCl and BIO treatment on the viability of cell monolayers 
was assessed using a WST-1 assay over a 72 h time course (Figure 12). A 
WST-1 assay was chosen over the MTT assay for improved accuracy. BIO 
is a naturally pigmented red compound and, therefore, background 
absorbance of BIO treatment taken up by cells had to be accounted for 
when interpreting the assay. This could be achieved more accurately by 
using the WST-1 assay as it lacks the solubilisation stage required for an 
MTT assay. This meant that the absorbance at each concentration of BIO 
could be more accurately quantified and accounted for within wells (by 



































SF188 was the most sensitive cell line to both treatment effects (Figure 12). 
At 24 h, which most closely correlates to the time point for the transwell 
assay, both cell lines demonstrated greater than 80 % viability when treated 
with LiCl (Figure 12). SF188 was more sensitive to treatment with BIO at 24 
h, with cell viability reduced to 72 % following 24 h treatment with 5 µM BIO; 
however, KNS42 was resistant to the effects of BIO with greater than 89 % 
cell viability demonstrated at 24 h across all concentrations (Figure 12).  
 
Over 72 h, when cultured as monolayers, both pHGG cell lines exhibited 
increased sensitivity to LiCl and BIO treatment compared to spheroid 
cultures. This is unsurprising since 3D aggregates of tumour cells, including 
pHGG cells, have been shown to be generally more drug resistant than 2D 
cultures (356,357). Finally, to demonstrate that LiCl and BIO are not directly 
cytotoxic at concentrations of 20 mM and 5 µM, respectively, monolayers of 
both pHGG cell lines were imaged by time-lapse microscopy following 
treatment with LiCl and BIO for 24 h. After 24 h, the drugs were removed, 
and both pHGG cell lines demonstrated recovery and resumed their normal 





Figure 12: Effects of LiCl and BIO on pHGG monolayer cell viability 
Cells were seeded (SF188 (A) at 2.5x103 cells/well, KNS42 (B) at 5x103 cells/well) in a flat- 
bottom 96 well plate and allowed to adhere overnight. Cells were then treated with culture 
medium or drugs (LiCl at 40, 20, 10, 5 mM in NaCl or BIO at 10, 5, 1, 0.5 µM in DMSO). Cell 
viability at 24, 48 and 72 h was determined by WST-1 assay and was expressed as a 
percentage of controls. Graphs show mean±SEM of n=3 individual experiments performed 





























































































































































Figure 13: LiCl and BIO are not directly cytotoxic to pHGG monolayers at 24 h 
pHGG cell lines SF188 (A) and KNS42 (B) were incubated with 20 mM LiCl, 5 µM BIO or 
culture medium and live cell imaging was performed for 24 h using the Nikon Biostation IM 
live cell imaging system. After 24 h, cells were washed with PBS to remove drug treatments 
and replenished with fresh drug-free culture medium. Cells were imaged for a further 24 h. 
Stills were taken from movies obtained using the Biostation IM-associated software at 0 and 
24 h and 0 and 24 h post-drug removal. Magnification x40. 
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3.9 LiCl and BIO inhibit pHGG cell migration on a topographic 
nanofibre-based migration assay 
 
A nanofibre-based assay was also used to assess the effect of GSK-3 
inhibition on migration of pHGG cell lines over a 3D scaffold.  This assay 
utilises aligned fibres of poly-ε-caprolactone to stimulate cell migration via 
topographic cues (351).  When cells are plated on the nanofibre scaffold 
they adhere, elongate and move along the fibre axis (Figure 14A). 
 
Firstly, it was noted that each pHGG cell line was able to migrate in this 
model system and further confirmation of the anti-migratory effect of the 
GSK-3 inhibitors LiCl and BIO was obtained. As seen in previous assays, 
SF188 was the most migratory cell line in terms of distance travelled. 
Perimeter indices (% increase from the spheroid perimeter to the perimeter 
marking the migrated cells) were calculated for each cell line. Treatment with 
LiCl and BIO resulted in a trend towards decreased migration index (Figure 
14C) and perimeter index (Figure 14D) for both pHGG cell lines when 
compared to controls. However, surprisingly the effect was more marked for 
KNS42 when compared to SF188. LiCl and BIO resulted in a statistically 
significant reduction in both migration and perimeter index for KNS42 
(mean±SEM: migration index: control 0.72±0.0123, LiCl 20 mM 0.337±0.061 
p=<0.001, BIO 5 µM 0.327±0.0107 p=<0.001; perimeter index: control 
50.6±2.50, LiCl 20 mM 20.2±5.04 p=0.0012, BIO 5 µM 20.6±3.27 p=0.0019). 
For SF188, LiCl and BIO resulted in a small but non-statistically significant 
reduction of migration index (Figure 14C) (mean±SEM migration index: 
control 0.911±0.001, LiCl 20 mM 0.88±0.0458 p=0.655, BIO 5 µM 
0.819±0.0293 p=0.076). BIO significantly reduced the perimeter index for 
SF188; however, LiCl only caused a small but non-significant reduction in 
this index (Figure 14D) (mean±SEM perimeter index: control 79.2±1.71, LiCl 

























   
 
Figure 14: LiCl and BIO reduce migration of paediatric glioma cells in an aligned 
nanofibre 3D migration assay 
Tumour cell aggregates formed from hanging drops of 1x103 cells of SF188 or KNS42 were 
placed in wells containing aligned poly-ε-caprolactone fibres and cultured ± 20 mM LiCl or 5 
µM BIO. Migration was imaged over 72 h using the EVOS cell imaging system. (A) 
Illustration of spheroids formed from cell line SF188 cultured ± 20 mM LiCl imaged over 72 
h. (B) Illustration of spheroids formed from cell line SF188 cultured ± 5 µM BIO imaged over 
72 h. Cells were labeled with CellTrackerTM dye to enhance visualisation of migrating cells 
(black and white images in A and B). Images at x4 magnification. Scale bar represent 400 
µm. (C) Quantification and comparison of the effects at 72 h of 20 mM LiCl and 5 µM BIO 
on migration index (MI) ((area of zone – area of core) ÷ total area) for both cell lines. (D) 
Quantification and comparison at 72 h of the effects of 20mM LiCl and 5 µM BIO on the 
perimeter index (% increase from the spheroid perimeter to the perimeter marking the 
migrated cells) for both cell lines. Graphs show mean±SEM of one experiment performed in 

















































































































































































































































































































































3.10 Live cell imaging of pHGG cell line migration 
 
Given the accumulating evidence that LiCl and BIO are able to reduce the 
migration of SF188 and KNS42 cells, direct changes in cell morphology and 
motility following treatment should be observable. Thus, the effects of LiCl 
and BIO on individual cell morphology were investigated by live cell imaging 
of random cell migration. SF188 and KNS42 cells were incubated with 20 
mM LiCl, 5 µM BIO or control and live cell imaging was performed over 24 h 
(Figure 15) (Movies 1-6).  
 
Interestingly, both LiCl and BIO appeared to affect cell morphology with cells 
rounding up after treatment, blebbing and, in the case of SF188, 
demonstrating loss of front-rear polarity (Figure 15A) (Movies 1-6). SF188 
cells treated with both LiCl and BIO appeared to lose the clear definition of 
their leading edge and trailing edge compared to cells mock-treated with 
culture medium. Individual cell tracking (Figure 15B) revealed that cells 
treated with either LiCl or BIO were less motile and became almost static 
over a 24 h time period and this difference was marked when compared to 
the tracking of cells treated with growth medium alone.  
 
In terms of motility, SF188 cells were more motile and demonstrated greater 
velocity than KNS42 cells (mean±SEM: velocity SF188: control 
0.295±0.0018 µm/min, velocity KNS42: control 0.0599±0.0048 µm/min) 
(Figure 15C-E). 20 mM LiCl and 5 µM BIO treatment resulted in a trend 
towards reduced velocity of SF188 cells (mean±SEM velocity: control 
0.295±0.0018 µm/min, LiCl 20 mM 0.153±0.047 µm/min p=0.049, BIO 5 µM 
0.21±0.041 µm/min p=0.247) whereas only treatment with 5 µM BIO 
indicated a tendancy towards reduced velocity of KNS42 cells (mean±SEM 
velocity: control 0.0599±0.0048 µm/min, LiCl 20 mM 0.0761±0.0063 µm/min 
p=0.101, BIO 5 µM 0.0501±0.041 µm/min p=0.352).  
 
Petrie et al. state that directionality of a migrating cell can be defined as it’s 
displacement divided by the total length of the path it travels (358). The 
authors also state that ‘cells contain polarity signalling machinery that can 
influence directional cell motility’ and that ‘stability of the front-rear axis 
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correlates with the extent of persistent directional cell movement’ (358). It is 
also well known that cell polarity is required to generate the front-rear axis 
required for random cell migration and that maintenance of such polarity is 
an essential part of cell migration (87). In this thesis, measurement of 
displacement was used to demonstrate the effect of drug treatment on cell 
polarity by proxy. This allowed measurement of the distance from the start 
point of the track of a moving cell to the point at the end of the experiment 
and not just the total length of distance travelled. Measuring displacement 
allowed illustration of whether a cell had actually moved away from its 
original starting point over time (a process that requires a cell to demonstrate 
polarity and generation of a front-rear axis), instead of just moving on the 
spot. 
 
SF188 cells were able to polarize (front-rear) under normal conditions; 
however, treatment with 20 mM LiCl and 5 µM BIO resulted in a trend 
towards reduced polarity as demonstrated by a reduction in displacement, 
but this did not reach statistical significance (mean±SEM: displacement 
SF188: control 176.5±74.6 µm, LiCl 20 mM 52.5±15.3 µm p=0.259, BIO 5 



























Figure 15: Live cell imaging of pHGG cell lines reveals differences in random cell 
migration velocity alongside changes in polarity and morphology following treatment 
with LiCl and BIO 
Paediatric glioma cell lines SF188 and KNS42 were incubated with 20 mM LiCl, 5 µM BIO 
or culture medium and live cell imaging was performed for 24 h using the Nikon Biostation 
IM live cell imaging system. Magnification x40. Stills taken at time 0 h and 24 h from movies 
of SF188 and KNS42 (A) treated with either 20 mM LiCl, 5 µM BIO or culture medium 
demonstrate changes in the morphological appearance of individual cells following 
treatment. Tracking analysis of SF188 and KNS42 (B) from live cell imaging using Image J 
with MTrack software following treatment with 20 mM LiCl or 5 µM BIO demonstrates 
differences in motility between cell lines and treatments. Quantification analysis of distance 
(C), displacement (D) and velocity (distance/time) (E), from live cell imaging of both cell 
lines following treatment with 20 mM LiCl or 5 µM BIO was completed using Image J with 
MTrack. Graphs show the mean±SEM obtained from two separate experiments, with 
multiple fields of cells analysed for each condition. *p<0.05 by one-way ANOVA for each 

























































































3.11 Immunofluorescence studies reveal cytoskeletal changes in 
pHGG cell lines following treatment with LiCl and BIO 
 
To investigate the effects of the GSK-3 inhibitors LiCl and BIO on the cell 
cytoskeleton, IF staining for microtubules and actin as well as focal 
adhesions were carried out on cells treated with culture medium ± drugs. 
Microtubules and actin, alongside intermediate filaments comprise the 
cytoskeleton and their interplay orchestrates cellular shape changes during 
migration (86). Focal adhesions reside at the end of large actin bundles and 
link the actin cytoskeleton to the ECM (90). Focal adhesions are highly 
dynamic and their constant assembly and disassembly allows the cell to 
generate traction forces to move forward (90).  
 
Both cell lines were characterised by distinctive microtubule network, actin 
cytoskeleton and focal adhesion staining patterns. Untreated SF188 cells 
appeared as large cells with prominent well-defined microtubule networks 
spreading across the whole cell body, elaborate actin stress fibres traversing 
across the whole cell body and a network of multiple focal adhesions 
interspersed across the whole cell body (Figure 16A). After treatment with 20 
mM LiCl or 5 µM BIO, the SF188 cells started to become more rounded and 
microtubules localised towards the cell surface. The most pronounced 
changes were seen in actin filament and focal adhesion distribution and, as 
such, at least 100 SF188 cells from each treatment condition were scored to 
determine the distribution of actin and focal adhesions ± drugs. Following 
treatment with 20 mM LiCl or 5 µM BIO, actin was no longer distributed 
across the whole cell body as well-defined stress fibres and staining 
appeared to be more diffuse throughout the cytoplasm (defined as ‘other’) 
(Figure 16B). Additionally, following treatment with 20 mM LiCl or 5 µM BIO, 
the overall presence of focal adhesions appeared to be diminished (defined 
as ‘diffuse’ staining) and when present, no longer appeared to be across the 
whole cell body as seen in control cells. Instead, LiCl and BIO treatment 
appeared to cause a redistribution of focal adhesions to the surface of the 
cell (defined as ‘cortical’ staining) (Figure 16C).  
 
 87 
KNS42 cells appeared as medium-sized elongated cells with a prominent 
microtubule network and diffuse actin stress fibres traversing across the 
whole cell body (Figure 16D and E). Focal adhesions appeared to be 
associated with actin filaments in untreated cells but were less marked and 
had a more diffuse distribution than seen in SF188 cells (Figure 16F). After 
addition of the inhibitors, the cells rounded up and appeared smaller by 
microscopy in comparison to the untreated cells. Actin stress fibres 
appeared to be less pronounced and re-localised towards the cell surface 
(defined as ‘cortical’ staining) following treatment with BIO (Figure 16E). 
Following treatment with 20 mM LiCl, actin staining appeared to be more 
diffuse throughout the cytoplasm and well-defined stress fibres were less 
marked compared to control-treated cells. Overall, focal adhesions appeared 






Figure 16: Immunofluorescence studies reveal cytoskeletal changes in two pHGG cell 
lines after LiCl and BIO treatment 
Paediatric glioma cell lines SF188 (A-C) and KNS42 (D-F) were grown on cover slips and 
incubated with 20 mM LiCl, 5 µM BIO or culture medium for 72 h. The effects of LiCl and 
BIO on microtubules, actin and focal adhesions (by vinculin) were evaluated by IF labeling 
of cell lines SF188 (A) and KNS42 (D). Green labeling: alpha-tubulin, actin or vinculin, red 
labeling: actin and, blue labeling: DAPI staining. Magnification x63. White scale bar 
represents 50 μm. At least 100 cells from each treatment condition were scored to 
determine changes in the distribution of the actin cytoskeleton (defined as cortical, stress 
fibres or other as illustrated) (B and E) or focal adhesion pattern (defined as cortical, diffuse 


































































































































































































pHGG and DIPG are devastating tumours associated with poor prognosis 
and despite attempts at aggressive therapy, tumours inevitably recur due to 
their diffuse and invasive nature. As a result, there is a need to identify and 
develop novel therapeutic approaches that target and block tumour invasion.  
In this chapter, the migratory and invasive behavior of two pHGG cell lines 
and one patient-derived DIPG cell line is characterised using both 2D and 
3D models. The ability of paediatric glioma cell lines (SF188, KNS42 and 
HSJD-DIPG-007) to grow as tumour spheroids was demonstrated and these 
spheroids were shown to be capable of invasion through a collagen matrix. 
To the best of my knowledge, this is the first time that DIPG invasion has 
been described using a 3D model. Each cell line investigated demonstrated 
a unique pattern of migration and invasion and KNS42 was noted to have a 
significantly reduced migration index when compared to that of SF188 and 
HSJD-DIPG-007. The motility of individual pHGG cells was examined by live 
cell imaging, which indicated different speeds and migratory morphology 
between the two cell lines. Again KNS42 was seen to be less motile and 
demonstrated reduced velocity when compared to SF188 under control 
conditions.  
 
In addition, the results within this chapter demonstrate, for the first time, that 
LiCl and BIO, which have anti-invasive effects in adult glioma cell lines  
(236,246), can also inhibit the migration and invasion of paediatric glioma 
cells in 2D (transwell) and 3D (spheroid invasion and nanofibre plate) 
assays.  All three paediatric glioma cell lines demonstrated a statistically 
significant reduction in migration index when treated with either 5 µM BIO or 
20 mM LiCl in the 3D spheroid invasion assay. This was not accompanied 
by marked loss of viability compared to appropriate controls when SF188 
and KNS42 cells were cultured as multicellular spheroids.  This data 
correlates with previously published results for these inhibitors in adult 
glioma models (236,246). Furthermore, LiCl and BIO treatment resulted in a 
tendancy towards reduced movement by tracking analysis (SF188 and 
KNS42) and loss of polarity (SF188) of individual pHGG cells. Cells rounded 
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up, demonstrated blebbing and for SF188, lost the clear definition of a 
leading and trailing edge when treated with either drug. Non-apoptotic 
plasma membrane blebbing has been implicated in cell movement, mode of 
migration and disruption of actin-membrane interactions (359). These 
observations are novel and demonstrate the specific effects of LiCl and BIO 
on cell morphology and motility.  
 
Finally, the results in this chapter show that treatment of pHGG cells with 5 
µM BIO or 20 mM LiCl can result in cytoskeletal rearrangements. Following 
treatment, prominent actin stress fibres traversing the whole cell body were 
lost and actin fibres appeared more diffusely distributed or re-organised to 
the cell surface. Focal adhesions were also re-organised and became either 
diffusely co-localised with actin filaments or redistributed towards the cell 
surface following drug treatment. Taken together, these observations offer 
some indication of how LiCl and BIO exert their anti-migratory and anti-
invasive effects. Overall, this study is amongst the very few to have identified 
existing clinical and pre-clinical agents which are capable of disrupting 
migration and invasion in pHGG and DIPG cell lines. 
 
Work from Dr Sean Lawler’s group has previously addressed the ability of 
LiCl and BIO to inhibit migration and invasion of adult HGG cells. In the first 
of two studies, Dr Lawler’s group concluded that 20 mM LiCl could potently 
block glioma cell migration in 3D spheroid, wound-healing and brain slice 
assays (236). The group’s follow-on study concluded that potent GSK-3 
inhibitors of the indirubin family (including 5 µM BIO) could reduce invasion 
of both adult glioma cells and glioma-initiating neurospheres in vitro and in 
vivo. Additionally, the indirubin 6-bromoindirubin acetoxime (BIA) showed 
significant therapeutic efficacy in mice (246).  
 
There are some correlations between the results presented in this chapter 
and those of Dr Lawler. Of note, 20 mM LiCl and 5 µM BIO appear to be the 
effective concentrations to significantly inhibit the invasion of both adult and 
pHGG cells in 3D spheroid invasion assays (236,246). Dr Lawler’s group 
conclude that the effects of indirubins on migration appear to be more 
pronounced than those of LiCl, as demonstrated by a transwell assay (246). 
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Whilst this appears to be the case for KNS42 in a similar transwell assay in 
our study, 20 mM LiCl resulted in a more pronounced and significant 
reduction in transwell migration of SF188 compared to 5 µM BIO treatment. 
This observation may reflect differences in individual cell line responses to 
the effects of drug treatment.  
 
The anti-migratory and anti-invasive effects of 20 mM LiCl and 5 µM BIO on 
paediatric glioma appear to be specific and not a consequence of 
cytotoxicity. The effects of the drugs on cytotoxicity can be distinguished 
from the effects on migration because: 1) spheroids of pHGG cell lines 
demonstrate a reduction in viability of only about 20 % following 72 h 
incubation with these drugs compared to culture medium and no marked 
change in viability when normalised to the NaCl or DMSO corresponding 
control; 2) in transwell assays, differences in migration were observed after 4 
h; however, viability data obtained from monolayers at 24 h still 
demonstrates over 72 % viability in all cell lines following drug treatment 
and; 3) pHGG cells treated with either 20 mM LiCl or 5 µM BIO for 24 h 
demonstrate recovery and return to their normal morphology following drug 
washout. In keeping with these results, Dr Lawler’s group also concluded 
that blockade of adult HGG migration with 20 mM LiCl or 5 µM BIO is not 
secondary to cytotoxicity and the authors demonstrated that the anti-
migratory effects of both LiCl and BIO are reversible, following drug washout 
(236,246).  
 
Finally, the effects of LiCl and BIO on pHGG invasion observed in our study 
do not appear to be related to an inhibitory effect on tumour spheroid growth. 
Although 40 mM LiCl appeared to significantly slow the growth of spheroids 
at 72 h, this effect was not noted at any other time point or with any other 
concentration of either drug. Surprisingly, 20 mM LiCl appeared to 
significantly increase the growth of pHGG spheroids over time, which is 
undesirable for a potential cancer treatment. Further work is required to 
evaluate whether the increased growth effects of 20mM LiCl on pHGG 
persist over a longer time period. Dr Lawler has previously shown that 20 
mM LiCl slows adult glioma cell proliferation, mainly through its effect on the 
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cell cycle (236); however, future work is required in order to evaluate the 
direct effects of LiCl specifically on pHGG cell proliferation. Additionally, the 
effects of 20 mM LiCl in combination with other chemotherapeutics that 
target proliferation and growth, remain to be investigated. Future studies are 
also required to determine the in vivo effects of LiCl on pHGG tumour growth 
and proliferation.  
 
One postulated mechanism for the anti-migratory effects of LiCl and BIO is 
through their ability to inhibit GSK-3. LiCl was one of the first GSK-3 
inhibitors to be described; however, it has a wide range of molecular targets, 
including IMPase (224). Dr Lawler’s group demonstrated that the anti-
migratory effects of LiCl were not attributable to its effect on IMPase as: 1) 
migration could not be rescued in cells treated with LiCl by the addition of 
inositol (depleted following IMPase blockade) and; 2) use of a potent IMPase 
inhibitor had no significant effect on glioma invasion (236). By contrast, 
specific pharmacological GSK-3 inhibitors mimicked the dose-dependent 
blockade of glioma invasion observed with LiCl (236). As GSK-3 inhibition 
can stabilise β-catenin and target it to the nucleus via the canonical Wnt 
signalling pathway (195), β-catenin reporter activity was investigated in adult 
HGG cells following LiCl treatment at a range of concentrations. LiCl 
treatment increased β-catenin reporter activity and the degree of GSK-3 
inhibition directly correlated with blockade of invasion (236). Dr Lawler’s 
group also demonstrated that β-catenin knockdown could rescue the anti-
migratory effects of BIO, suggesting that β-catenin stabilisation following 
GSK-3 inhibition may also play an important role in inhibiting glioma 
migration (246). Other in vivo studies have demonstrated contradictory 
findings demonstrating that β-catenin can be pro- (360,361) or anti- (362) 
migratory within glioma.  
 
In our study, β-catenin localisation was studied by IF following the treatment 
of pHGG cells with LiCl and BIO and a marked internalisation of β-catenin to 
the cytoplasm and nucleus was observed following drug treatment. This 
observation has also been noted in adult glioma following LiCl and BIO 
treatment (363) and provides evidence to support the effectiveness of LiCl 
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and BIO as an inhibitor of GSK-3 in pHGG. Furthermore, qualitative 
interpretation of Western blot analysis of pHGG lines showed that LiCl 
treatment increased Ser9 phosphorylated GSK-3β (inactivated form), 
although this was also accompanied by an increase in the activating 
phosphorylated tyrosine form of GSK-3αβ. BIO decreased the activating 
tyrosine of GSK-3αβ, although this was also associated with a decrease in 
the inactivated form of GSK-3β. These findings were similar to the work of 
Dr Lawler’s group, who also showed that BIO reduced Tyr216 
phosphorylation of GSK-3β (246) while also causing a slight decrease in 
inhibitory Ser9 phosphorylated GSK-3β (363). Simòn et al. have 
demonstrated that ‘GSK-3 kinase activity is not necessarily correlated with 
the extent of tyrosine phosphorylation’ and this may be one possible 
explanation to why LiCl, a known inhibitor of GSK-3 (224), can cause an 
increase in the activating phosphorylated tyrosine form of GSK-3αβ in our 
system as well as increasing the inactivating form (Ser9 phosphorylated 
GSK-3β) (364). It appears that within cells, GSK-3 regulation is complex, 
involving a combination of; post-translational phosphorylation, interaction 
with other proteins in complexes, priming phosphorylation of the substrate 
and distribution within the cell (196). The results within this chapter start to 
provide evidence that LiCl and BIO can cause changes in the 
phosphorylation of GSK-3 in pHGG which can alter its activity; however, 
given the multiple layers of regulation of GSK-3 activity within a cell and its 
complex nature, additional studies are required to further prove this 
hypothesis.  
 
Cell migration may be achieved by a set of component processes, which are 
often regulated by the same effectors, regardless of the cell type and the 
mode of migration. Broadly, these processes are based on polarisation, 
protrusion and adhesion, translocation of the cell body and retraction of the 
rear. They are also coordinated and integrated by extensive transient 
signalling networks (91). GSK-3 is thought to be a key player in the control of 
cell migration (202,213). GSK-3 has a role in promoting actin polymerisation 
and lamellipodia formation in the migrating cell (213,216,217) and is also 
critical for the determination of cell polarity (110).  GSK-3 is also involved in 
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the organisation of microtubule networks (213,219,220) and plays an 
important role in the formation of adhesions and cell spreading (213,222). In 
this study, it was observed that LiCl and BIO treatment could induce 
changes in the microtubule cytoskeleton, actin skeleton and focal adhesion 
dynamics of pHGG cells. Following drug treatment, microtubules re-localised 
to the surface of cells, actin fibres re-localised to the cell periphery and there 
was a change in focal adhesion distribution with re-distribution to the cell 
surface and apparent loss of focal adhesion foci. Live cell imaging of random 
cell migration revealed that the cells appeared to be immobilised in response 
to either a loss of polarity and/or motility. Taken together, these observations 
account for the inability of pHGG cells to migrate following LiCl or BIO 
treatment. In conclusion, the results contained within this chapter, together 
with the work of Dr Lawler (236,246), suggests that GSK-3 inhibition may be 
one potential mechanism explaining the observed anti-migratory effects of 
LiCl and BIO in pHGG cells. Future studies are needed to evaluate a wide 
range of potent specific pharmacological inhibitors of GSK-3 in order to 
further prove this hypothesis and to identify drug candidates to take forward 
for clinical testing.  
 
Both LiCl and BIO have potential for clinical application. LiCl has been used 
to treat psychiatric conditions such as bipolar disorder for many decades  
(365) and BIO is part of the family of indirubins, which have been identified 
as the active ingredient of the Chinese medicine Danggui Longhui Wan, 
which has anti-leukemic activity (238). Other GSK-3 inhibitors have been 
developed and tested in a variety of pre-clinical studies (196,226); however, 
current hurdles for the use of such drugs in clinical practice include 
optimisation of drug delivery and avoidance of toxic systemic accumulation 
of the drug. In particular, LiCl has a narrow therapeutic window, inducing 
nephrotoxicity at concentrations greater than 1.5 mM in vivo (236). Although 
data within this chapter indicates significant anti-migratory and anti-invasive 
effects on paediatric glioma at concentrations as low as 5 mM, alternative 
methods of drug delivery such as convection-enhanced delivery or local 
delivery with polymers may be required to attain localised high 
concentrations of the drug in human brain tumours (236,366) and this 
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requires further evaluation in vivo with pre-clinical models. Alternatively, 
development of specific novel GSK-3 inhibitors capable of crossing the BBB 
at concentrations associated with clinically acceptable side effect profiles will 
help overcome this problem. Finally, due to a lack of available mouse 
models of paediatric glioma invasion, the anti-migratory effects of GSK-3 
inhibitors on pHGG tumours in vivo have not been addressed. Studies of 
adult glioma have shown that GSK-3 inhibitors of the indirubin family are 
able to reduce invasion of glioma cells in vivo (246) and development of a 
paediatric orthotopic xenograft model of migration to test novel GSK-3 
inhibitors forms a major part of ongoing studies in this area (see chapter 6).    
 
In this study, multi-cellular spheroids were used to simulate a 3D tumour. 
Most spheroids beyond 500 μm in size consist of a necrotic core, 
surrounded by an outer rim (approximately 100-300 μm thick) of viable and 
proliferating cells (367). Quiescent, yet intact, viable cells may also be found 
surrounding the necrotic core (367). Use of this model is well established in 
cancer biology research and emulates the organisation of an in vivo tumour 
mass (367). The use of the 96 well low adhesion plate was an extremely 
efficient way of making spheroids that were uniform in size. This 
methodology was much superior to the hanging drop method of spheroid 
formation (350), which resulted in the formation of spheroids that were less 
uniform in size and that sometimes disaggregated on transfer from petri dish 
lids. This was one of the main disadvantages of the nanofibre scaffold 
assay, which relied upon spheroids being formed by hanging drops.  
 
When spheroids are embedded in a hydrogel matrix, cells can invade into 
the matrix outward from the core representing a model of the process of 
tumour invasion (236,368). In this study, a collagen matrix was used. 
Although many different matrix material are commercially available, collagen 
was chosen as it is well established for use in this invasion assay 
(75,236,369) and intra-tumoural fibrillar collagens have been shown to be an 
integral part of the ECM in a subset of glioblastomas (370). Collagen is also 
seen around blood vessels and the pial surface in the brain (24,115). One of 
the drawbacks of this model of spheroid invasion was that it was sometimes 
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difficult to fully encase each spheroid within the collagen matrix. Spheroids 
that were not fully encased in collagen, obstructed from view by air bubbles 
or that had moved and encased at the periphery of a well, had to be 
discounted from analysis. Additionally, quantification of the migration index 
was time consuming and definition of different zones could potentially be 
fraught by inter-observer error. Future work aims to develop computer 
software to quantify the number of cells migrating into pre-defined zones, 
which will improve both accuracy and throughput for larger scale analysis 
(368).  
 
Finally, working with the DIPG primary-derived cell line HSJD-DIPG-007 was 
a challenge. Initially the growth of four other DIPG cell lines that were gifted 
by Dr Angel M Carcaboso was attempted (HSJD-DIPG-008, HSJD-DIPG-
011, HSJD-DIPG-012, HSJD-DIPG-013); however, these lines failed to 
culture in the laboratory. Although HSJD-DIPG-007 could be cultured, the 
cells sometimes failed to re-form neurospheres following passage and this 
unpredictability made it difficult to plan experiments, bulk up large numbers 
of cells and perform multiple repeats. Additionally, HSJD-DIPG-007 can be 
differentiated to a monolayer by removing growth factors from the medium 
and culturing the cells in TSM plus HI-FCS; however, this alters cell 
phenotype and, therefore, a direct comparison between HSJD-DIPG-007 
grown as neurospheres and differentiated monolayers could not be made. In 
this thesis, all assays evaluating HSJD-DIPG-007 were therefore conducted 
on cells grown as neurospheres as this method of culture was felt to be 
more representative of the human disease.   
 
To conclude, the migratory and invasive behaviour of paediatric glioma cell 
lines has been characterised using 2D and 3D models, uncovering 
differences in their pattern of migration, invasion, motility and morphology. 
For the first time, GSK-3 inhibitors such as LiCl and BIO have been 
demonstrated as novel candidates for migration and invasion inhibition in 
pHGG and DIPG and, as such, warrant further investigation as therapeutics 
for this challenging group of tumours.  
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4 Chapter 4: An investigation into the effects of oncolytic viruses on 




OVs are anti-cancer agents that are capable of selectively infecting and 
lysing cancer cells, while leaving normal tissue unharmed (252,253).  
Alongside their ability to kill infected cancer cells, OVs can also generate an 
anti-cancer immune response, by enhancing the immunogenicity of the 
tumour microenvironment and activating innate and adaptive immune 
responses against infected tumour cells (253). Thus, OVs have huge clinical 
potential for poor prognosis tumours through their ability to act as selective 
cytotoxic and immunogenic agents. 
 
However, very little is known about the effects of OVs on cancer cell 
invasion and migration. In order for a cell to move and migrate it needs to be 
able to alter its shape, a process made possible by the presence of the cell 
cytoskeleton (86). Given that the cell cytoskeleton also plays a critical role in 
regulating the life cycle of infecting viruses (308-311), OVs may be able to 
influence cancer cell migration through their interplay with the host cancer 
cell cytoskeleton.  If OVs have the potential to inhibit cancer cell migration, 
they would be a highly sought after therapeutic option for poor prognosis 
invasive tumours such as pHGG and DIPG. 
 
In this chapter, the hypothesis that OVs (HSV, reovirus and VV) are capable 
of specifically inhibiting the migration and invasion of pHGG and DIPG cells 
is tested using both 2D and 3D in vitro models. In addition, the effects of 
oncolytic HSV, reovirus and VV on pHGG and DIPG cell viability, 
proliferation and growth are evaluated. To the best of our knowledge, this is 
the first time that OVs have been evaluated as potential anti-migratory  and 
anti-invasive treatments for pHGG and DIPG and this offers a highly 




4.2 Evaluation of the effects of oncolytic viruses on pHGG migration 
in a 2D scratch assay 
 
The ability of three OVs (HSV, reovirus and VV) to block the migration of two 
pHGG cell lines (SF188 and KNS42) and one mouse glioma cell line 
(GL261-Luc) using a scratch assay, was evaluated. In this model, a scratch 
was applied to a near confluent monolayer of cells to form a cell-free zone. 
Cells were then treated ± virus and the migration of cells across the scratch 
over 24 h was evaluated using cell imaging (Figure 17). Images were 
quantified using Image J software to evaluate the percentage change in the 
area of the scratch over 24 h. The mouse glioma cell line GL261-Luc was 
included in the in vitro analysis as this cell line was to be used in the 
development of an in vivo mouse model of glioma migration.  
 
In all three cell lines investigated, oncolytic HSV was able to significantly 
reduce the migration of cells across the scratch (Figure 18A, 19A and 20A). 
A statistically significant reduction of migration was achieved by HSV at 1 
and 10 pfu/cell for SF188 (Figure 18A) (mean±SEM: percentage change of 
the scratch from time 0 h: control 89.4±3.4 %, HSV 1 pfu/cell 69±9.7 % 
p=0.038, HSV 10 pfu/cell 19.2±1.3 % p<0.001), 10 pfu/cell HSV for KNS42 
(Figure 19A) (mean±SEM: percentage change of the scratch from time 0 h: 
control 15.9±3 %, HSV 10 pfu/cell 0.41±0.66 % p=0.025) and 50 pfu/cell for 
GL261-Luc (Figure 20A) (mean±SEM: percentage change of the scratch 
from time 0 h: control 59.4±5.3 %, HSV 50 pfu/cell 5.7±1.1 % p<0.001).  
 
Conversely, reovirus treatment did not significantly alter cell migration over 
24 h in any of the cell lines (Figure 18B, 19B, 20B), and this was particularly 
evident for SF188 (Figure 18B) and GL261-Luc cells (Figure 20B), where the 
percentage change in the area of the scratch over 24 h remained almost 
identical for control and reovirus treatments at all virus concentrations.  
 
VV treatment resulted in a statistically significant reduction of migration over 
24 h for SF188 and GL261-Luc in a dose-dependent manner (Figure 18C 
and 20C) (mean±SEM: percentage change of the scratch from time 0 h 
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SF188: control 89.4±3.4 %, VV 0.1 pfu/cell 50±12.2 % p=0.0014, VV 1 
pfu/cell 55.3±10.8 % p=0.0048, VV 10 53.4±7.6 % p=0.0031; percentage 
change of the scratch from time 0 h GL261-Luc: control 59.4±5.3 %, VV 1 
pfu/cell 34.7±5.2 % p=0.0246, VV 10 pfu/cell 9±1.8 % p<0.001, VV 50 
pfu/cell -2.8±5.5 % p<0.001). However, when examined microscopically, VV 
also appeared to be exerting cytotoxic effects in all three lines in a dose-
dependent manner, with cells displaying apoptotic morphology - rounding up 
and reducing in size by 24 h. For KNS42 and GL261-Luc (Figure 19C and 
20C), the average area of the scratch increased in size by 24 h following VV 
treatment (KNS42 at 0.01 pfu/cell and 10 pfu/cell, GL261-Luc at 50 pfu/cell), 








                   
 
 
Figure 17: Illustrations of the effects of oncolytic viruses on pHGG migration over 24 
h 
SF188 were seeded into 24 well plates at 1x105 cells/well. After 24 h, a scratch was applied 
across the monolayer and wells were treated ± each virus at 10 pfu/cell (HSV, reovirus 
(Reo) and VV). Plates were imaged at x4 magnification in the IncuCyte ZOOM® incubator. 
Images shown are representative stills from movies created with IncuCyteTM software at 













Figure 18: The effects of oncolytic viruses on SF188 migration over 24 
h 
SF188 were seeded into 24 well plates at 1x105 cells/well. After 24 h, a 
scratch was applied across the monolayer and wells were treated ± each 
virus at 0.01, 0.1, 1 and 10 pfu/cell HSV (A), reovirus (Reo) (B) or VV (C). 
Plates were imaged at 0 h and 24 h using the EVOS cell imaging system at 
x4 magnification. Migration was quantified from images using Image J 
software to determine the percentage change in the area of the scratch over 
24 h. Graphs show mean±SEM of n=3 individual experiments. *p<0.05, 

























































































































































































Figure 19: The effects of oncolytic viruses on KNS42 migration over 24 
h 
KNS42 were seeded into 24 well plates at 1x105 cells/well. After 24 h, a 
scratch was applied across the monolayer and wells were treated ± each 
virus at 0.01, 0.1, 1 and 10 pfu/cell HSV (A), reovirus (Reo) (B) or VV (C). 
Plates were imaged at 0 h and 24 h using the EVOS cell imaging system at 
x4 magnification. Migration was quantified from images using Image J 
software to determine the percentage change in the area of the scratch over 
24 h. Graphs show mean±SEM of n=3 individual experiments. *p<0.05, 


























































































































































































Figure 20: The effects of oncolytic viruses on GL261-Luc migration 
over 24 h 
GL261-Luc were seeded into 24 well plates at 1x105 cells/well. After 24 h, a 
scratch was applied across the monolayer and wells were treated ± each 
virus at 0.1, 1, 10 and 50 pfu/cell HSV (A), reovirus (Reo) (B) or VV (C). 
Plates were imaged at 0 h and 24 h using the EVOS cell imaging system at 
x4 magnification. Migration was quantified from images using Image J 
software to determine the percentage change in the area of the scratch over 
24 h. Graphs show mean±SEM of n=3 individual experiments. *p<0.05, 































































































































































































4.3 Evaluation of the effects of oncolytic viruses on paediatric glioma 
invasion 
 
To investigate the effects of OVs on pHGG and DIPG invasion, the 3D 
tumour spheroid assay described previously was used (section 2.4.1 and 
3.4).  Tumour spheroids of each cell line (SF188, KNS42, HSJD-DIPG-007 
and GL261-Luc) were encased in a collagen matrix and then overlaid with 
OV at varying concentration. Tumour spheroid invasion was imaged over 72 
h using the EVOS cell imaging system (Figure 21).  
 
In order to evaluate whether OV could penetrate the collagen matrix and 
then replicate within tumour spheroids, a GFP-expressing virus (HSV or VV) 
was imaged using the IncuCyte ZOOM® following co-culture with tumour 
spheroids encased in collagen. Within the first 24 h, the tumour spheroid 
began to emit green fluorescence, which increased in intensity by 70 h, 
indicating that the oncolytic HSV and VV were able to enter and replicate 
within the encased tumour spheroid (Figure 22). Reovirus entry and 
replication in tumour spheroids could not be evaluated by this method as the 
laboratory did not possess a GFP-modified virus.  
 
The migration index was calculated for the images obtained from each virus 
condition (as described in section 2.4.1) and was used to evaluate the 
invasion front and leading edge zone for each treatment. Oncolytic HSV 
significantly reduced invasion of pHGG (SF188 and KNS42), DIPG (HSJD-
DIPG-007) and mouse glioma (GL261-Luc) tumour spheroids by 72 h in a 
dose- and time-dependent manner (Figure 23A, 24A, 25A, 26A).  A 
statistically significant reduction in both the invasion zone and leading edge 
zone at 72 h was observed following treatment with 10 pfu/cell HSV for 
SF188 and HSJD-DIPG-007 (mean±SEM: SF188 leading edge: control 
0.94±0.004, HSV 10 pfu/cell 0.63±0.047 p<0.001; HSJD-DIPG-007 leading 
edge: control 0.75±0.051, HSV 10 pfu/cell 0.52±0.038 p=0.0061, HSV 50 
pfu/cell 0.40±0.041 p<0.001) and by 1 pfu/cell HSV for KNS42 and GL261-
Luc (mean±SEM: KNS42 leading edge: control 0.42±0.033, HSV 1 pfu/cell 
0.23±0.029 p=0.0014, HSV 10 pfu/cell 0.20±0.05 p<0.001; GL261-Luc 
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leading edge: control 0.47±0.031, HSV 1 pfu/cell 0.28±0.035 p=0.0026, HSV 
10 pfu/cell 0.18±0.044 p<0.001, HSV 50 pfu/cell 0.069±0.034 p<0.001).  
 
Unlike the results obtained in the 2D scratch assay, reovirus was capable of 
significantly reducing the invasion of SF188, HSJD-DIPG-007 and GL261-
Luc tumour spheroids in the 3D tumour spheroid model (Figure 23B, 25B, 
26B). A statistically significant reduction in both invasion zone and leading 
edge zone was reached at 1 pfu/cell reovirus for SF188, HSJD-DIPG-007 
and GL261-Luc (mean±SEM: SF188 leading edge: control 0.94±0.004, 
reovirus 1 pfu/cell 0.83±0.031 p=0.0012, reovirus 10 pfu/cell 0.67±0.040 
p<0.001; HSJD-DIPG-007 leading edge: control 0.75±0.051, reovirus 1 
pfu/cell 0.42±0.034 p<0.001, reovirus 10 pfu/cell 0.47±0.060 p<0.001, 
reovirus 50 pfu/cell 0.37±0.051 p<0.001; GL261-Luc leading edge: control 
0.47±0.031, reovirus 1 pfu/cell 0.31±0.054 p=0.019, reovirus 10 pfu/cell 
0.29±0.060 p=0.0075). The invasion of KNS42 tumour spheroids was not 
affected by reovirus treatment (Figure 24B).  
 
Finally, VV treatment was capable of significantly reducing invasion in all 
four cell lines (Figure 23 C, 24C, 25C and 26C). A statistically significant 
reduction in both the invasion zone and leading edge zone was reached at 1 
pfu/cell VV for SF188 and HSJD-DIPG-007 (mean±SEM: SF188 leading 
edge: control 0.94±0.004, VV 1 pfu/cell 0.9±0.007 p=0.0089, VV 10 pfu/cell 
0.89±0.011 p=0.0045; HSJD-DIPG-007 leading edge: control 0.75±0.051, 
VV 1 pfu/cell 0.53±0.053 p=0.0105, VV 10 pfu/cell 0.51±0.037 p=0.0053, VV 
50 pfu/cell 0.43±0.063 p<0.001) and 0.1 pfu/cell VV for KNS42 and GL261-
Luc (mean±SEM: KNS42 leading edge: control 0.42±0.033, VV 0.1 pfu/cell 
0.29±0.034 p=0.037, VV 1 pfu/cell 0.23±0.042 p<0.001, VV 10 pfu/cell 
0.072±0.028 p<0.001;  GL261-Luc leading edge: control 0.47±0.031, VV 0.1 
pfu/cell 0.31±0.046 p=0.012, VV 1 pfu/cell 0.28±0.073 p=0.017,  VV 10 







Figure 21: Inhibition of paediatric glioma tumour spheroid invasion by 
oncolytic viruses 
Tumour spheroids (SF188) were encased in collagen and incubated ± 
nominal 10 pfu/cell of OV (HSV, reovirus (Reo) and VV) for 72 h. Tumour 
spheroid invasion was evaluated at 24, 48 and 72 h using the EVOS cell 
imaging system at x4 magnification. White scale bar represents 1000 μm. 
















Figure 22: Oncolytic viruses can enter and replicate in pHGG tumour 
spheroids embedded in a collagen matrix  
Tumour spheroids (SF188) were encased in collagen and incubated ± 
nominal 10 pfu/cell of oncolytic HSV or VV expressing GFP. Plates were 
imaged at x4 magnification using the IncuCyte ZOOM® incubator over 70 h. 
Images shown are representative stills from movies created with IncuCyteTM 
software which have been taken around the start, midway and end of the 70 





Figure 23: Analysis of the effects of oncolytic viruses on the migration 
index of tumour spheroids of SF188 
Tumour spheroids (SF188) were encased in collagen and incubated in 
culture medium ± OV (HSV at nominal 1 and 10 pfu/cell (A), reovirus (Reo) 
(B) and VV (C) at nominal 0.1, 1 and 10 pfu/cell). Invasion was evaluated at 
72 h using the EVOS cell imaging system. Images generated were analysed 
using Image J software by calculating the area of the invasion zone and the 
leading edge zone (as defined in section 2.4.1). A migration index for both 
the invasion zone and leading edge zone ((area of zone – area of core) ÷ 
total area) was calculated. Graphs show mean±SEM of multiple repeats 
pooled from up to n=3 individual experiments. * p<0.05, ** p<0.01, *** 























































































































































Figure 24: Analysis of the effects of oncolytic viruses on the migration 
index of tumour spheroids of KNS42  
Tumour spheroids (KNS42) were encased in collagen and incubated in 
culture medium ± OV (HSV at nominal 1 and 10 pfu/cell) (A), reovirus (Reo) 
(B) and VV (C) at nominal 0.1, 1 and 10 pfu/cell). Invasion was evaluated at 
72 h using the EVOS cell imaging system. Images generated were analysed 
using Image J software by calculating the area of the invasion zone and the 
leading edge zone (as defined in section 2.4.1). A migration index for both 
the invasion zone and leading edge zone ((area of zone – area of core) ÷ 
total area) was calculated. Graphs show mean±SEM of multiple repeats 
pooled from up to n=3 individual experiments. * p<0.05, ** p<0.01, *** 






















































































































































Figure 25: Analysis of the effects of oncolytic viruses on the migration 
index of tumour spheroids of HSJD-DIPG-007  
Tumour spheroids (HSJD-DIPG-007) were encased in collagen and 
incubated in culture medium ± OV (HSV (A), reovirus (Reo) (B) or VV (C) at 
nominal 1,10 and 50 pfu/cell). Invasion was evaluated at 72 h using the 
EVOS cell imaging system. Images generated were analysed using Image J 
software by calculating the area of the invasion zone and the leading edge 
zone (as defined in section 2.4.1). A migration index for both the invasion 
zone and leading edge zone ((area of zone – area of core) ÷ total area) was 
calculated. Graphs show mean±SEM of multiple repeats pooled from up to 





































































































































































Figure 26: Analysis of the effects of oncolytic viruses on the migration 
index of tumour spheroids of mouse glioma  
Tumour spheroids (GL261-Luc) were encased in collagen and incubated in 
culture medium ± OV (HSV at nominal 0.1, 1, 10 and 50 pfu/cell (A), 0.1, 1 
and 10 pfu/cell reovirus (Reo) (B) and 0.1, 1 and 10 pfu/cell VV (C). Invasion 
was evaluated at 72 h using the EVOS cell imaging system. Images 
generated were analysed using Image J software by calculating the area of 
the invasion zone and the leading edge zone (as defined in section 2.4.1). A 
migration index for both the invasion zone and leading edge zone ((area of 
zone – area of core) ÷ total area) was calculated. Graphs show mean±SEM 
of multiple repeats pooled from up to n=3 individual experiments. * p<0.05, 








































































































































































4.4 Effects of oncolytic viruses on pHGG monolayer viability  
 
The results described in section 4.2 and 4.3 indicate that OVs are capable of 
reducing the migration and invasion of pHGG and DIPG cells in 2D and 3D 
assays. However, to verify that the effects observed were anti-migratory and 
anti-invasive and not a direct consequence of cytotoxicity, the effects of OVs 
on pHGG and DIPG cytotoxicity and viability were also investigated. 
 
The effects of OV (HSV, reovirus and VV) on pHGG monolayer cytotoxicity 
and viability were evaluated. A LIVE/DEAD® assay was used as a measure 
of cytotoxicity. In this assay, ethidium homodimer is taken up by dead cells 
with damaged plasma membranes to produce a bright fluorescence upon 
binding with nucleic acid, which can be quantified by FACS analysis (371).  
Using this assay, monolayers of SF188 appeared to be the most sensitive 
cell line to OV-mediated cytotoxicity (Figure 27, 28 and 29). At 24 h, which 
corresponds to the time point where migration was analysed by scratch 
assay in monolayers, HSV and reovirus exerted no significant cytotoxic 
effects in any of the three cell lines (SF188, KNS42 and GL261-Luc). Less 
than 8.1 % dead cells were detected following any HSV or reovirus 
treatment (Figure 27, 28 and 29). This result indicates that the effects of 
oncolytic HSV and reovirus on cytotoxicity at 24 h can clearly be 
distinguished from their effects on migration demonstrated in the scratch 
assay. 
 
Over time (96 h), significant cytotoxic effects began to be observed following 
SF188 treatment with HSV and reovirus. SF188 was much more sensitive to 
the cytotoxic effects of reovirus than HSV. By 72 h and 96 h, respectively, 10 
pfu/cell reovirus treatment of SF188 resulted in 68.3 % and 81 % dead cells, 
compared to only 16.8 % and 31.3 % following SF188 treatment by 10 
pfu/cell HSV (Figure 27). KNS42 appeared to be completely resistant to the 
cytotoxic effects of reovirus (Figure 28B). Additionally, KNS42 demonstrated 
no significant cytotoxicity over 72 h of HSV treatment; however, a very small 
but statistically significant increase in cytotoxicity was reported at 96 h (5.3 
% dead cells p<0.001) (Figure 28A). GL261-Luc appeared to be completely 
resistant to the effects of HSV and reovirus treatment over 96 h (Figure 29).   
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VV was notably more cytotoxic to the monolayers of all three cell lines, with 
significant cytotoxic effects noted by 24 h following treatment of KNS42 and 
GL261-Luc with 10 pfu/cell (Figure 27, 28 and 29) (KNS42: 24 % dead cells 
p=0.0046, GL261-Luc: 45 % dead cells p=0.0092). By 48 h, 10 pfu/cell VV 
treatment resulted in significant cytotoxicity in all three cell lines (SF188: 37 
% dead cells p<0.001, KNS42: 29 % dead cells p=0.0013, GL261-Luc: 69 % 
dead cells p<0.001). This matched the observations made with the Nikon 
eclipse microscope following 24 h of VV treatment, where the cells were 
noted to display apoptotic morphology (rounding, blebbing and reduction in 
size) and lifted away from the scratch.  
  
The effect of OVs on cell viability of SF188 and KNS42 monolayers was also 
determined by MTT assay (Figure 30 and 31). Both cell lines demonstrated 
significant changes in viability/metabolic activity in response to HSV at all 
viral concentrations tested (Figure 30A and 31A). SF188 was very sensitive 
to the effects of reovirus and demonstrated a marked and significant change 
in viability in a dose- and time-dependent manner (Figure 30B). Again, 
KNS42 was resistant to the effects of reovirus and demonstrated no change 
in metabolic activity over time (Figure 31B). Both cell lines demonstrated 
changes in metabolic activity over time when treated with VV; however, this 
did not reach statistical significance for KNS42 (Figure 30C and 31C). 
Significant changes in viability were seen for SF188 following VV treatment 







Figure 27: Effects of oncolytic viruses on SF188 monolayer cell 
viability 
Cells (SF188) were seeded at 1x105 cells/well in a 12 well plate and allowed 
to attach for 4 h. Cells were then incubated ± 0.1, 1 or 10 pfu/cell OV (HSV 
(A), reovirus (Reo) (B) or VV (C)). At 24, 48, 72 or 96 h all cells were 
harvested, washed and incubated with LIVE/DEAD® cell stain (red for 
HSV/reovirus-treated cells, yellow for VV-treated cells). Cells were then fixed 
in 1 % PFA and the percentage of dead stained cells was determined by 
FACS analysis. Graphs show mean±SEM of n=3 individual experiments.       









































































































































































Figure 28: Effects of oncolytic viruses on KNS42 monolayer cell 
viability 
Cells (KNS42) were seeded at 1x105 cells/well in a 12 well plate and left for 
4 h to adhere. Cells were then incubated ± 0.1, 1 or 10 pfu/cell OV (HSV (A), 
reovirus (Reo) (B) or VV (C)). At 24, 48, 72 or 96 h all cells were harvested, 
washed and incubated with LIVE/DEAD® cell stain (red for HSV/reovirus- 
treated cells, yellow for VV-treated cells). Cells were then fixed in 1 % PFA 
and the percentage of dead stained cells was determined by FACS analysis. 
Graphs show mean±SEM of n=3 individual experiments. * p<0.05, ** p<0.01, 


























































































































































Figure 29: Effects of oncolytic viruses on GL261-Luc monolayer cell 
viability 
Cells (GL261-Luc) were seeded at 1x105 cells/well in a 12 well plate and left 
for 4 h to adhere. Cells were then incubated ± 0.1, 1, 10 or 50 pfu/cell OV 
(HSV (A), reovirus (Reo) (B) or VV (C)). At 24 and 48 h all cells were 
harvested, washed and incubated with LIVE/DEAD® cell stain (red for 
HSV/reovirus-treated cells, yellow for VV-treated cells). Cells were then fixed 
in 1 % PFA and the percentage of dead stained cells was determined by 
FACS analysis. Graphs show mean±SEM of n=3 individual experiments.  




















































































































































Figure 30: Cell viability of SF188 monolayers treated with oncolytic 
viruses  
SF188 cells were seeded in triplicate in a 96 well plate at 8 x 103 cells/well 
and allowed to adhere for a minimum of 4 h. Serial dilutions of OVs (HSV 
(A), reovirus (B) and VV (C)) were added to each well. Cell viability was 
determined by MTT assay and was expressed as a percentage of controls. 
Graphs show mean±SEM of n=3 individual experiments. * p<0.05, ** p<0.01, 









































































































































































































































Figure 31: Cell viability of KNS42 monolayers treated with oncolytic 
viruses 
KNS42 cells were seeded in triplicate in a 96 well plate at 8 x 103 cells/well 
and allowed to adhere for a minimum of 4 h. Serial dilutions of the OVs (HSV 
(A), reovirus (B) and VV (C)) were added to each well. Cell viability was 
determined by MTT assay and was expressed as a percentage of controls. 
Graphs show mean±SEM of n=3 individual experiments. * p<0.05, ** p<0.01, 











































































































































































4.5 Effects of oncolytic viruses on paediatric glioma tumour spheroid 
viability  
 
Next, the effects of the OVs on tumour spheroid viability were investigated 
using the WST-1 assay. This assay has previously been described as a valid 
methodology to determine the viability of cells grown as spheroids (355). 
Cytotoxicity of tumour spheroids could not be accurately evaluated by 
LIVE/DEAD® assay as this assay requires a single cell suspension, so an 
estimation of viability by WST-1 assay was used as a proxy measurement. 
The viability of tumour spheroids was evaluated at 72 h to correlate with the 
anti-invasive results of the spheroid in collagen assay.  
 
In the 3D spheroid system, both pHGG cell lines (SF188 and KNS42) 
displayed viability of at least 67 % at 72 h following all treatments with HSV 
(SF188: 82.2 % viability at 72 h following 10 pfu/cell HSV p<0.001; KNS42: 
67.9 % viability at 72 h following 10 pfu/cell HSV p<0.001) (Figure 32A and 
33A). Both cell lines also displayed viability of at least 68 % at 72 h following 
all reovirus treatment (SF188: 76.3 % viability at 72 h following 10 pfu/cell 
reovirus p<0.001; KNS42: 77 % viability at 72 h following 10 pfu/cell reovirus 
p=0.043) (Figure 32B and 33B). KNS42 was slightly more sensitive to the 
effects of VV than SF188, with viability reduced to 60.4 % at 72 h compared 
to 79.1 % at 72 h for SF188 following treatment with 10 pfu/cell (Figure 32C 
and 33C). Although evaluated using different assays of viability and 
cytotoxicity, overall, both pHGG cell lines exhibited increased sensitivity to 
virus treatment when cultured as monolayers compared to 3D aggregates. 
This is unsurprising, as 3D aggregates of tumor cells have been shown to be 
more drug-resistant than corresponding 2D cultures (356,357).  
 
Figure 34 assesses the viability of HSJD-DIPG-007 spheroids treated with 
HSV, reovirus or VV. The data within this figure represents the average of 
two individual experiments and therefore statistical analysis could not be 
performed. HSJD-DIPG-007 spheroids demonstrated a tendency to be more 
sensitive to treatment with VV, compared to HSV and reovirus treatments 
(Figure 34). HSJD-DIPG-007 responded to treatment with HSV in a dose- 
and time-dependent manner, displaying viability at 72 h of 63.4 % following 
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10 pfu/cell HSV treatment and 53.1 % following 50 pfu/cell treatment (Figure 
34A). HSJD-DIPG-007 demonstrated a tendancy to be least sensitive to 
reovirus-induced cytotoxicity, with viability of at least 70 % following 
treatment with reovirus at 0.1, 1 and 10 pfu/cell at 72 h (Figure 34B). Finally, 
VV treatment at 10 and 50 pfu/cell resulted in an overall trend towards 
reduced HSJD-DIPG-007 viability, with viability reducing to approximately 45 





Figure 32: The effects of oncolytic viruses on SF188 tumour spheroid 
viability 
SF188 cells at 1x103 cells per well were seeded in an ultra-low attachment 
round-bottom 96 well plate to form spheroid aggregates. Following 72 h 
incubation, cells were incubated ± OV (HSV (A), reovirus (Reo) (B) and VV 
(C)), at nominal 0.1, 1 and 10 pfu/cell. Cell viability at 24, 48, 72 and 96 h 
was determined by WST-1 assay and was expressed as a percentage of 
controls. Graphs show mean±SEM of n=3 individual experiments. * p<0.05, 











































































































































































Figure 33: The effects of oncolytic viruses on KNS42 tumour spheroid 
viability 
KNS42 cells at 1x103 cells per well were seeded in an ultra-low attachment 
round-bottom 96 well plate to form spheroid aggregates. Following 72 h 
incubation, cells were incubated ± OV (HSV (A), reovirus (Reo) (B) and VV 
(C)), at nominal 0.1, 1 and 10 pfu/cell.   Cell viability at 24, 48, 72 and 96 h 
was determined by WST-1 assay and was expressed as a percentage of 
controls. Graphs show mean±SEM of n=3 individual experiments. * p<0.05, 































































































































































Figure 34: The effects of oncolytic viruses on HSJD-DIPG-007 tumour 
spheroid viability 
HSJD-DIPG-007 cells at 1x103 cells per well were seeded in an ultra-low 
attachment round-bottom 96 well plate to form spheroid aggregates. 
Following 72 h incubation, cells were incubated ± OV (HSV (A), reovirus 
(Reo) (B) and VV (C)), at nominal 0.1, 1, 10 and 50 pfu/cell.   Cell viability at 
24, 48, 72 and 96 h was determined by WST-1 assay and was expressed as 




































































































































































4.6 Evaluation of the effects of oncolytic viruses on paediatric glioma 
proliferation and tumour spheroid growth 
 
Next, the effects of oncolytic OVs on paediatric glioma proliferation and 
tumour spheroid growth were evaluated. This was important to confirm that 
the observed effects on migration and invasion following each OV treatment 
were not, in fact, caused by effects of the virus on proliferation and tumour 
growth. In order to evaluate tumour spheroid growth for pHGG and mouse 
glioma cell lines, changes in the area of treated tumour spheroid cores over 
72 h were measured from images taken during the spheroid in collagen 
invasion assay. To evaluate growth over time, the area of a spheroid core at 
each given time point was divided by it’s area at time 0 h and this fraction 
was expressed as a percentage. This method could not be used for HSJD-
DIPG-007 tumour spheroids as during invasion into collagen, the DIPG 
spheroid core became elongated and lost definition, making it difficult to 
accurately measure (Figure 4). Thus, for HSJD-DIPG-007 tumour spheroids, 
changes in the area of the spheroid following virus treatment were evaluated 
by images taken during the WST-1 assay.  
 
When SF188 and KNS42 were grown as tumour spheroids, none of the OV 
treatments resulted in a significant change in growth at any time point 
evaluated (Figure 35A-C and 36A-C). GL261-Luc overall demonstrated no 
significant change in tumour spheroid growth when treated with oncolytic 
HSV or VV (Figure 37A and C). Following GL261-Luc treatment with 
reovirus, 0.1 pfu/cell reovirus caused a small but significant increase in 
tumour spheroid growth; however, this was not noted at any other virus 
concentration or time point (Figure 37B). Both HSV and VV treatment 
reduced the growth of HSJD-DIPG-007 tumour spheroids at 72 h (% of area 
of initial spheroid: control 275 %, HSV 10 pfu/cell 183 %, HSV 50 pfu/cell 
161 %; VV 10 pfu/cell 156 %, VV 50 pfu/cell 159 %) (Figure 38A and C). 
Reovirus treatment overall had no effect on HSJD-DIPG-007 tumour 
spheroid growth when compared to control-treated spheroids at any time 
point (Figure 38B). 
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A Ki67 intracellular FACS assay was used to evaluate proliferation in virus- 
treated pHGG monolayers. Ki67 was used as a marker of proliferation as its 
expression is strictly associated with cell proliferation (372). Ki67 is present 
throughout all active phases of the cell cycle (G(1), S, G(2), and mitosis), but 
is absent from resting cells (G(0)) (373). The Ki67 intracellular FACS assay 
could not be used for VV, as the RFP incorporated into the virus could affect 
the FACS analysis channel that detects the emission from the PE-Cy7 Ki67 
antibody.  Neither pHGG cell line investigated demonstrated a significant 
change in the percentage of Ki67-positive cells following 24 h of treatment 
with oncolytic HSV or reovirus (Figure 35D-E and 36D-E). HSV treatment 
tended to increase proliferation of both SF188 and KNS42 cells but this did 
not reach statistical significance (mean±SEM SF188 Ki67 positive cells: 
control 4.5±0.87, HSV 10 pfu/cell 10.5±4.1 p=0.19; KNS42 Ki67 positive 
cells: control 5.6±3.5, HSV 10 pfu/cell 30.1±22.6 p=0.43) (Figure 35D and 
































Figure 35: The effects of oncolytic viruses on SF188 tumour spheroid growth and cell 
proliferation  
(A-C) SF188 tumour spheroids were encased in collagen and incubated in culture medium 
± OV at nominal 1 and 10 pfu/cell HSV (A) and 0.1, 1 and 10 pfu/cell reovirus (B) and 0.1, 1 
and 10 pfu/cell VV (C). Tumour spheroids were imaged at 0, 24, 48 and 72 h using the 
EVOS cell imaging system. The area of the tumour spheroid core was measured at each 
time point using Image J software. Growth over time ((area of spheroid at a given time point 
÷ area of spheroid at time 0 h) x100) was calculated. Graphs show mean±SEM of multiple 
repeats pooled from up to n=3 individual experiments. Results were not statistically 
significant following evaluation by two-way ANOVA. (D-E) 1x105 SF188 cells were seeded 
into 12 well plates and left to adhere for 4 h. Culture medium ± OV (HSV at 1 and 10 pfu/cell 
(D) or reovirus at 1 and 10 pfu/cell (E)) were added to each well. After 24 h treatment, cells 
were harvested, washed and fixed with 10 % PFA, before re-suspension into 0.3 % saponin 
followed by incubation with the Ki67 PE-Cy7 mouse anti-human antibody. Ki67 staining was 
then detected by FACS. Graphs show mean±SEM of at least n=3 individual experiments. 





































































































































































































Figure 36: The effects of oncolytic viruses on KNS42 tumour spheroid growth and 
cell proliferation  
(A-C) KNS42 tumour spheroids were encased in collagen and incubated in culture medium 
± OV at nominal 1 and 10 pfu/cell HSV (A) and 0.1, 1 and 10 pfu/cell reovirus (B) and 0.1, 1 
and 10 pfu/cell VV (C). Tumour spheroids were imaged at 0, 24, 48 and 72 h using the 
EVOS cell imaging system. The area of the tumour spheroid core was measured at each 
time point using Image J software. Growth over time ((area of spheroid at a given time point 
÷ area of spheroid at time 0 h) x100) was calculated. Graphs show mean±SEM of multiple 
repeats pooled from up to n=3 individual experiments. Results were not statistically 
significant following evaluation by two-way ANOVA. (D-E) 1x105 KNS42 cells were seeded 
into 12 well plates and left to adhere for 4 h. Culture medium ± OV (HSV at 1 and 10 pfu/cell 
(D) or reovirus at 1 and 10 pfu/cell (E)) were added to each well. After 24 h treatment, cells 
were harvested, washed and fixed with 10 % PFA, before re-suspension into 0.3 % saponin 
followed by incubation with the Ki67 PE-Cy7 mouse anti-human antibody. Ki67 staining was 
then detected by FACS. Graphs show mean±SEM of at least n=3 individual experiments. 













































































































































































































Figure 37: The effects of oncolytic viruses on GL261-Luc tumour spheroid growth  
 
GL261-Luc tumour spheroids were encased in collagen and incubated in culture medium ± 
OV at nominal 0.1, 1, 10 and 50 pfu/cell HSV (A), 0.1, 1, 10 and 50 pfu/cell reovirus (B) and 
0.1, 1 and 10 pfu/cell VV (C). Tumour spheroids were imaged at 0, 24, 48 and 72 h using 
the EVOS cell imaging system. The area of the tumour spheroid core was measured at 
each time point using Image J software. Growth over time ((area of spheroid at a given time 
point ÷ area of spheroid at time 0 h) x100) was calculated. Graphs show mean±SEM of 

















































































































































Figure 38: The effects of oncolytic viruses on HSJD-DIPG-007 tumour spheroid 
growth  
.  
1x103 cells per well of HSJD-DIPG-007 were seeded in an ultra-low attachment round 
bottom 96 well plate to form spheroid aggregates. Following 72 h incubation, cells were 
treated with culture medium ± nominal 0.1, 1, 10 and 50 pfu/cell HSV (A), reovirus (B) or VV 
(C). Tumour spheroids were imaged at time 0, 24, 48 and 72 h following drug treatment. 
Growth over time ((area of spheroid at a given time point ÷ area of spheroid at time 0 h) 
x100) was calculated. Graphs show mean±SEM of one experiment performed with multiple 

























































































































































4.7 Evaluation of the effects of oncolytic viruses on cytokine 
production 
 
OVs are known to be capable of altering the balance of cytokine production 
within tumours (253). Cytokines are small molecules which have a diverse 
range of effects on tumour growth, proliferation, inflammation and immune 
response (374). The glioblastoma microenvironment contains a multitude of 
cytokines, contributing to tumour pathogenicity. IL-8 is a pro-inflammatory 
cytokine, expressed at high levels in glioblastoma and plays a role in 
promoting tumour invasion and angiogenesis (374,375). VEGF is critical for 
new vessel formation and is also overexpressed in glioblastoma (374,376). 
Additionally, VEGF has been shown to promote an EMT phenotype, which is 
associated with increased migration and invasion of tumour cells (377). 
Thus, the effects of OVs on pHGG IL-8 and VEGF production were 
evaluated to determine whether changes in cytokine expression may 
contribute to the anti-migratory effects observed.  
 
The expression of IL-8 from pHGG cell lines (SF188 and KNS42) following 
OV treatment over 72 h, was evaluated by ELISA. Oncolytic HSV treatment 
of SF188 at 10 pfu/cell resulted in a statistically significant reduction in IL-8 
at 48, 72 and 96 h (mean±SEM: IL-8 48 h: control 2732±874 pg/ml, HSV 10 
pfu/cell 416±584 pg/ml p= 0.012; IL-8 72 h: control 3065±148 pg/ml, HSV 10 
pfu/cell 128±189 pg/ml p=0.0014; IL-8 96 h: control 3170±318 pg/ml, HSV 1 
pfu/cell 1108±141 pg/ml p=0.0272, HSV 10 pfu/cell 411±446 pg/ml 
p=0.0026) (Figure 39A). Although this trend was observed in KNS42, 
statistical significance was not reached following analysis (Figure 40A). 
Conversely, reovirus treatment resulted in a statistically significant increase 
in SF188 IL-8 expression at: 10 pfu/cell at 24 h (mean±SEM IL-8: control 
1201±219 pg/ml, reovirus 10 pfu/cell 12171±3235 pg/ml p=0.0079) 0.1, 1 
and 10 pfu/cell at 48 and 72 h (mean±SEM: IL-8 48 h: control 2732±874 
pg/ml, reovirus 0.1 pfu/cell 12456±2215 pg/ml p=0.0196, reovirus 1 pfu/cell 
13771±2052 pg/ml p=0.0074, reovirus 10 pfu/cell 14358±1941 pg/ml 
p=0.0047; IL-8 72 h: control 3065±145 pg/ml, reovirus 0.1 pfu/cell 
15211±4099 pg/ml p=0.0031, reovirus 1 pfu/cell 14345±3938 pg/ml 
p=0.0062, reovirus 10 pfu/cell 12934±4552 pg/ml p=0.0177) and 0.1 and 10 
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pfu/cell at 96 h (mean±SEM IL-8 96 h: control 3170±318 pg/ml, reovirus 0.1 
pfu/cell 12292±1885 pg/ml p=0.03, reovirus 10 pfu/cell 12155±1829 pg/ml 
p=0.033) (Figure 39B). Again, this trend was observed from 48 h in KNS42 
cells; however it did not reach statistical significance (Figure 40B). 10 
pfu/cell VV treatment resulted in a significant reduction of SF188 IL-8 
expression at 72 and 96 h (mean±SEM: IL-8 72 h: control 3065±148 pg/ml, 
reovirus 10 pfu/cell 154±270 pg/ml p=0.0057; IL-8 96 h: control 3170±318 
pg/ml, reovirus 10 pfu/cell 688±540 pg/ml p=0.0199) (Figure 39C); however, 
this was not observed for KNS42 (Figure 40C).  
 
Treatment of KNS42 cells with 0.1, 1 and 10 pfu/cell HSV at 96 h resulted in 
a significant reduction in VEGF (mean±SEM VEGF: control 322±239 pg/ml, 
HSV 0.1 pfu/cell 91.1±27.5 pg/ml p=0.492, HSV 1 pfu/cell 50.5±11.4 pg/ml 
p=0.178, HSV 10 pfu/cell 60±33.5 pg/ml p=0.0226) (Figure 42A). No 
significant changes were noted for HSV treatment of SF188 cells (Figure 
41A). Reovirus and VV treatment of both SF188 and KNS42 did not 






Figure 39: The effects of oncolytic viruses on SF188 IL-8 expression 
SF188 cells were seeded at 1x105 cells/well in a 12 well plate and left for 4 h 
to adhere. Cells were then incubated ± 0.1, 1 or 10 pfu/cell OV (HSV (A), 
reovirus (Reo) (B) or VV (C)). At 24, 48, 72 or 96 h supernatants were 
collected and assayed for IL-8 by ELISA. Graphs show mean±SEM of n=3 
individual experiments, each performed in triplicate. * p<0.05, ** p<0.01, *** 



































































































Figure 40: The effects of oncolytic viruses on KNS42 IL-8 expression  
KNS42 cells were seeded at 1x105 cells/well in a 12 well plate and left for 4 
h to adhere. Cells were then incubated ± 0.1, 1 or 10 pfu/cell OV (HSV (A), 
reovirus (Reo) (B) or VV (C)). At 24, 48, 72 or 96 h supernatants were 
collected and assayed for IL-8 by ELISA. Graphs show mean±SEM of n=3 
individual experiments, each performed in triplicate. * p<0.05, ** p<0.01, *** 



















































































Figure 41: The effects of oncolytic viruses on SF188 VEGF expression  
SF188 cells were seeded at 1x105 cells/well in a 12 well plate and left for 4 h 
to adhere. Cells were then incubated ± 0.1, 1 or 10 pfu/cell OV (HSV (A), 
reovirus (Reo) (B) or VV (C)). At 24, 48, 72 or 96 h supernatants were 
collected and assayed for VEGF by ELISA. Graphs show mean±SEM of n=3 
individual experiments, each performed in triplicate. * p<0.05, ** p<0.01, *** 


























































































Figure 42: The effects of oncolytic viruses on KNS42 VEGF expression 
KNS42 cells were seeded at 1x105 cells/well in a 12 well plate and left for 4 
h to adhere.  Cells were then incubated ± 0.1, 1 or 10 pfu/cell OV (HSV (A), 
reovirus (Reo) (B) or VV (C)). At 24, 48, 72 or 96 h supernatants were 
collected and assayed for VEGF by ELISA. Graphs show mean±SEM of n=3 
individual experiments, each performed in triplicate. * p<0.05, ** p<0.01, *** 
































































































OVs are anti-cancer agents that are capable of promoting toxicity through 
both selective tumour cell killing and the induction of systemic anti-tumour 
immune response (254). However, very little is known about the effects of 
OVs on cancer cell migration and invasion. In this chapter, the anti-migratory 
and anti-invasive properties of a range of OVs on pHGG, DIPG and mouse 
glioma cell lines have been demonstrated using both 2D (scratch assay) and 
3D (spheroid invasion in collagen) in vitro models.  
 
Oncolytic HSV significantly inhibited the migration and invasion of pHGG, 
DIPG and mouse glioma cell lines. This was not as a result of cytotoxicity 
when the cell lines were cultured as monolayers at a corresponding 24 h 
time point, although pHGG monolayers did display a significant reduction in 
viability as measured by MTT assay 24 h following oncolytic HSV treatment. 
However, there was no marked loss of viability when cell lines were cultured 
as multicellular spheroids over 72 h, the time point corresponding with the 
invasion assay. Reovirus also significantly reduced invasion (but not 2D 
migration) of pHGG, DIPG and mouse glioma cell lines in a 3D assay. Again, 
this anti-invasive effect was not associated with a marked reduction in 
tumour spheroid viability. Furthermore, VV treatment was also capable of 
significantly reducing both migration and invasion of pHGG, DIPG and 
mouse glioma cell lines; however, all four cell lines appeared to be the most 
sensitive to early cytotoxic effects of this virus treatment. In addition, 
oncolytic HSV and reovirus did not cause a statistically significant change in 
pHGG proliferation when evaluated by Ki67 intracellular FACS assay, 
providing further evidence that the anti-migratory and anti-invasive effects 
observed were specific and not a consequence of anti-proliferative effects.  
 
Finally, the results from this chapter show that OVs can alter pHGG cytokine 
production. Oncolytic HSV and VV treatment of pHGG cells resulted in an 
overall reduction of IL-8, a cytokine known to be associated with tumour 
invasion (374,375). Interestingly, reovirus treatment (which failed to inhibit 
migration of pHGG monolayers) resulted in increased IL-8 production.  
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Taken together, these observations suggest, for the first time, that OVs 
possess anti-migratory and anti-invasive activity against pHGG, DIPG and 
mouse glioma cells. Of the three viruses investigated, oncolytic HSV 
represents the most promising candidate to take forward for further 
investigation, as both its anti-migratory and anti-invasive effects do not 
appear to be a consequence of cytotoxicity, reduced proliferation or changes 
in tumour spheroid growth. Overall, these results are highly novel and 
suggest that OVs may have therapeutic benefits for pHGG and DIPG as an 
anti-invasive agent, potentially improving outcomes for this patient group.  
 
Unlike its adult counterpart, only a small amount of research has focused on 
the effects of oncolytic virotherapy for pHGG (378) and there are currently 
no published studies reporting the effects of OVs on DIPG. Freidman et al. 
have reported that the paediatric cerebellar glioblastoma xenograft, DM456, 
containing both tumour and cancer stem cells, is sensitive to killing by a 
range of modified HSVs (323,379). No published studies to date have 
evaluated the effects of oncolytic VV or reovirus on pHGG viability or 
cytotoxicity. In addition, there are no reported studies in the literature 
evaluating the effects of OVs on pHGG or DIPG migration and invasion, 
suggesting that the results described in this chapter are highly novel.  
 
In this study, oncolytic HSV appeared to be the most promising candidate to 
take forward for further investigation as a clinical anti-migratory and anti-
invasive agent, in addition to its potential cytotoxic activity over time.  There 
was clear evidence to suggest that the anti-migratory and anti-invasive 
effects of oncolytic HSV on pHGG and DIPG were not a consequence of 
cytotoxicity. At 24 h, which corresponds to the time point at which migration 
was analysed by scratch assay in monolayers, over 94 % of cells were still 
alive following 10 pfu/cell HSV treatment when evaluated by LIVE/DEAD® 
assay. In this assay, ethidium homodimer is taken up by dead cells with 
damaged plasma membranes to produce a bright fluorescence upon binding 
with nucleic acid, which can be quantified by FACS analysis (371). However, 
at the same corresponding 24 h time point, oncolytic HSV treatment at 0.156 
to 10 pfu/cell resulted in approximately 50% reduction in pHGG monolayer 
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viability when measured by MTT assay. In the MTT assay, tetrazolium MTT 
is reduced to water insoluble formazan crystals by active mitochondrial 
dehydrogenase enzymes resulting in a colour change and this assay 
therefore measures the metabolic activity of live cells (380). The above 
results illustrate the differences that may be seen when using an assay of 
viability compared to cytotoxicity. One possible explanation for the 
discrepancy between the results of the LIVE/DEAD® assay and the MTT 
assay following 24 h of oncolytic HSV infection of pHGG monolayers is, that 
the results of the MTT assay may be reflecting a change in the metabolic 
activity of the cells following virus infection. Overall, these discrepancies 
highlight a potential limitation in our study when using viability assays such 
as MTT and WST-1 as a proxy measurement for cytotoxicity. Unfortunately 
the cytotoxic effects of OV treatment could not be evaluated for tumour 
spheroids by LIVE/DEAD® assay as a single cell solution is required for 
FACS analysis, so the WST-1 assay of viability was used as proxy 
measurement despite its limitations. Spheroids of SF188 cells demonstrated 
a reduction in viability of no more than 18 % following all HSV treatments by 
72 h. Both KNS42 and HSJD-DIPG-007 cell lines were slightly more 
sensitive, demonstrating a reduction in viability of 32 % and 37 %, 
respectively, following 10 pfu/cell treatment over 72 h. Oncolytic HSV 
treatment did not significantly alter proliferation of pHGG cells or tumour 
spheroid growth. The next chapter will evaluate the potential mechanisms by 
which oncolytic HSV can inhibit pHGG cell migration and invasion, in 
particular focusing on the effects of oncolytic HSV on the cell cytoskeleton. 
HSV at 10 pfu/cell was chosen as the dose to use in further studies, as it 
was the dose associated with a significant reduction of migration and 
invasion for both SF188 and KNS42 cell lines.   
 
Paediatric HGG cell lines were overall more sensitive to VV treatment with 
marked and significant changes in cytotoxicity observed by 96 h. Given the 
sensitivity of the cell lines to this virus, it is hard to distinguish whether the 
anti-migratory effects observed were in fact attributable to cytotoxicity. 
However, these results do highlight the potential clinical benefit of 
developing oncolytic VV as a cytotoxic therapeutic agent for pHGG. Over 
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time, all three OVs began to exert significant cytotoxic effects on the pHGG 
cell lines. This highlights a potential dual mechanism of action for therapy. 
Early infusion of OV may initially prevent migration and invasion of the 
tumour; however, over time the cytotoxic effects of the virus may 
predominate, resulting in tumour cell death. Future work involves testing this 
hypothesis in an in vivo model of pHGG and evaluating potential therapeutic 
effects. 
 
Oncolytic HSV and VV treatment of pHGG cells resulted in an overall 
reduction of IL-8 expression. IL-8 is best characterised for its role as a 
chemotactic agent involved in the inflammatory response and is capable of 
promoting neutrophil, basophil, and T lymphocyte migration (374). 
Additionally, IL-8 plays a role in tumour metastasis, and is associated with 
the invasion of several tumour types including glioblastoma (381-384). IL-8 
is highly prevalent in glioblastoma (374,375) and has been shown to be 
necessary for glioma cell invasion (381). Raychaudhuri et al. published that 
both silencing of the IL-8 gene by use of siRNA or treatment with an IL-8 
neutralising antibody, can decrease the invasion of glioblastoma cell lines 
(381). Furthermore, addition of IL-8 to stem cell medium has been shown to 
increase transwell migration of patient-derived glioblastoma cancer stem 
cells (385). Given that IL-8 appears to play an important role in glioblastoma 
migration, the reduction of IL-8 following oncolytic HSV and VV treatment 
may, in part, contribute to the anti-migratory effects observed following 
treatment of pHGG cell lines. In keeping with this hypothesis is the 
observation that reovirus treatment, which failed to inhibit migration of pHGG 
monolayers, resulted in increased IL-8 detection. Reovirus has previously 
been shown to increase secretion of IL-8 in other tumour models (253,386).  
 
Oncolytic HSV treatment significantly reduced the expression of VEGF at 96 
h in KNS42 cells. VEGF stimulation of normal epithelial cells and 
differentiated carcinoma cells has been shown to induce EMT, promoting a 
more invasive cell phenotype (66,377). VEGF can enhance Snail 
expression, which acts to repress E-Cadherin transcription, in turn promoting 
EMT and cell migration (387). The reduction in VEGF following oncolytic 
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HSV treatment of KNS42 may in part contribute to the anti-migratory and 
anti-invasive effects observed. Additionally, this observation highlights 
heterogeneity between pHGG cell lines SF188 and KNS42 in response to 
OV treatment, as oncolytic HSV treatment of SF188 did not alter VEGF 
expression at 96 h.  
 
In this study, a scratch assay was used to evaluate the ability of OVs to 
block pHGG and mouse glioma migration. Although this assay offers the 
advantage that it requires no specialist equipment and easily allows cell 
movement and morphology to be imaged in real time, it has several 
disadvantages (76,388). One major drawback is that using a pipette tip to 
create a scratch can result in intra- and inter-experimental variation in the 
size and shape of the scratch (76). Additionally, the process of scratching 
the cell monolayer itself can damage cells, and result in the release of 
factors that may influence subsequent cell migration (76).  
 
Growth of tumour spheroids was evaluated by taking into account the 
change in the area of the tumour spheroid core, which was embedded in 
collagen over time following virus treatment. It was not possible to count 
changes in the number of cells contained within tumour spheroid aggregates 
over time in our system to allow an evaluation of proliferation. Using this 
method, the OVs investigated in this study did not significantly affect pHGG 
tumour spheroid growth over time. Proliferation was however evaluated in 
monolayers of pHGG cells following oncolytic HSV and reovirus treatment 
using a Ki67 intracellular FACS assay. Ki67 is a nuclear marker used to 
demonstrate the proliferative phase of the cell cycle as it is expressed in all 
phases of the cell cycle apart from G0. Ki67 has been reported to be a more 
specific marker of proliferation than proliferating cell nuclear antigen (PCNA) 
(389).  
 
In conclusion, the results described in this chapter demonstrate that OVs 
can inhibit the migration and invasion of pHGG, DIPG and mouse glioma 
cells. Oncolytic HSV represents the most promising candidate to take 
forward for further investigation in this regard, as both its anti-migratory and 
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anti-invasive effects do not, overall, appear to be a consequence of 
cytotoxicity,reduced proliferation or changes in tumour spheroid growth. The 
following chapter will evaluate a potential mechanism employed by oncolytic 
HSV to inhibit pHGG cell migration and invasion and will focus on the effects 





























5 Chapter 5: Potential mechanism underlying the observed anti-
migratory and anti-invasive effects of oncolytic HSV 
 
 
The results described in the previous chapter show that oncolytic HSV can 
specifically inhibit the migration and invasion of pHGG and DIPG cells in 
vitro. In this chapter, one potential mechanism underlying this phenomenon 
is explored. 
 
Cell movement is made possible by the presence of the cell cytoskeleton, 
which is composed of actin microfilaments, microtubules and intermediate 
filaments (86). Microtubules play a key role in regulating cell migration 
through their ability to influence cell mechanics, intracellular trafficking and 
cell signalling (93). Alongside their ability to orchestrate cell movement, 
microtubules are also critical for viral replication, forming networks allowing 
transport of viruses within a host cell (308-310). The results contained in this 
chapter explore the hypothesis that oncolytic HSV may be able to influence 
paediatric glioma migration and cancer cell movement through its ability to 
alter microtubule dynamics.  
 
GSK-3 has a multi-faceted role in controlling cell migration and can influence 
microtubule remodelling, cell polarity and cell adhesion (213). The results 
described in chapter three highlight the importance of GSK-3 in glioma 
migration and demonstrate that GSK-3 inhibition can disrupt the migration 
and invasion of pHGG and DIPG cell lines. Wild type HSV has previously 
been shown capable of altering normal human fibroblast microtubule 
dynamics through inactivation of GSK-3 (311); however, the effects of 
oncolytic HSV on human cell GSK-3 are unknown. In this chapter, the 
effects of oncolytic HSV on pHGG GSK-3 activity are evaluated in vitro, 
exploring the potential interaction of oncolytic HSV with molecular pathways 











The effects of oncolytic HSV on pHGG cell morphology, velocity and polarity 
were investigated by live cell imaging of random cell migration. SF188 and 
KNS42 were incubated with or without 10 pfu/cell oncolytic HSV and time- 
lapse imaging was performed over 48 h (Movies 7-10). Image J MTrack 
software was used to track the individual movement of pHGG cells and to 
evaluate their velocity and polarity. 
 
Over 48 h, oncolytic HSV treatment markedly changed pHGG cell 
morphology (Movies 7-10) (Figure 43A and B). SF188 cells cultured in 
normal medium were highly motile and polarised, with a distinct front-rear 
axis defining a leading protrusive front and a trailing edge. The cell leading 
edge clearly protruded as filopodia and lamellipodia and the trailing edge tail 
visibly retracted, progressing the cell forward (Movie 7) (Figure 43A). When 
treated with oncolytic HSV, SF188 cells were notably less motile and 
demonstrated a pronounced loss of polarity. Cells exhibited a loss of their 
distinct leading and trailing edges when compared to cells in culture medium 
only. SF188 HSV-treated cells became elongated and developed protrusive 
tails that appeared unable to retract (Movie 8). Overall, following HSV 
treatment, the SF188 cells appeared anchored to the surface and unable to 
generate the contractive or retractile forces required to propel the cell 
forward (Movie 8) (Figure 43A).   
 
As previously demonstrated in chapter three (Figure 15), KNS42 cells were 
observed to be overall much less motile than SF188 (Movie 9). KNS42 cells 
cultured in normal medium appeared to have diffuse, extended and well-
defined lamellipodia which, unlike SF188, appear to be orientated in 
opposite directions with no clear front-rear definition. Oncolytic HSV 
treatment of KNS42 cells resulted in cells rounding up with no discernable 
lamellipodia (Movie 9 and 10). Oncolytic HSV-treated KNS42 cells also 
developed multiple thin-branching protrusions over time (Movie 10) (Figure 
43B).   
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Tracking analysis of individual cell movement highlighted that pHGG cells 
(SF188 and KNS42) treated with oncolytic HSV are much less motile than 
corresponding controls (Figure 43C) however, when velocity was quantified, 
a statistically significant reduction was seen only for SF188 cells; (oncolytic 
HSV treatment of SF188 cells significantly reduced velocity (mean±SEM 
velocity: control 0.33±0.041 µm/min, HSV 0.078±0.007 µm/min p<0.001) 
(Figure 43D); however, no significant change in velocity was observed 
following HSV treatment of KNS42 cells (mean±SEM velocity: control 
0.13±0.014 µm/min, HSV 0.15±0.022 µm/min p=0.506) (Figure 43F)). 
Treatment with oncolytic HSV significantly reduced polarity of SF188 cells as 
demonstrated by a reduction in displacement (mean±SEM displacement: 
control 193±31 µm, HSV 50.5±11.2 µm p<0.001) (Figure 43E); however, 
given that KNS42 cells fail to polarise under normal conditions, it is 
unsurprising that there are no significant differences in displacement 
observed following HSV treatment of KNS42 (mean±SEM displacement: 
control 104±23.6 µm, HSV 71.4±20.1 µm p=0.305) (Figure 43G).   
 
Taken together, the observations documented above may start to explain 
why pHGG cells incubated with oncolytic HSV demonstrated a reduction in 
migration. The effects of oncolytic HSV on velocity and polarity were only 
seen for SF188, which may reflect the fact that overall SF188 is a much 

























Figure 43: Analysis of the effects of oncolytic HSV treatment on pHGG 
cell morphology, velocity and polarity 
Paediatric glioma cell lines SF188 and KNS42 were incubated ± nominal 10 
pfu/cell oncolytic HSV in an Ibidi imaging dish. Live cell imaging was 
performed for 48 h using the Nikon Biostation IM live cell imaging system. 
Magnification x40. Stills were taken at time 0 h (start) and 48 h (end) from 
movies of SF188 (A) and KNS42 (B) treated ± 10 pfu/cell oncolytic HSV. 
Tracking analysis of the individual cell movements over 48 h of SF188 and 
KNS42 were performed from live cell imaging movies using Image J with 
MTrack software following treatment ± oncolytic HSV (C). Quantification 
analysis of velocity (distance/time) (D and F) and displacement (E and G) 
was obtained from live cell imaging using Image J with MTrack software of 
both cell lines (SF188 D and E, KNS42 F and G) following treatment ± 
oncolytic HSV. Graphs show the mean±SEM obtained from five different 




































































































































5.2 Evaluation of the effects of oncolytic HSV on acetylated and 
detyrosinated tubulin 
 
Microtubules are polymers of α- and β- tubulin dimers that bind to form stiff 
cylindrical hollow tubes that play a critical role in cell migration (93). 
Microtubules are dynamic and can undergo polymerisation (growth) and 
depolymerisation (shrinkage) during a process known as dynamic instability, 
in order to search, explore and interact with cellular organelles and target 
sites (93,95,99,100). Whilst the majority of microtubules undergo dynamic 
instability with relatively short half-life, a subgroup of more ‘stable’ 
microtubules demonstrate longer half-lives, secondary to the accumulation 
of post-translational tubulin modifications, including acetylation and 
detyrosination (93,100,111). These more ‘stable’ microtubules are more 
resistant to disassembly and can facilitate directional trafficking and 
preferential transportation of organelles, vesicles or proteins within the cell 
(93,100,112-114). The ability of oncolytic HSV to stabilise pHGG 
microtubules through the accumulation of post-translational tubulin 
modifications was evaluated by Western blotting and IF.  
 
The expression of acetylated tubulin from pHGG cell lysates treated ± 10 
pfu/cell oncolytic HSV was evaluated by Western blot (Figure 44). Oncolytic 
HSV treatment of SF188 increased the expression of acetylated tubulin at 24 
and 48 h; however, this failed to reach statistical significance (mean±SEM 
intensity of band, normalised to actin: 24 h: control 0.376±0.177, HSV 
0.863±0.263 p=0.209; 48 h: control 0.289±0.115, HSV 1.13±0.356 p=0.133) 
(Figure 44A and B). Oncolytic HSV treatment of KNS42 also revealed a 
trend towards increased acetylated tubulin expression by 48 h (mean±SEM 
intensity of band, normalised to actin: 24 h: control 0.77±0.484, HSV 
0.73±0.242 p=0.946; 48 h: control 0.271±0.061, HSV 1.17±0.398 p=0.160) 
(Figure 44A and C).  
 
Acetylated and detyrosinated tubulin expression from pHGG cells treated ± 
10 pfu/cell oncolytic HSV was quantified by IF following 24 and 48 h 
treatment. Taxol was used as an internal control as it is a known microtubule 
 148 
stabilising agent (175). SF188 cells treated with 10 pfu/cell oncolytic HSV 
resulted in a statistically significant increase in both acetylated and 
detyrosinated tubulin at 24 and 48 h compared to control treated cells 
(mean±SEM intensity normalised to control: Acetylated tubulin: 24 h: control 
1±0.785, HSV 513±135 p=0.00427; 48 h: control 1±0.523, HSV 246±60.8 
p<0.001; Detyrosinated tubulin: 24 h: control 1±0.983, HSV 62.4±22.2 
p=0.0186; 48 h: control 1±0.397, HSV 4.5±0.594 p<0.001)(Figure 45 and 
46). Expression of both acetylated and detyrosinated tubulin appeared to be 
increased at the 24 h time point. The effects of HSV treatment on SF188 
acetylated and detyrosinated tubulin expression were more marked than the 
effects of 100nM taxol. 
 
For KNS42, oncolytic HSV treatment resulted in a statistically significant 
increase in acetylated tubulin by 48 h when evaluated by IF (mean±SEM 
intensity normalised to control: Acetylated tubulin: 24 h: control 1±0.997, 
HSV 11.5±5.02 p=0.0672; 48 h: control 1±0.804, HSV 6038±2272 p=0.0289) 
(Figure 47). KNS42 appeared to be more sensitive to the effects of taxol 
than SF188, with statistically significant increases in both acetylated and 
detyrosinated tubulin noted following 24 and 48 h of treatment (mean±SEM 
intensity normalised to control: Acetylated tubulin: 24 h: control 1±0.997, 
taxol 24.8±5.8 p=0.00258; 48 h: control 1±0.804, taxol 5727±709 p=<0.001; 
Detyrosinated tubulin: 24 h: control 1±0.099, taxol 1.35±0.12 p=0.04; 48 h: 
control 1±0.084, taxol 1.81±0.34 p=0.0475) (Figure 47 and 48). Oncolytic 
HSV did not significantly increase KNS42 expression of detyrosinated 
tubulin, although a trend towards this was observed (mean±SEM intensity 
normalised to control: detyrosinated tubulin: 24 h: control 1±0.099, HSV 
















Figure 44: Western blot analysis of the effects of oncolytic HSV on 
pHGG acetylated tubulin expression  
pHGG cell lines SF188 and KNS42 were treated ± 10 pfu/cell oncolytic HSV. 
Following either 24 or 48 h incubation, cell lysates were obtained. 
Expression of acetylated tubulin was determined by Western blotting (A). 
Beta-actin control was included to evaluate protein loading and transfer. 
Intensity of the acetylated tubulin band was quantified and normalised to the 
β-actin control using Image J software. (B) Quantification of SF188 
acetylated tubulin expression following 24 and 48 h treatment ± 10 pfu/cell 
oncolytic HSV. (C) Quantification of KNS42 acetylated tubulin expression 
following 24 and 48 h treatment ± 10 pfu/cell oncolytic HSV. Graphs show 





















































































Figure 45: Evaluation of the effects of oncolytic HSV on SF188 acetylated tubulin 
expression by immunofluorescent labelling 
2x105 cells (SF188) were grown on sterile cover slips and treated ± 10 pfu/cell oncolytic 
HSV or 100 nM taxol for 24 or 48 h. The effects of treatment at 24 (A) or 48 h (B) on 
acetylated tubulin expression were evaluated by IF labelling. Red labelling: acetylated 
tubulin, green labelling: tubulin, blue labelling: DAPI staining. Magnification x63. White scale 
bar represents 50 μm. At least 75 cells from each treatment condition were evaluated to 
determine the intensity of acetylated tubulin labelling normalised to the control at 24 (C) and 
48 h (D). Error bars are expressed as ±SEM. **p<0.01, ***p<0.001 by Student’s two-tailed t-






























































































Figure 46: Evaluation of the effects of oncolytic HSV on SF188 detyrosinated tubulin 
expression by immunofluorescent labelling 
2x105 cells (SF188) were grown on sterile cover slips and treated ± 10 pfu/cell oncolytic 
HSV or 100 nM taxol for 24 or 48 h. The effects of treatment at 24 (A) or 48 h (B) on 
detyrosinated tubulin expression were evaluated by IF labelling. Red labelling: detyrosinated 
tubulin, green labelling: tubulin, blue labelling: DAPI staining. Magnification x63. White scale 
bar represents 50 μm. At least 40 cells from each treatment condition were evaluated to 
determine the intensity of acetylated tubulin labelling normalised to the control at 24 (C) and 
48 h (D). Error bars are expressed as ±SEM. **p<0.01, ***p<0.001 by Student’s two-tailed t-
















































































Figure 47: Evaluation of the effects of oncolytic HSV on KNS42 acetylated tubulin 
expression by immunofluorescent labelling 
2x105 cells (KNS42) were grown on sterile cover slips and treated ± 10 pfu/cell oncolytic 
HSV or 100 nM taxol for 24 or 48 h. The effects of treatment at 24 (A) or 48 h (B) on 
acetylated tubulin expression were evaluated by IF labelling. Red labeling: acetylated 
tubulin, green labeling: tubulin, blue labeling: DAPI staining. Magnification x63. White scale 
bar represents 50 μm. At least 80 cells from each treatment condition were evaluated to 
determine the intensity of acetylated tubulin labelling normalised to the control at 24 (C) and 
48 h (D). Error bars are expressed as ±SEM. **p<0.01, ***p<0.001 by Student’s 2-tailed t-






















































































Figure 48: Evaluation of the effects of oncolytic HSV on KNS42 detyrosinated tubulin 
expression by immunofluorescent labelling 
2x105 cells (KNS42) were grown on sterile cover slips and treated ± 10 pfu/cell oncolytic 
HSV or 100 nM taxol for 24 or 48 h. The effects of treatment at 24 (A) or 48 h (B) on 
detyrosinated tubulin expression were evaluated by IF labelling. Red labelling: detyrosinated 
tubulin, green labelling: tubulin, blue labelling: DAPI staining. Magnification x40. White scale 
bar represents 100 μm. At least 80 cells from each treatment condition were evaluated to 
determine the intensity of acetylated tubulin labelling normalised to the control at 24 (C) and 
48 h (D). Error bars are expressed as ±SEM. **P<0.01, ***P<0.001 by Student’s two-tailed 



























































































GSK is a serine/threonine protein kinase that plays a key role in 
orchestrating cell migration through regulation of cell structure, motility, 
adhesion and cytoskeleton dynamics (195,202,213). The results described 
in chapter three highlight the importance of GSK-3 in pHGG cell migration 
and invasion. In a study designed to investigate the mechanism of wild-type 
HSV spread, HSV was shown to induce the formation of stable microtubule 
subsets through inactivation of GSK-3β in normal human dermal fibroblasts 
(311). The effects of oncolytic HSV on human cell GSK-3 expression are 
currently unknown. Here, for the first time, the effects of oncolytic HSV on 
pHGG GSK-3 expression are evaluated. Western blotting was employed to 
analyse the total, activated and inactivated forms of GSK-3 protein isoforms 
following oncolytic HSV treatment of pHGG cell lines. 
 
Oncolytic HSV treatment of SF188 significantly increased Ser9 
phosphorylated GSK-3β (inactivated form) at 24 h (mean±SEM intensity of 
band, normalised to actin: control 0.391±0.197, HSV 1.49±0.214 p=0.0199) 
(Figure 49A and B). This effect was much less marked at 48 h (mean±SEM 
intensity of band, normalised to actin: control 0.621±0.092, HSV 
0.736±0.239 p=0.688). For KNS42, oncolytic HSV treatment resulted in a 
trend towards increased Ser9 phosphorylated GSK-3β at both 24 and 48 h 
(mean±SEM intensity of band, normalised to actin: 24 h: control 
0.956±0.446, HSV 1.93±0.078 p=0.156; 48 h: control 0.457±0.12, HSV 
1.2±0.495 p=0.270) (Figure 49A and C). Conversely, oncolytic HSV 
treatment resulted in a trend towards decreased expression of the activating 
tyrosine of GSK-3αβ for both pHGG cell lines at 24 and 48 h (mean±SEM 
SF188 intensity of band, normalised to actin: 24 h: control 1.47±0.591, HSV 
0.999±0.481 p=0.574; 48 h: control 0.586±0.227, HSV 0.201±0.086 
p=0.226; KNS42 intensity of band, normalised to actin: 24 h: control 
2.061±0.92, HSV 1.11±0.624 p=0.446; 48 h: control 1.17±0.321, HSV 
0.364±0.028 p=0.126) (Figure 50). Overall, oncolytic HSV treatment resulted 
in a trend towards decreased total GSK-3β expression at 24 and 48 h for 
both pHGG cell lines (mean±SEM SF188 intensity of band, normalised to 
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actin: 24 h: control 1.28±0.382, HSV 0.995±0.287 p=0.586; 48 h: control 
1.23±0.167, HSV 0.636±0.273 p=0.153; KNS42 intensity of band, 
normalised to actin: 24 h: control 1.32±0.515, HSV 1.1±0.281 p=0.735; 48 h: 
control 1.61±0.508, HSV 0.992±0.368 p=0.388) (Figure 51).  
 
Although the majority of the results described above do not reach statistical 
significance, they do represent a consistent trend that fits with the biological 
hypothesis and small differences in kinase activity may have large biological 
consequences. In conclusion, the trend demonstrated by the results support 
the hypothesis that oncolytic HSV can decrease GSK-3β activity of pHGG 
cells, increasing the inactive GSK-3 isoform and reducing the activating 
































Figure 49: Western blot analysis of the effects of oncolytic HSV on 
pHGG phosphorylated GSK-3β Ser9 
pHGG cell lines SF188 and KNS42 were treated ± 10 pfu/cell oncolytic HSV. 
Following either 24 or 48 h incubation, cell lysates were obtained. 
Expression of phosphorylated GSK-3β Ser9 (inactivated form) was 
determined by Western blotting (A). Beta-actin control was included to 
evaluate protein loading and transfer. Intensity of the phosphorylated GSK-
3β Ser9 band was quantified and normalised to the β-actin control using 
Image J software. (B) Quantification of SF188 phosphorylated GSK-3β Ser9 
expression following 24 and 48 h treatment ± 10 pfu/cell oncolytic HSV. (C) 
Quantification of KNS42 phosphorylated GSK-3β Ser9 expression following 
24 and 48 h treatment ± 10 pfu/cell oncolytic HSV. Graphs show mean ± 

















































































         
      
 
Figure 50: Western blot analysis of the effects of oncolytic HSV on 
pHGG Tyr216/279 phosphorylated GSK3αβ 
pHGG cell lines SF188 and KNS42 were treated ± 10 pfu/cell oncolytic HSV. 
Following either 24 or 48 h incubation, cell lysates were obtained. 
Expression of Tyr216/279 phosphorylated GSK3αβ (active form) was 
determined by Western blotting (A). β-actin control was included to evaluate 
protein loading and transfer. Intensity of the Tyr216/279 phosphorylated 
GSK3αβ band was quantified and normalised to the β-actin control using 
Image J software. (B) Quantification of SF188 Tyr216/279 phosphorylated 
GSK3αβ expression following 24 and 48 h treatment ± 10 pfu/cell oncolytic 
HSV. (C) Quantification of KNS42 Tyr216/279 phosphorylated GSK3αβ 
expression following 24 and 48 h treatment ± 10 pfu/cell oncolytic HSV. 













































































               
 
 
Figure 51: Western blot analysis of the effects of oncolytic HSV on 
pHGG total GSK3β 
pHGG cell lines SF188 and KNS42 were treated ± 10 pfu/cell oncolytic HSV. 
Following either 24 or 48 h incubation, cell lysates were obtained. 
Expression of total GSK3β was determined by Western blotting (A). β-actin 
control was included to evaluate protein loading and transfer. Intensity of the 
total GSK3β band was quantified and normalised to the β-actin control using 
Image J software. (B) Quantification of SF188 total GSK3β expression 
following 24 and 48 h treatment ± 10 pfu/cell oncolytic HSV. (C) 
Quantification of KNS42 total GSK3β expression following 24 and 48 h 
treatment ± 10 pfu/cell oncolytic HSV. Graphs show mean ± SEM of n=3 
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5.4 Evaluation of the effects of oncolytic HSV on APC localisation 
 
 
GSK-3 plays an important role in regulating the polarity of migrating cells 
(93,213). Polarity cues result in the localised inhibition of GSK-3, which 
promotes APC to cluster at microtubule plus ends at the leading edge of 
cells, controlling the direction of movement (93,110). Given that the results in 
section 5.3 suggest that oncolytic HSV decreases GSK-3β activity in pHGG 
cells, the effects of virus treatment on APC distribution were evaluated by IF.  
 
SF188 cells cultured in normal medium demonstrated a clear localisation of 
APC to the leading edge of cells (Figure 52A). This effect was not notable for 
KNS42; however, this may be a reflection of the fact that this cell line was 
much less motile than SF188 (Figure 52B). Following treatment with 
oncolytic HSV, SF188 cells demonstrated diffuse staining of APC throughout 
the cytoplasm, with a clear loss of APC clustering to a leading edge (Figure 
52A). A similar diffuse distribution of APC was seen in SF188 cells treated 
with the GSK-3 inhibitor BIO.  

























Figure 52: The effects of oncolytic HSV on pHGG APC localisation 
2x105 cells (SF188 (A) or KNS42 (B)) were grown on sterile cover slips and 
treated ± 10 pfu/cell oncolytic HSV or 5 μM BIO for 24 h. The effects of 
treatment at 24 h on APC localisation (white arrows) were evaluated by IF 
labelling. Red labeling: APC, green labeling: tubulin, blue labeling: DAPI 







5.5 Evaluation of the effects of oncolytic HSV on DOCK3 
 
DOCK3 is a protein predominantly expressed in the CNS (390) that can 
drive mesenchymal cancer cell migration and movement (80,391,392). 
DOCK3 has also been shown to be able to bind and inactivate GSK-3β, by 
inducing GSK-3 phosphorylation at Ser9 (393). Given that the results in 
section 5.3 suggest that oncolytic HSV can decrease GSK-3β activity of 
pHGG cells by increasing the inactive GSK-3 isoform (GSK-3β Ser9), the 
effects of virus treatment on DOCK3 expression were evaluated.  
 
DOCK3 protein expression was initially investigated by Western blotting of 
pHGG cell lysates treated ± oncolytic HSV. DOCK3 protein was 
undetectable in pHGG cell lines using this technique. Further investigation of 
DOCK3 expression in pHGG cells treated ± oncolytic HSV was carried out 
by IF. IF labelling revealed increased detection of DOCK3 in virus-treated 














Figure 53: Evaluation of the effects of oncolytic HSV on pHGG DOCK3 
by immunofluorescent labelling 
2x105 cells (SF188 or KNS42) were grown on sterile cover slips and treated 
± 10 pfu/cell oncolytic HSV. The effects of treatment at 24 h on DOCK3 
expression were evaluated by IF labelling. Red labelling: DOCK3, green 
labelling: tubulin, blue labelling: DAPI staining. Magnification x63. White 


















The results contained within this thesis demonstrate that oncolytic HSV can 
inhibit both the in vitro migration and invasion of pHGG and DIPG cells. In 
this chapter, live cell imaging confirmed that oncolytic HSV can alter the 
movement of individual pHGG cells, resulting in reduced motility and a loss 
of cell polarity. Both cell lines investigated altered their morphology following 
oncolytic HSV treatment. SF188 cells exhibited the loss of distinct leading 
and trailing edges and developed protrusive tails that were unable to fully 
retract. KNS42 cells generally adopted a rounded morphology and 
developed multiple thin-branching protrusions following virus treatment. 
These observations were much more marked for SF188 than KNS42, 
reflecting the fact that SF188 is a more migratory and motile cell line. These 
results are highly novel and demonstrate the ability of an OV to alter pHGG 
movement and morphology.  
 
Oncolytic HSV treatment stabilised pHGG microtubules, as demonstrated by 
the accumulation of post-translational tubulin modifications. Over 48 h, 
oncolytic HSV treatment led to increased acetylated and detyrosinated 
tubulin expression in pHGG cell lines when compared to controls.  Again, 
these observations were generally more marked for the highly migratory cell 
line SF188, compared to KNS42.  
 
In addition, oncolytic HSV resulted in a trend towards decreased GSK-3β 
activity in pHGG cells following treatment. GSK-3β is a protein kinase that 
plays a critical role in regulating cell motility, adhesion and cytoskeleton 
dynamics. Treatment with oncolytic HSV resulted in a tendancy towards 
increased Ser9 phosphorylated GSK-3β (inactive form) and a trend towards 
a reduction in the activating tyrosine of GSK-3αβ. Furthermore, oncolytic 
HSV treatment of SF188 resulted in a clear loss of APC clustering to the 
leading edge of the cell. Instead, virus treatment resulted in the diffuse 
redistribution of APC throughout the cytoplasm. Given that APC localisation 
plays a critical role in controlling the direction of cell movement, this diffuse 
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redistribution following oncolytic HSV treatment may explain why the virus- 
treated cells lost their polarity.  
 
Finally, a tendancy towards increased DOCK3 expression was observed in 
virus-treated pHGG cells compared to controls when evaluated by IF 
labelling. Given that DOCK3 is able to bind and inactivate GSK-3β, inducing 
GSK-3 phosphorylation at Ser9 (393), this observation again demonstrates 
the potential of oncolytic HSV to alter molecular pathways critical for cell 
migration and movement. In summary, the results obtained here begin to 
outline the mechanisms underlying the ability of oncolytic HSV to prevent 
pHGG cell migration and invasion.  
 
The cell cytoskeleton is composed of highly dynamic adaptable structures 
that allow a cell to: modulate its shape; migrate; divide; organise intracellular 
transportation and exert mechanical strength (86,309,394). Viruses have 
evolved the ability to hijack components of the cytoskeleton in order to 
facilitate their replication cycle and spread. In doing so, virus infection of a 
cell can result in the rearrangement of cytoskeletal filaments and influence 
overall cytoskeletal dynamics (308,309,395). The interaction of HSV with the 
host cytoskeleton has been well studied (309). HSV replicates and 
assembles nucleocapsids within the nuclei of infected host cells and, thus, 
successful replication utilises an effective strategy to transport the virus to 
and away from the nucleus through the cytoplasm (309). In order to achieve 
this, HSV makes use of microtubules to provide intracellular tracks for 
efficient bidirectional transportation of virion particles to and from the nucleus 
(308,309,396). Microtubules are polarised structures, with highly dynamic 
plus ends, capable of polymerising (growing) and depolymerising (shrinking) 
during the process of dynamic instability and relatively stable minus ends, 
which are associated with the MTOC (93,95,309). Molecular motors 
associated with microtubules allow the bidirectional trafficking of virus cargo, 
with plus end directed motors called kinesins directing transport to the cell 
periphery and minus end motors known as dyneins facilitating movements 
towards the cell centre (308,309,396-398).  
 
 165 
The dynamics and distribution of the microtubules are governed by multiple 
factors including: post-translational modification of tubulin; MAPs; and GTP 
hydrolysis (309,399). Herpes simplex family viruses are capable of inducing 
the acetylation of tubulin, a known marker of microtubule stabilisation, early 
during the infection of host cells (394,400). Microtubule acetylation is also 
associated with kinesin binding and may enhance microtubule motor-
dependent trafficking (114,395). Viruses such as HSV may have evolved to 
rely upon such post-translational modifications to identify particular subsets 
of microtubules that lead to specific cellular destinations (114). Given that 
the rate of growth of microtubules in vivo is slower than the rate of vesicle 
transport (approximately 0.2 μm/s versus 2 μm/s), viruses may preferentially 
rely upon stable, ready-formed microtubule tracks for transportation and 
these stable microtubule networks may be identifiable to virus through the 
accumulation of specific post-translational modifications (114,401-403).  
 
It is postulated that dynamic microtubules are required for cell migration 
(404-406). The accumulation of post-translational modifications such as 
acetylated tubulin, that mark microtubules as stable, have been shown to 
reduce focal adhesion turnover and subsequent cell migration (407). 
Additionally, suppression of microtubule dynamics by drugs such as 
paclitaxel, appears to inhibit cell locomotion by interfering with the ability of 
the migrating cell to retract its tail (406). As oncolytic HSV appears capable 
of stabilising microtubules, through accumulation of post-translational 
modifications such as acetylated and detyrosinated tubulin in pHGG cells, 
this may explain the reduction in pHGG motility, migration and invasion 
observed. Furthermore, microtubule stabilisation may also account for the 
inability of SF188 cells to fully retract their tails following treatment with 
oncolytic HSV, again contributing to the overall reduction in cell motility. 
 
Work by Naghavi et al. has explored the mechanism by which wild-type 
HSV-1 can manipulate microtubule networks in primary human cell lines 
(311). The authors demonstrate that HSV-1 infection induces microtubule 
stabilisation through accumulation of acetylated tubulin and that this involves 
GSK-3β inactivation by the viral serine/threonine kinase, Us3 (311). Us3 
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appears to be central for HSV spread and coordinates microtubule 
regulation of the host cell (311,408,409). In keeping with the work of Naghavi 
et al., the results contained within this chapter suggest that oncolytic HSV is 
capable of decreasing GSK-3β activity in pHGG cell lines, through 
increasing the inactive form of GSK-3β (Ser9 phosphorylated GSK-3β). 
Although the exact mechanism by which this is achieved by the OV remains 
unclear, this GSK-3 inactivation may facilitate microtubule stabilisation of 
pHGG cell lines. Further experiments are required to prove this hypothesis 
and to fully determine the mechanism by which oncolytic HSV inhibits GSK-
3β activity.  
 
One potential mechanism by which oncolytic HSV may inhibit GSK-3β 
activity in pHGG cells involves DOCK3. DOCK3 is one of 11 members of the 
DOCK family of proteins that, alongside multiple cellular functions, regulate 
the actin cytoskeleton, cell adhesions and migration (80). DOCK3 has been 
shown to promote membrane recruitment of GSK-3β, binding and 
inactivating it through Ser9 GSK-3β phosphorylation (393). Given that 
oncolytic HSV treatment appears to be associated with an increase in 
DOCK3 expression within pHGG cells, it is possible that elevated DOCK3 
may be able to influence the activity of GSK-3β. One potential hypothesis, 
which remains the subject of future work, is that elevated levels of DOCK3 
may contribute towards the increase in Ser9 phosphorylation of GSK-3β 
seen in pHGG cells following oncolytic HSV treatment. 
 
Work by Etienne-Manneville and Hall has highlighted the importance of 
GSK-3β in the determination of cell polarity (110). Cell polarity is essential in 
migration and is required to generate a front-rear axis (87). The authors 
demonstrated that phosphorylation of GSK-3β at the leading edge of a 
migrating cell results in the interaction of APC with microtubule plus ends, 
promoting directional cell protrusion (110). This localisation of inactive GSK-
3β and consequent APC clustering appears to be critical to cell polarity 
(110). SF188 cells treated with normal medium demonstrated clear 
localisation of APC to the leading edge; however, following treatment with 
oncolytic HSV, APC was diffusely distributed throughout the cytoplasm. This 
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observation highlights the importance of functionally active GSK-3β within 
pHGG cells, as global inhibition of GSK-3β by oncolytic HSV appears to 
prevent localised GSK-3β inactivation and APC clustering. Subsequent loss 
of cell polarity may explain why this cell line demonstrated a marked and 
significant reduction in both migration and invasion following oncolytic HSV 
infection. 
 
It is well established that GSK-3β regulates cell migration, influencing 
dynamics of the cytoskeleton, microtubule remodelling, cell polarity and cell-
ECM adhesions (213). The results within this thesis suggest that GSK-3β 
plays a key role in pHGG cell migration and invasion. Chapter three 
highlights that pharmacological inhibition of GSK-3β with the known 
inhibitors LiCl and BIO, significantly reduces pHGG migration and invasion. 
Furthermore, it appears that oncolytic HSV, also capable of significantly 
inhibiting pHGG migration and invasion, inactivates GSK-3β. Global GSK-3β 
inactivation may facilitate microtubule stabilisation of pHGG cell lines and 
may account for the diffuse redistribution of APC, preventing the formation of 
a polarised cell axis.  
 
In conclusion, oncolytic HSV treatment resulted in changes in pHGG cell 
morphology, motility, polarity and microtubule dynamics and this may, in 
part, be governed by inhibition of GSK-3β. The results documented within 
this chapter are highly novel and have not previously been reported: they 
begin to document the molecular mechanisms by which OV such as 
















pHGG and DIPG are highly invasive tumours associated with poor survival 
outcomes and new treatments that effectively target brain tumour invasion 
are very much needed. Unfortunately, compared to adult HGG, there is a 
paucity of robust in vivo models of pHGG and DIPG available for drug 
testing. Orthotopic xenotransplantation of pHGG or DIPG cells into mice has 
been successfully used as a pre-clinical tool (29,61-63).  
 
Within this thesis, the anti-migratory and anti-invasive effects of two GSK-3 
inhibitors, LiCl and BIO, and oncolytic HSV have been demonstrated using 
2D and 3D in vitro models.  Within this chapter, the ability of oncolytic HSV 
to block glioma invasion and infiltration in vivo is explored in two separate 
mouse models. First, the ability of oncolytic HSV to inhibit the invasion and 
infiltration of GL261-Luc intracranial tumours is evaluated in a syngeneic 
orthotopic mouse model of glioma. Second, the ability of oncolytic HSV to 
improve survival and reduce invasion and infiltration of HSJD-DIPG-007 
cells in an orthotopic xenograft model of DIPG is investigated. These 
experiments form part of ongoing efforts to develop an effective in vivo 
model of glioma invasion, in order to effectively screen novel  anti-invasive 

















6.2 Evaluation of the anti-invasive effects of oncolytic HSV in an in 
vivo high grade glioma tumour model 
 
 
The ability of the pHGG cell line SF188 to establish orthotopic xenografts in 
Balb/c nude mice was evaluated. The SF188 cell line was transfected with 
luciferase to allow for bioluminescence imaging of established intracranial 
tumours. 2.5x105 cells were intracranially injected; however, unfortunately 
tumours failed to establish, as confirmed by minimal luminescence signal 
detection at 40 days-post tumour implantation. 
 
In the absence of an orthotopic xenograft model of pHGG, the well-
established GL261 mouse model of glioma was considered as a suitable 
alternative. GL261 cells contain several molecular biological alterations seen 
in human glioma (410). The GL261 model has a high tumour-take rate with 
survival time proportionate to the number of cells injected: following 
intracranial injection of 1x105 GL261 cells, median survival is reported to be 
approximately 32.5±5.3 days (410,411). The results in chapter four confirm 
that oncolytic HSV is capable of significantly reducing GL261-Luc migration 
(Figure 20) and invasion (Figure 26) and GL261-Luc cells appear to be 
resistant to the cytotoxic effects of oncolytic HSV when investigated over 48 
h in vitro (Figure 29).  
 
One major drawback of the GL261 mouse model of glioma is that GL261 
tumours have limited, if any, infiltration in vivo. Pellegatta et al. state that 
intracranial tumours of adherent cell GL261 in C57BL/6 mice form ‘non-
infiltrating tumours bearing little resemblance to primary mouse glioma’ 
(411).  The authors demonstrate that intracranial tumours of GL261 
neurospheres however can form tumours that display increased infiltration in 
vivo (411).  On the other hand, Szatmári et al. charachterised the GL261 
tumour model for experimental glioblastoma therapy and showed that 
‘intracranial tumours had a rapid growth rate with slightly invasive growth 
pattern’ (410). Within this thesis, the GL261 cells used correspond to 
adherent cell GL261, and therefore this is identified as a potential limitation 
of the mouse model.  
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GL261-Luc tumours were established in the brains of two groups (n=8 per 
group) of C57BL/6 mice. For one group of mice, GL261-Luc cells were 
premixed with oncolytic HSV at 10 pfu/cell prior to intracranial injection. Four 
mice per group were sacrificed on day 15 and the remainders on day 25 in 
order to evaluate the invasion and infiltration of the established tumours into 
the surrounding brain at different time points.  
 
Analysis of the brains harvested from the control group of mice, injected with 
untreated GL261-Luc cells, revealed a moderate degree of infiltrative tumour 
growth at day 15 and 25 by H&E staining (Figure 54-56). By day 15, single 
cells were seen starting to migrate and invade away from the tumour edge 
and lymphocyte infiltration was noted at the tumour migrating front (Figure 
54). By day 25, tumours again were noted to demonstrate a moderate 
degree of infiltration into the normal surrounding brain tissue (Figure 55). 
Heterogeneity was noted within the tumours, with one tumour sample clearly 
displaying a non-infiltrative border, despite some tumour infiltration and 
single cell migration and invasion away from all the other tumour edges 
(Figure 55). Tumour cells were seen to migrate and invade in the proximity 
of white matter tracts (Figure 56), a well-defined characteristic pattern of 
HGG migration (24,72,73), however, this may also represent the tumour 
expending towards the myelin tracts during growth.  
 
Unexpectantly, tumours were not detected by day 25 in brains harvested 
from mice that received intracranial GL261-Luc premixed with oncolytic HSV 
(Figure 57 and 58).  Consequently, the effects of oncolytic HSV on glioma 
invasion could not be evaluated within this experiment. Examination of the 
H&E stained sections of mouse brains injected with tumour cells plus HSV 
identified multiple sites of inflammation, with perivascular clustering of 
lymphocytes. Interestingly, these localised inflammatory changes were also 
noted within the brains of control group mice treated with GL261-Luc cells 
alone (Figure 57). These changes were not noted within normal mouse 
brains. Finally, one section obtained from a mouse brain injected with 
GL261-Luc cells premixed with oncolytic HSV revealed evidence of a local 
inflammatory reaction along the potential injection tract (Figure 58).  
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Unfortunately, tumour growth was not evaluated by bioluminescent imaging 
throughout this experiment. As a result, no conclusions can be drawn as to 
whether GL261-Luc cells premixed with oncolytic HSV formed tumours 
which were cleared as a result of virus treatment or whether this group of 
mice failed to grow tumours in the first instance, due to premixing of the virus 







Figure 54: Evaluation of the in vivo invasive behavior of GL261-Luc tumours on day 
15 
5x104 GL261-Luc cells in 2 μl PBS were stereotactically injected into the brains of 6-8-week-
old C57BL/6 mice. Mice were sacrificed on day 15-post injection and brains were 
immediately harvested into 4 % PFA. Brains were then sliced into coronal sections, 
embedded in paraffin and sectioned to 4 microns thick. Tissue sections were stained with 
H&E. (A) Black arrows point to the sites of single tumour cells demonstrating migration and 
invasion away from day 15- established GL261-Luc tumours. Image taken at x5 
magnification using the SPOT Insight camera and Leitz DMRB microscope. (B) Red arrow 
points to a site of lymphocyte infiltration at the invading edge of a day 15-established 
GL261-Luc tumour. Image taken at x10 magnification using the SPOT Insight camera and 












Figure 55: Evaluation of the in vivo invasive behavior of GL261-Luc tumours on day 
25 
5x104 GL261-Luc cells in 2 μl PBS were stereotactically injected into the brains of 6-8-week-
old C57BL/6 mice. Mice were sacrificed on day 25-post injection and brains were 
immediately harvested into 4 % PFA. Brains were then sliced into coronal sections, 
embedded in paraffin and sectioned to 4 microns thick. Tissue sections were stained with 
H&E. (A) Black arrows point to the sites of tumour cell infiltration into the normal 
surrounding mouse brain in day 25-established GL261-Luc tumours. Image taken at x5 
magnification using the SPOT Insight camera and Leitz DMRB microscope. (A and B) Red 
arrow points to the edge of the same day 25 established GL261-Luc tumour that appears to 
be non-infiltrative and has a distinct well defined border. Image taken at x10 magnification 









Figure 56: GL261-Luc tumour cells can be seen migrating and invading along white 
matter tracts.   
5x104 GL261-Luc cells in 2 μl PBS were stereotactically injected into the brains of 6-8-week-
old C57BL/6 mice. Mice were sacrificed on day 15- (A) or day 25- (B) post injection and 
brains were immediately harvested into 4 % PFA. Brains were sliced into coronal sections, 
embedded in paraffin and sectioned to 4 microns thick. Tissue sections were stained with 
H&E. (A) Black arrow indicates white matter tracts within mouse brain. Red arrow highlights 
tumour cells from day 15-established GL261-Luc tumours migrating and invading in the 
proximity of the white matter tract. Image taken at x5 magnification using the SPOT Insight 
camera and Leitz DMRB microscope. (B) Black arrow indicates white matter tracts within 
mouse brain. Red arrow highlights tumour cells from day 25-established GL261-Luc 
tumours migrating and invading in the proximity of white matter tracts. Image taken at x10 




Figure 57: Brain slices of GL261-Luc tumours treated ± oncolytic HSV demonstrate 
localised sites of inflammation and perivascular clustering of lymphocytes 
5x104 GL261-Luc cells in 2 μl PBS were stereotactically injected into the brains of two 
groups of 6-8-week-old C57BL/6 mice. For one group of mice, GL261-Luc cells were 
premixed with oncolytic HSV at 10 pfu/cell prior to intracranial injection. Mice were sacrificed 
on day 15-post injection and brains were immediately harvested into 4 % PFA. Brains were 
then sliced into coronal sections, embedded in paraffin and sectioned to 4 microns thick. 
Tissue sections were stained with H&E. (A and B) H&E stained brain slices from mouse 
brains injected with GL261-Luc cells premixed with oncolytic HSV. Black arrows indicate 
sites of inflammation, with perivascular clustering of lymphocytes noted. Images taken at 
x10 magnification using the SPOT Insight camera and Leitz DMRB microscope. (C and D) 
H&E stained brain slices from mouse brains injected with GL261-Luc cells only. Black 
arrows indicate sites of inflammation, with perivascular clustering of lymphocytes. Red 
arrow indicates the presence of an infiltrative GL261-Luc day 15-established tumour. Image 
C taken at x10 magnification and image D taken at x20 magnification using the SPOT 










Figure 58: GL261-Luc tumour treated with oncolytic HSV demonstrates localised 
inflammatory reaction along the potential injection tract 
 5x104 GL261-Luc premixed with oncolytic HSV at 10 pfu/cell were stereotactically injected 
into the brains of 6-8-week-old C57BL/6 mice. Mice were sacrificed on day 15 post injection 
and brains were immediately harvested into 4 % PFA. Brains were then sliced into coronal 
sections, embedded in paraffin and sectioned to 4 microns thick. Tissue sections were 
stained with H&E. Black arrow highlights a localised inflammatory reaction along the 
potential injection tract. Images taken at x10 magnification using the SPOT Insight camera 




















6.3 Evaluation of the effects of oncolytic HSV as an anti-invasive 
therapy for DIPG  
 
 
An orthotopic xenograft model of DIPG was established by injecting HSJD-
DIPG-007 cells into the fourth ventricle of NOD.SCID mice, allowing tumour 
cells to grow and invade into the brainstem. In order to evaluate the effects 
of oncolytic HSV therapy in this model, mice were either injected with HSJD-
DIPG-007 cells premixed with PBS (n=6) or HSJD-DIPG-007 cells premixed 
with oncolytic HSV at 10 pfu/cell (n=6).  
 
Analysis of sections obtained from the brains of mice in the control group, 
injected with untreated HSJD-DIPG-007 cells, showed a moderate increase 
in cellularity within the brainstem, adjacent cortex and cerebellum by 
diffusely infiltrating sheets of atypical glial cells (Figure 59A). These cells had 
hyperchromatic and moderately pleomorphic nuclei and fine fibrillary 
cytoplasm (Figure 59B). Mitotic activity was high; however, there was no 
evidence of necrosis or vascular proliferation. These HSJD-DIPG-007 
tumour cells did not form a solid mass as seen within mouse brain following 
GL261-Luc intracranial injection but appeared to diffusely migrate, invade 
and infiltrate evenly throughout the midbrain, medulla and cerebellum 
following their injection into the brainstem (Figure 60A). Invasion also 
continued until cells reached the subpial surface where they then continued 
to spread horizontally in clusters (Figure 60B).   
 
Conversely, the brain sections obtained from mice that received intracranial 
injection of HSJD-DIPG-007 premixed with oncolytic HSV demonstrated 
well-contained collections of increased cellularity within the brainstem, with 
very limited infiltration into the surrounding structures (Figure 61A). These 
well-contained collections consisted of abnormal looking cells where the 
nucleus was elongated and mixed with apoptotic bodies, indicative of tumour 
cells (Figure 61B and 62). One section showed a blood vessel surrounded 
by a cuff of slightly pleomorphic cells, with oval and elongated misshapen 
nuclei and frequent apoptotic bodies, again likely to be tumour cells (Figure 
63). The tumour injection site was noted within the pons, characterised by 
small areas of cholesterol clefts and microcalcifications and there was a 
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raised possibility of tumour cells at the site of injection indicated by 
hyperchromatic misshapen nucleic and a slight focal increase in cellularity 
(Figure 64).   
 
Finally, the therapeutic efficacy of oncolytic HSV treatment was evaluated in 
an orthotopic xenograft model of DIPG (Figure 65). Oncolytic HSV treatment 
prolonged survival (median survival: control PBS treated: 71 days, HSV 








Figure 59: HSJD-DIPG-007 cells diffusely infiltrate mouse brains following intracranial 
injection 
5x105 disaggregated HSJD-DIPG-007 cells premixed with PBS were stereotactically 
injected into the brains of 4-5-week-old NOD.SCID mice. Tumours were left to establish and 
mice were sacrificed when showing signs of disease (i.e. severe ataxia or >15 % weight 
loss). Images from mouse brain obtained on day 62-post surgery. Brains were harvested 
into 4 % PFA, sliced into coronal sections, embedded in paraffin and sectioned to 4 microns 
thick. Tissue sections were stained with H&E. (A) Brainstem section showing diffuse 
infiltration of tumour cells into the pons (P) and adjacent cerebellum (C). There is moderate 
increase in cellularity with even distribution of cells in a diffuse pattern. Image taken at x2.5 
magnification using the SPOT Insight camera and Leitz DMRB microscope. (B) Brainstem 
section of pons at x20 magnification showing the diffuse distribution of tumour cells. Black 
arrow indicates normal neuron with prominent nucleolus. Green arrow indicates a white 
matter tract. Blue arrow indicates mitotic activity. Red arrow shows representative examples 
of atypical cells with pleomorphic hyperchromatic nuceli indicative of tumour cells. Image 







Figure 60: HSJD-DIPG-007 cells are highly infiltrative within mouse brains following 
intracranial injection.  
5x105 disaggregated HSJD-DIPG-007 cells premixed with PBS were stereotactically 
injected into the brains of 4-5-week-old NOD.SCID mice. Tumours were left to establish and 
mice were sacrificed when showing signs of disease (i.e. severe ataxia or >15 % weight 
loss). Images from mouse brain obtained on day 62-post surgery. Brains were harvested 
into 4 % PFA, sliced into coronal sections, embedded in paraffin and sectioned to 4 microns 
thick. Tissue sections were stained with H&E. (A) Brain section through the cerebellum 
shows defined granular (G), purkinje (P) and molecular (M) layers. There is moderate to 
high increase in cellularity by atypical glial cells within the molecular layer indicating diffuse 
tumour infiltration (black arrows show representative examples). Image taken at x10 
magnification using the SPOT Insight camera and Leitz DMRB microscope. (B) Brain 
section showing clusters of tumour cells (black arrows) accumulating within the subpial 
region and starting to migrate and invade horizontally. A is arachnoid, P is pia. Image taken 







Figure 61: HSJD-DIPG-007 cells treated with oncolytic HSV are well contained within 
the brainstem following intracranial injection 
5x105 disaggregated HSJD-DIPG-007 cells premixed with oncolytic HSV at 10 pfu/cell were 
stereotactically injected into the brains of 4-5-week-old NOD.SCID mice. Tumours were left 
to establish and mice were sacrificed when showing signs of disease (i.e. severe ataxia or 
>15 % weight loss). Images from a mouse brain obtained on day 123-post surgery. Brains 
were harvested into 4 % PFA, sliced into coronal sections, embedded in paraffin and 
sectioned to 4 microns thick. Tissue sections were stained with H&E. (A) Cross section of 
the pons (P) and cerebellum (C). There is an attenuated area of low cellularity possibly 
representing the injection site (Black arrow) and a well-contained collection of abnormal 
looking cells (red arrow). There is no overall increase in cellularity within this section. Image 
taken at x2.5 magnification using the SPOT Insight camera and Leitz DMRB microscope. 
(B) x40 magnification of the boxed area in figure A, showing the collection of abnormal cells 
within the pons. There are clusters of small cells with elongated and misshapen 
hyperchromatic nuclei (black arrow) and apoptotic bodies (green arrow) indicative of tumour 
cells around blood vessels (red arrow). Image taken at x40 magnification using the SPOT 






Figure 62: HSJD-DIPG-007 cells treated with oncolytic HSV display well-contained 
collections of abnormal cells within the pons  
5x105 disaggregated HSJD-DIPG-007 cells premixed with oncolytic HSV at 10 pfu/cell were 
stereotactically injected into the brains of 4-5-week-old NOD.SCID mice. Tumours were left 
to establish and mice were sacrificed when showing signs of disease (i.e. severe ataxia or 
>15 % weight loss). Images from mouse brain obtained on day 78-post surgery. Brains 
were harvested into 4 % PFA, sliced into coronal sections, embedded in paraffin and 
sectioned to 4 microns thick. Tissue sections were stained with H&E. Brainstem section 
showing an area of increased cellularity within the pons. There are small nests of tumour 
cells (black arrow) seen close to blood vessels (red arrow) which are well-contained. Image 






























Figure 63: HSJD-DIPG-007 cells treated with oncolytic HSV form localised clusters 
around blood vessels within the pons 
5x105 disaggregated HSJD-DIPG-007 cells premixed with oncolytic HSV at 10 pfu/cell were 
stereotactically injected into the brains of 4-5-week-old NOD.SCID mice. Tumours were left 
to establish and mice were sacrificed when showing signs of disease (i.e. severe ataxia or 
>15 % weight loss). Images from mouse brain obtained on day 78-post surgery. Brains 
were harvested into 4 % PFA, sliced into coronal sections, embedded in paraffin and 
sectioned to 4 microns thick. Tissue sections were stained with H&E. Brainstem section 
through the pons showing blood vessel surrounded by a cuff of mildly atypical cells with 
frequent apoptotic bodies indicative of tumour cells. Image taken at x20 magnification using 






























Figure 64: HSJD-DIPG-007 cells treated with oncolytic HSV accumulate around 
intracranial injection site 
5x105 disaggregated HSJD-DIPG-007 cells premixed with oncolytic HSV at 10 pfu/cell were 
stereotactically injected into the brains of 4-5-week-old NOD.SCID mice. Tumours were left 
to establish and mice were sacrificed when showing signs of disease (i.e. severe ataxia or 
>15 % weight loss). Images from mouse brain obtained on day 137-post surgery. Brains 
were harvested into 4 % PFA, sliced into coronal sections, embedded in paraffin and 
sectioned to 4 microns thick. Tissue sections were stained with H&E. Brainstem section 
through the pons showing needle like clefts (black arrow) probably consisting of cholesterol, 
surrounded by microcalcifications (blue arrow), possible atypical cells (green arrow) and 
evidence of possible apoptotic bodies (red arrow) at the potential site of tumour injection. 











Figure 65: Oncolytic HSV therapy in an orthotopic xenograft model of 
DIPG 
5x105 disaggregated HSJD-DIPG-007 cells premixed with PBS or oncolytic 
HSV at 10 pfu/cell were stereotactically injected into the brains of two groups 
of 4-5-week-old NOD.SCID mice (control and treatment group n=6). 
Tumours were left to establish and mice were sacrificed when showing signs 



































The results contained within this chapter highlight the challenges involved in 
trying to establish an in vivo model of paediatric glioma invasion. The 
orthotopic xenograft model of the pHGG cell line SF188 failed to establish. 
Although GL261-Luc formed tumours which demonstrated a moderate 
degree of infiltration into the normal surrounding brain tissue in vivo, tumours 
were not detected in mice when oncolytic HSV was premixed with GL261-
Luc cells prior to intracranial injection. Consequently, the effects of oncolytic 
HSV on glioma invasion could not be evaluated within this experiment. 
Although it is possible that oncolytic HSV was capable of clearing GL261-
Luc tumours, no firm conclusion can be drawn as tumour establishment 
following premixing of virus with GL261-Luc cells was not determined by 
bioluminescent imaging. 
 
Following intracranial injection into the brainstem, HSJD-DIPG-007 cells 
diffusely infiltrated into the cerebellum, pons, midbrain and medulla. 
However, when mice received intracranial injection of HSJD-DIPG-007 
premixed with oncolytic HSV, brainstem sections no longer revealed a 
diffuse and even pattern of tumour cell infiltration. Instead, oncolytic HSV- 
treated mice had well-contained collections of abnormal cells within the 
brainstem, indicative of tumour cells and there was very limited infiltration 
into the surrounding structures. Thus, in keeping with in vitro findings, 
oncolytic HSV treatment appeared to reduce tumour infiltration in a mouse 
orthotopic xenograft model of DIPG. Furthermore, oncolytic HSV treatment 
may also prolong survival in this model (though confirmation of this is 
required), highlighting the future clinical potential for use of this OV in 
patients with DIPG.  
 
One potential drawback with the design of these in vivo experiments is that 
oncolytic HSV was premixed with both GL261-Luc and DIPG cells prior to 
intracranial injection. An alternative and superior methodology would involve 
the intracranial injection of early established tumours with oncolytic HSV; 
however, this was not possible within our facility at the time of study. 
Premixing of the virus with tumour cells prior to injection was deemed a 
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reasonable alternative as GL261-Luc monolayers appear resistant to the 
cytotoxic effects of oncolytic HSV over 48 h and HSJD-DIPG-007 cells 
appear viable following treatment at this time point. This would allow time for 
the injected viable cells to establish tumours within the brain environment. It 
is possible that GL261-Luc cells premixed with oncolytic HSV did form 
tumours that were then cleared by the cytotoxic and immunogenic effects 
induced by oncolytic HSV treatment; however, it is also possible that 
premixing of the virus with tumour cells in the GL261-Luc model prevented 
their ability to establish intracranial tumours. Future in vivo experiments 
should be designed to include intracranial injection of OV into established 
tumours and should aim to monitor the establishment and subsequent 
growth of tumours using appropriate imaging techniques. Imaging of 
established virus-treated tumours would also help to identify the appropriate 
time point to harvest brains in order to try and evaluate any changes in 
tumour invasion following oncolytic HSV treatment.  
 
Another potential drawback of the GL261-Luc mouse model used within this 
chapter was that adherent GL261 cells, as used in this thesis, have been 
shown to form non-infiltrating tumours in vivo with little resemblance to 
primary mouse glioma (411). GL261 adherent cells can be cultured as 
neurospheres by supplementing the culture medium with growth factors 
required for neural stem cells (411). GL261 neurospheres can form 
aggressively infiltrating intracranial tumours in C57BL/6 mice (411). Future in 
vivo experiments could be designed evaluating the effects of oncolytic HSV 
on intracranial tumours of GL261 neurospheres, which represents a superior 
model of in vivo tumour invasion. Alternatively, the syngeneic orthotopic CT-
2A mouse astrocytoma model could be evaluated as a potential model of 
brain tumour invasion (412,413). CT-2A tumours have been demonstrated to 
infiltrate into mouse brain parenchyma, including satellite lesions, and CT-2A 
cells and neurospheres have been shown to have in vitro invasive 





An additional strategy that can be used to study glioma invasion within brain 
tissue is the organotypic brain slice culture (236,414,415). In this assay, 
brain slices are maintained in culture in order to maintain the brain 
cytoarchitecture and the biochemical and electrophysiological properties of 
neuronal and supporting cells (414,415). Glioma cell spheroids can then be 
placed on the brain slice and migration across and invasion into the brain 
tissue can be imaged (415). Although this model cannot be considered as an 
equivalent alternative to in vivo experimentation, it does provide a relatively 
simple, reproducible three-dimensional system that allows evaluation of 
migration and invasion within brain tissue. Evaluation of the invasion of 
pHGG and DIPG cell line spheroids within this assay ± oncolytic HSV is a 
focus of our future work.  
 
Although oncolytic HSV treatment was shown to enhance therapy in an 
orthotopic xenograft model of DIPG, this failed to reach statistical 
significance. This may be due to the small number of mice per treatment 
group (n=6).  Larger scale studies are required in order to make more 
powered evaluations of the therapeutic efficacy of oncolytic HSV in a mouse 
model of DIPG.  
 
pHGG and DIPG remain a treatment challenge due to their diffuse and 
invasive nature. Novel therapeutic anti-invasive strategies are very much 
needed. Within this thesis, in vitro studies have highlighted the potential of 
GSK-3 inhibitors and oncolytic HSV as novel candidates for future anti-
invasive drug development. Future studies aim to develop pre-clinical testing 
of these therapies within effective in vivo models of pHGG and DIPG 
invasion. The work within this chapter forms the foundation for future studies 
to develop an effective and reproducible methodology to test the efficacy of 








7 Chapter 7: Conclusion 
 
 
pHGG and DIPG are highly aggressive tumours associated with diffuse 
infiltrative growth patterns. This invasive phenotype contributes towards 
limited therapeutic response and, as such, there is a clear pressing clinical 
need to develop novel therapies that effectively target tumour migration and 
invasion. Within this thesis the migratory and invasive characteristics of 
pHGG and DIPG cell lines were explored, confirming distinct differences in 
morphology, velocity, migration and invasion patterns.  
 
In addition, for the first time, the small molecule GSK-3 inhibitors LiCl and 
BIO, previously shown to block migration and invasion of adult HGG cells, 
were shown to significantly inhibit the migration and invasion of pHGG and 
DIPG cell lines. Both migration and invasion were evaluated in 2D (transwell 
membrane, live cell imaging, IF) and 3D (migration on nanofibre plates and 
spheroid invasion in collagen) systems. In the presence of GSK-3 inhibitors, 
pHGG cells displayed overall reduced movement and, in the case of SF188, 
loss of polarity. Both LiCl and BIO instigated pHGG cytoskeletal 
rearrangement of actin stress fibres and focal adhesions.  Overall, this work 
has demonstrated that it is possible to pharmacologically target migration 
and invasion of pHGG and DIPG in vitro using the GSK-3 inhibitors LiCl and 
BIO. In conclusion, these agents and their derivatives warrant further pre-
clinical investigation as novel anti-migratory and anti-invasive drugs for poor 
prognosis infiltrative childhood brain tumours. 
 
The work contained within this thesis also highlights that oncolytic 
virotherapy has the potential to offer an exciting new treatment paradigm for 
pHGG and DIPG. This project shows, for the first time, that OVs (HSV, 
reovirus and VV) can inhibit the migration and invasion of pHGG, DIPG and 
mouse glioma cells. Oncolytic HSV was considered to represent the most 
interesting candidate, as both its anti-migratory and anti-invasive effects did 
not appear to be a consequence of cytotoxicity or overall altered cellular 
proliferation. In the presence of oncolytic HSV, pHGG cells displayed 
reduced movement and, in the case of SF188, loss of polarity. Additionally, 
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oncolytic HSV appeared to alter IL-8 production within pHGG cell lines, a 
cytokine known to be associated with tumour invasion.  
 
The possible mechanism by which oncolytic HSV may reduce pHGG 
migration and invasion was also explored. Oncolytic HSV altered pHGG 
cytoskeletal dynamics, stabilising microtubules through the accumulation of 
post-translational tubulin modifications. Furthermore, oncolytic HSV altered 
molecular pathways critical for cell polarity, migration and movement. 
Oncolytic HSV treatment of pHGG cell lines resulted in a tendancy towards 
inhibited GSK-3β activity and increased DOCK3 expression and prevented 
the localised clustering of APC to the leading edge of the cell. These 
observations are highly novel and begin to document the molecular 
mechanisms by which oncolytic HSV may inhibit pHGG migration and 
invasion.   
 
Finally, the ability of oncolytic HSV to inhibit glioma invasion was explored in 
vivo. These experiments indicated that mice receiving intracranial injection of 
HSJD-DIPG-007 cells premixed with oncolytic HSV could demonstrate 
reduced tumour infiltration and enhanced therapy, compared to controls, in 
an orthotopic xenograft model of DIPG. This work forms part of ongoing 
efforts to develop in vivo models of glioma invasion, in order to efficiently 
screen novel anti-invasive therapies for paediatric brain tumours.  
 
Future work related to this project will mainly focus on the further 
development of reproducible methodology to test the efficacy of potential 
anti-invasive therapies in vivo. Animal studies will focus on drug and virus 
delivery to brain tumours, either by intracranial or i.v. injection. Alternative 
drug delivery techniques, such as convection enhanced delivery catheters or 
local delivery with polymers, could also be explored as mechanisms to 
overcome the BBB. Subsequent in vivo experiments should also monitor the 
establishment and growth of tumours using appropriate imaging techniques.  
 
Furthermore, a mouse organotypic brain slice assay for use with pHGG and 
DIPG tumour spheroids is currently planned. This assay offers a 
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reproducible three-dimensional system to effectively screen drug and virus 
candidates, evaluating their ability to alter paediatric glioma cell migration 
and invasion within human brain tissue. 
 
Additional work is also planned to evaluate the specific effects of GSK-3β 
inhibition on pHGG microtubule dynamics and post-translational 
modifications. The direct effects of DOCK3 knockdown and overexpression 
on pHGG GSK-3β activity and migration also remain to be explored. Finally, 
screening the effects of a diverse panel of novel GSK-3β inhibitors on pHGG 
and DIPG migration and invasion remains a major part of ongoing studies in 
this area.  
 
Although relatively rare, pHGG and DIPG are associated with dismal 
prognosis. Five-year survival outcome is approximately 15-35 % for patients 
with pHGG and 90 % of children with DIPG will succumb to their disease 
within two years of diagnosis (36-38,416). Despite advances in the field of 
radiotherapy and the onset of novel biologically targeted therapeutics, 
survival statistics have failed to improve over the past couple of decades 
(20). The hallmark characteristic of glioma cells to invade and diffusely 
infiltrate normal brain tissue substantially contributes towards poor prognosis 
by preventing complete surgical resection and localisation of tumour for 
radiotherapy. The development of effective anti-invasive strategies, as 
proposed within this thesis, would be very much welcomed and could 
considerably improve clinical outcomes in this field.  
 
Both LiCl and BIO have potential for clinical application, although current 
hurdles for the use of such agents in the paediatric clinical arena include 
optimisation of drug delivery, determination of effective working dosage and 
avoidance of toxic systemic accumulation. Pre-clinical in vivo drug testing 
and evaluation of clinical experience from adult dosing regimens could begin 
to address these issues and are required in order to develop these agents 
for use in paediatric oncology patients. 
 
 192 
Oncolytic virotherapy offers a completely novel treatment approach for poor 
prognosis children’s brain tumours. Although clinical experience for use in 
children with intracranial tumours is limited to a few case reports 
(325,328,329), promising results have been demonstrated in adult patients 
with glioma in terms of safety, tolerability and multiple dose delivery 
(334,336-338). Excitingly, a phase I trial evaluating the safety of injecting 
oncolytic HSV1716 into or near the tumour resection cavity of relapsed or 
refractory HGGs is currently recruiting paediatric patients between 12 and 21 
years of age (332). Rationale for this study is based upon the known 
cytotoxic and immunogenic effects of oncolytic virotherapy as well as clinical 
experience of delivering oncolytic HSV to paediatric patients with 
extracranial solid tumours (252,254,279,408,409,417). Importantly, the 
results within this thesis suggest, for the first time, that oncolytic HSV may 
also have a role as an anti-invasive therapeutic, potentially reducing tumour 
migration and infiltration from residual cancer cells. This additional 
mechanism of action against a principle hallmark of cancer again highlights 
the clinical potential for oncolytic virotherapy and opens the door to an 
exciting new era of treatments for paediatric neuro-oncology, with the 
potential to improve outcomes in this patient population.  
 
In conclusion, the studies contained within this thesis provide compelling 
evidence that pHGG and DIPG migration and invasion can be effectively 
targeted and highlight the exciting clinical potential of two novel anti-invasive 
















8.1 Appendix 1 - List of Suppliers 
 
Abcam  330 Cambridge Science Park, 
Milton Road, Milton, Cambridge, 
CB4 0FL, UK 
 
AbD Serotec Endeavour House, The Langford 
Business Park, Langford Lane, 
Kidlington, Oxfordshire, OX5 1GE, 
UK  
 
Atom Scientific  Arrow Trading Estate, Corporation 
Road, Audenshaw, Manchester, 
M34 5LR, UK 
 
BD Biosciences  The Danby Building, Edmund 
Halley Road, Oxford, OX4 4DQ, UK 
 
BDH 100 Matsonford Road, Radnor, PA 
19087-6880, USA  
 
Bio-Rad Laboratories Ltd.  Bio-Rad House, Maxted Road, 
Hemel Hempstead, Hertfordshire, 
HP2 7DX, UK 
 
Biotium 3159 Corporate Place, Hayward, 
CA 94545, USA 
 
Calbiochem 10394 Pacific Center, San Diego, 
CA 92121, USA 
 
Cell Signaling Technology 3 Trask Lane, Danvers, MA 01923, 
USA 
 
Corning Ltd.  Elwy House, Lakeside Business 
Village, St. David's Park, CH5 3XD, 
UK 
 
Dako Ltd.  Cambridge House, St Thomas 
Place, Ely, Cambridgeshire, CB7 
4EX, UK 
 
Essen BioScience 300 West Morgan Road, Ann Arbor, 
MI 48108, USA 
 
Genelux Corporation 3030 Bunker Hill Street, 310 San 




Genetex Inc.  2456 Alton Parkway, Irvine, CA 
92606, USA 
 
Graph Pad Software Inc.    7825 Fay Avenue, Suite 230, La 
Jolla, CA 92037,USA 
 
 
Greiner Bio-One Unit 5, Brunel Way, Stonehouse, 
GL10 3SX, UK 
 
IBM United Kingdom Ltd.   PO Box 41, North Harbour, 
Portsmouth, Hampshire, PO6 3AU, 
UK   
 
Labtech International Ltd.  2 Birch House, Brambleside, 
Uckfield, East Sussex, TN22 1QQ, 
UK 
 
Leica  Larch House, Woodlands Business 
Park, Breckland, Linford Wood, 
Milton Keynes, MK14 6FG, UK 
 
Microsoft  Microsoft UK Headquarters, 
Microsoft Campus, Thames Valley 
Park Reading, Berkshire, RG6 
1WG, UK 
 
Millipore Ltd. Number One Industrial Estate, 
Consett, DH8 6SZ, UK 
 
Molecular Devices  1311 Orleans Drive, Sunnyvale, CA 
94089, USA   
 
Nanofiber solutions LLC 1275 Kinnear Road, Columbus, OH 
43212, USA 
 
Nikon Shinagawa Intercity Tower C, 2-15-
3, Konan, Minato-ku, Tokyo 108-
6290  
 
Oncolytics Biotech Inc. 210, 1167 Kensington Crescent, 
North West Calgary, AB, T2N 1X7, 
Canada 
 
Peprotech EC Ltd.  29 Margravine Road, London, W6 
8LL, UK 
 
Perkin-Elmer Inc. 940 Winter Street, Waltham, 




R&D systems  614 McKinley Place NE, 
Minneapolis, MN 55413, USA  
 
 
Roche Charles Avenue, Burgess Hill, West 
Sussex, RH15 9RY, UK 
 
Sarstedt Ltd. 68 Boston Road, Leicester, LE4 
1AW, UK 
 
Scientific Laboratory Supplies Ltd.  The Square, Hessle, North 
Humberside, HU13 0AE, UK 
 
Selleckchem Unit 7, Acorn Business Centre, 
Oaks Drive, Newmarket, Suffolk, 
CB8 7SY, UK 
 
Sigma-Aldrich Company Ltd. The Old Brickyard, New Road, 
Gillingham, Dorset, SP8 4XT, UK 
 
Solmedia Unit 2, Battlefield Enterprise Park, 
Vernon Drive, Shrewsbury, SY1 
3TF, UK 
 
SouthernBiotech 160 Oxmoor Boulevard, Number 
100, Birmingham, AL 35209, USA 
 
SPOT Imaging 6540 Burrough, Sterling Heights, MI 
48314, USA 
 
Starlab UK 4 Tanners Drive, Blakelands, Milton 
Keynes, MK14 5NA, UK 
 
The Jackson Laboratory 600 Main Street, Bar Harbor, ME 
04609, USA  
 
Thermo Fisher Scientific  Stafford House, Boundary Way, 
Hemel Hempstead, HP2 7GE, UK 
 
Virttu Biologics 2nd, Western Infirmary, McGregor 
Building, Glasgow, G11 6NT, UK 
 
Weber Scientific International Ltd.  40 Udney Park Road, Teddington, 
Middlesex, TW11 9BG, UK 
 
Zeiss 509 Coldhams Lane, Cambridge, 





8.2 Appendix 2 – Media, Buffers and Reagents 
 
General chemicals were ‘AnalaR’ or molecular biology grade and were 
purchased from BDH or Sigma-Aldrich unless otherwise stated. 
 
Tumour stem medium (TSM) base 
 
Reagent Vendor Volume 
(ml) 
Neurobasal-A medium (1x) liquid Thermo Fisher 
Scientific 
250 
DMEM/F-12 (1x) liquid 1:1 Thermo Fisher 
Scientific 
250 
HEPES buffer solution (1 M) Thermo Fisher 
Scientific 
5 
Sodium Pyruvate 100 mM liquid Thermo Fisher 
Scientific 
5 





GlutaMAX-1 supplement Thermo Fisher 
Scientific 
5 




Table 9: Constituents of tumour stem medium (TSM) base for HSJD-






In PBS:  0.1 % sodium azide 





In PBS: 1 % Nonidet P40    
  0.1 % SDS       
  0.5 % sodium deoxycholate     





Loading Buffer (2x) 
 
  100 mM Tris pH 6.8 
   4 % (w/v) SDS 
   0.2 % (w/v) bromophenol blue  
  20 % (v/v) glycerol  
  Made with ddH2O   
                      Before use add 200 mM dithiothreitol (DTT) 
 
 




Component volumes (ml) per 10 ml gel volume  
6 % Gel 10 % Gel 
H2O 5.3 4 
30 % acrylamide mix 2 3.3 
1.5M Tris (pH 8.8) 2.5 2.5 
10 % SDS 0.1 0.1 
10 % ammonium 
persulfate 
0.1 0.1 
TEMED 0.008 0.004 
 
Table 10: Solutions for preparing 5 and 10 % gels for tris-glycine 
SDS polyacrylamide gel electrophoresis 
 
 
Running buffer (1x) 
 
25 mM Tris 
250 mM glycine 
0.1 % SDS 
Made with ddH2O 
 
Novex Tris Glycine Transfer Buffer (1x) 
  12 mM Tris 
  96 mM glycine 
  Made with ddH2O 
 
 198 
TBS buffer (10x) 
  200 mM Tris 
  5 M NaCl 
  Made with ddH2O 
pH to7.5 with concentrated HCl 
 
Coating buffer (10x) 
    1 M NaHCO3 pH 8.2  
    then dilute 1:10 with ddH2O 
 
8.3 Supplementary material included on CD  
 
Movie 1: Live cell imaging of SF188 in culture medium  
Movie 2: Live cell imaging of SF188 treated with LiCl  
Movie 3: Live cell imaging of SF188 treated with BIO  
Movie 4: Live cell imaging of KNS42 in culture medium  
Movie 5: Live cell imaging of KNS42 treated with LiCl  
Movie 6: Live cell imaging of KNS42 treated with BIO  
Movie 7: Live cell imaging of SF188 in culture medium  
Movie 8: Live cell imaging of SF188 treated with oncolytic HSV  
Movie 9: Live cell imaging of KNS42 in culture medium  
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